FEDERAL TRADE COMMISSION

PATENT REFORM WORKSHOP

APRIL 16, 2004

BANCROFT HOTEL, BERKELEY, CALIFORNIA
PROFESSOR MERGES: Okay, I think it is probably time to get started here. We have had our April sprinkles, so we are all woken up and ready to go onto the substantive part of the program. I just want to welcome everybody back on behalf of the Berkeley Center for Law and Technology and U.C. Berkeley, generally, plus all of our many co-sponsors. Thanks for coming out.

Today is the substantive part of the program. We are going to dig into some details from the Federal Trade Commission Report. And now that the press has gone off to file their stories from yesterday, we might actually hear some more meat and potatoes on the National Academy of Sciences Report, too, I am told. So today is going to be a real good day.

For those of us who used to teach patent law courses to rooms not so full of 12 or 16 somewhat desultory students, it is always kind of mind numbing to realize that patent reform and patent law generally has gotten to be such a hot topic.

I also wanted to say while I had a chance that this is sort of our last chance to say farewell on behalf of the Berkeley Center for Law and Technology to our colleague, Mark Lemley, who is leaving us soon for that
university down by the old railroad here, and Mark has
done just tremendously wonderful things for us, and I
just wanted to take this opportunity to publicly thank
him for all his good work and to wish him the very best.
We are sad on a personal level that he is going and we
are going to miss having him around.

Just a quick note of what is going on now and
what is coming up. On April 20\textsuperscript{th}, which is a moderately
typical day around here, we have a roundtable coming up
on the technology and digital content industries, a
roundtable. And we have people coming in from I-tunes
and the Electronic Freedom Foundation, from the
powerhouse Hollywood entertainment law firm, Mitchell-
Silverberg, and we have people coming up from Universal
Music to talk about what is going on with the digital
content industries and how the technology companies can
get in the game and how those guys can cooperate. And
that is typical of the kind of activities that we always
have going on.

On the same day, I think, the Computers,
Freedom, and Privacy, the CFP Conference, which is an
internationally famous conference, begins over at the
Claremont. This year it has been organized and largely
energized by our own Deardra Mulligan from the Samuelson
Clinic, and we are proud to be participating in a very
strong way in that this year. We just finished our
Intellectual Property Speaker Series, and I think the
last two people through are typical of the kind of folks
that we have coming up here to Berkeley now. We had
Peter Nelson, who was the main lawyer for the Lord of the
Rings movies, and when my 12-year-old son heard about
that, he wanted a ticket to get in. We also had Jay
Cooper, who is Jerry Seinfeld’s lawyer, which has to be
one of the more interesting jobs in the world. He came
and spoke to us also.

In the Samuelson Clinic, they always have a lot
of good activities going on, let me just name two that
are currently under way. One is they are beginning a
multi-year project on the issue of pervasive censors and
privacy issues that go along with that. That is
something that many of you have probably heard about if
you read the science pages, but it is one of those issues
that is likely to percolate up to the front page of the
New York Times one of these days and, when it does, Pam
Samuelson and the Samuelson Clinic, Deardra Mulligan, and
others, will be the people that the New York Times call
because they will have been studying it for five years
and will know all about it.

We also have a major initiative coming in on
Intellectual Property and Entrepreneurship. The George
Kaufman Foundation in Kansas City, which is sort of the premier philanthropic organization that funds research on entrepreneurship has given us a seed grant to begin some research in that area, so that is a major initiative also probably over the next few years. And one last project is another Samuelson Clinic Project. The Electronic Freedom Foundation has heard the calls in terms of the need for a public interest patent re-examination effort. I was just talking to somebody about that yesterday. There is a need for a public interest organization to try to identify sort of high social cost bad patents, and to go after them. And the EFF is teaming up with our own Samuelson Clinic in an initiative to start that process here at Berkeley. So you can see why we are not going to have too much time to hang our heads -- tons of great stuff going on.

The list goes on and on and on every year. Of course, the reason that happens is that we have this community of people who keep coming back and who keep feeding us with fantastic and interesting ideas, keep us on the cutting edge, and create this really interesting mix that makes this whole thing really work.

One more thing does come to mind, actually. I think we are going to have kind of an informal student lunch with some lawyers from the Morgan Lewis firm, and
they were involved in the Microsoft Intertrust Patent settlement recently. And that is exactly the kind of thing that prospective students love to hear about because that is kind of insider information that is hard to get anywhere else, and it is coming here in a very timely way, and when you come here that is the kind of stuff you are exposed to. And, you know, frankly that is one of the reasons that we are really pleased with the organization we have built and super excited for the future.

So, anyway, after that plug for everything that we are doing, let me also say, before I forget to thank, once again, David Grady and Helane Schweitzer, who have really put so much effort into this conference, and they are the kind of professionals that make the Center really run and really make it what it is. I also want to thank our new Dean, Chris Edley, for making some comments yesterday. There is a tremendous feeling of excitement at Boalt, generally, with Dean Edley and his interest in the Center is something that we are very pleased with.

Okay, today’s main topic is the real substantive issues involved in patent reform, and to start us off on that topic, I am going to introduce Mark Myers in just a second; however, let me just make two sort of housekeeping notes before we get to Mark. The
first is that we are being transcribed. We are being recorded for transcription, so I thought I better give fair notice to everybody. The transcript will help the editors of the Berkeley Technology Law Journal when they prepare the Journal issue that will come out of this conference. How did I forget the BTLJ? There are so many exciting things going on there I could go on for half an hour just on that. They are one of the keystones, the cornerstones of what makes this thing work, too.

When the conference issue is published for this conference, it will automatically be, you know, one of the most prominent sort of sources of information on the current debate around patent reform. And when we have young scholars around the country publishing their kind of crown jewel, their treasure pieces that they are trying to get tenure with, in the BTLJ, and considering that a coup, we know we have really built something that is quite special. So there is my BTLJ plug, which I almost forgot.

Back to the housekeeping. So we are going to transcribe, just in case anybody needs to know that, and the second issue for those of you who are speakers, we have a dedicated laptop here in this position, and so the trick is going to be if you have Powerpoint to kind of
rotate through to the presenter’s spot, and I would ask you to bring your name tag when you do that so we all know who you are, and so the transcriber can know who you are, and then just kind of circulate to the empty chair if you are the speaker who is finishing. Okay? So with those housekeeping notes, let me turn it over to Mark Myers who has promised some real substantive comments for us this morning. Thank you.

MR. MYERS: Thank you. I am Mark Myers. I was Co-Chair of the National Academy of Sciences study with respect to Intellectual Property, which we have named “The Patent System for the 21st Century.” And this study was carried under the Science Technology Economic Policy Board of the National Research Council, which looks at issues of technology, economics, and policy.

The conditions that we’re interested in is, basically over the last 50 years there has been a significant and continuing strengthening of the patent processes within the United States and the world. You have had patenting extended to new technologies in the biotech area, patenting extended to technologies that previously were not subject to this form of intellectual property, such as software, the encouraging emergence of new players, universities and public research institutions, strengthening of the position of patent
holders vs. alleged infringers, and relaxed antitrust
constraints on patent use, and the extended reach of
patenting upstream into scientific tools, materials and
discoveries.

So this has been a 50 year period of greatly
enhancing the Patent System. But it has created strains.
Patents are being more zealously sought and aggressively
enforced, the volume is increasing, the cost is
increasing, and the benefits of a patent stimulating
innovation varies considerably across different parts of
the industrial sector.

So, in fact, as we undertook the study four
years ago, there are several of the members of this study
that is within the group. We basically are a committee
composed of economists, scientists, engineers, inventors,
business majors, legal scholars, as well as practitioners
with a great variety of experience.

An important part of the study was in fact –
the first phase was defining the problem and then a
second phase was defining solutions. But to define the
solutions, we carried out nine areas or contracted
research, and that research is available, it has been
published, published about a year ago, and it deals with
patent quality and examination, two studies -- patent
challenges in Europe and the United States, two studies,
litigation, two studies, patenting software, patenting internet business methods, and licensing and Biotech.

The focus of our study was restricted to looking at the patent system, particularly with respect to issues of backlog and the productivity of the system, as well as two problem areas which were in biotech and business practice patents. So, we looked at the patent system really through the lens of seven criteria, that we desire as we go forward; a patent system that can accommodate new technologies with flexibility, a system that rewards only inventors that meet the statutory tests of novelty, utility and meet the obviousness standard, a patent system that is effective at disseminating information, administrative and judicial decisions are timely and at reasonable cost, access to patented technologies is important to basic research, and in the development of cumulative technologies.

Greater integration or reciprocity is needed among three major patent systems, that is, Japan, the United States, and Europe to increase the overall productivity and reduce the transaction costs. And there should be a level playing field that all holders of patents are subject to the same benefits and constraints in all jurisdictions.

So we have seven recommendations. These
recommendations will formally be announced next Monday. The documents are being shipped today for those who are expecting to receive it. But the seven that we are recommending is: Preserve an open-ended, unitary, flexible patent system -- I will say more about that; reinvigorate the non-obvious standard -- you have a panel with respect to that today and that discussion is an important one; institute an open review procedure -- another panel that is being held today and an important discussion; strengthen the U.S. Patent Office resources; shield some research uses of patents from liability and infringement; modify or remove the subjective elements of litigation; and reduce redundancies and inconsistencies among national Patent Systems.

I will just make a few remarks about some of the key areas of this. Preserve an open-ended unitary Patent System, flexible -- as one thinks about approaching the area of remedy, of issues that there is actually in litigation, but there is also working within the procedures with the Patent Office and the judicial system itself, and that there are some advantages, significant advantages, of making the changes through the work processes of the Patent Offices and the precedents of the judicial system because legislation is a much less flexible way to work, and so we make a number of
recommendations in that area.

Re-invigorate the non-obvious standard -- we have considered the non-obvious standard extremely important. We believe that there has been some lowering of the bar of that standard, it is a hard issue to deal with, that in business method patents which we have a concern in that area, there are different solutions that one would consider in biotech. And so approaching this is probably going to require remedies very specific to the technology area.

A key area with respect to our recommendations is to institute an open review procedure. We looked, as I indicated in our studies, intensively at the European system. The European system brings many of the benefits that we feel a third party initiated review that can challenge a patent under any standards in the USPTO, and that the outcome of that would be confirmation, cancellation, or amendment of any claim. Or, we envision the courts, the District Courts, or the Court of Appeal could also refer validity questions to such a body, and then there would be an appeal process to the Board of Patent Appeals and to the Federal Circuit.

One of our studies with respect to the economics of such a system finds significant social welfare economically that such a system would bring

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
compared to our current legal processes and, so, if
properly designed, and I do not believe such a system has
been properly designed, that yet there is great
opportunities.

I think given the time, I am not going to go
further into the strengthening of the USPTO, other than
we need to address the issue of adequate compensation for
examiners, as well as adequate numbers of examiners.
But, also, there are significant investments in
electronic file processing and database searches that
need to be funded and supported.

It would be impossible for the National Academy
not to remark on protecting the interest of basic
research, and we feel that the Madcy-Duke Decision
creates a cloud that needs to be addressed, and that
there are both legislative and administrative actions,
strategies that could be considered to remove that cloud.

And the final two that I will just mention is
that we believe in an overall tone of making a more
productive, efficient system, that we need to remove
those processes that are not really contributing to the
working of the system, and that is why we propose
removing the subjective elements of litigation which
would include best mode, willful infringement, and that
would help, also, with respect to some of the
organization issues.

And, finally, with respect to harmonization, that there are issues that we feel there needs to be trilateral, bilateral negotiations between the major Patent Systems -- that is, Europe, United States, and Japan. The issues for harmonization would be application priority, of course a grace period for filing, best mode U.S. exception to the rule of publication. I think those are manageable.

I did speak at the Conference of the European Commission Patent Office in November in Strassborg. Another raised there when we discussed this and the issue of business practice patents for Europeans will be a harder problem to resolve. I am not implying that others will be easy, but that one would be more intractable.

That, I think, is a quick run-over.

PROFESSOR MERGES: Okay, so now we know what to look for when we get our NAS reports in the mail. Let me now quickly introduce Commissioner Mozelle Thompson from the FTC, again, for a couple of quick comments so we can get going on our panel. Thank you.

COMMISSIONER THOMPSON: Good morning. You know, for all of you students who spent most of your legal career trying to avoid early classes on Friday, this is what you have to look forward to.
Well, it is good to see all of you here today and you must be all very committed to the idea of patent reform. You know, the Commission has been looking at the subject of technology and competition and innovation for quite a long time.

Yesterday at our press conference, I mentioned that one of the most critical issues facing us in America is how we maintain our position as a world leader in innovation because innovation has played a central role in economic growth in the United States, and providing consumers with products and services that are of the highest quality, the greatest variety, and lowest cost. And I also noted that no one knows that better than the people here in Northern California who have witnessed the impact of innovation and the transformational effects it has.

And so, it was appropriate for us to come here almost two years ago to conduct hearings and meet with industry that was based out here to talk about competition and intellectual property, and it is similarly fitting that we come back here now that we have issued a report that makes certain recommendations about patents. That report provides a variety of perspectives about the goals and policies behind patent law and competition and their interaction, and how we might be
able to do better in supporting the future of innovation.

Now, how many people here are from industry? And how many people here are from academia? And how many people here are just looking for a way to make money off either -- no -- are here to advise others as to how they should think about the future of patents? Okay. I think that is a pretty big deal. I think that is a pretty big deal because, collectively, you are all sitting here at this event in what I think is going to be a watershed event, to talk about what the future of innovation is going to look like. Those opportunities do not occur very often, and a group of people like this one actually do not sit together and talk about it very often. So it is your opportunity to give voice to perspectives that, frankly, do not often get aired and especially do not get heard very often in Washington, D.C. where we are charged with looking at policy and have to look at what the future is going to be.

So I am happy to participate, to see you all here talking about the details of our report -- Susan DeSanti here may not be quite as comfortable looking at the details of our report, she has been living with it for all of this time. But it does give us a chance, perhaps, to take a step back and think about this important opportunity that we have because many of you
are stakeholders. You have a stake in what the future outcome is going to be. And to the extent this year represents the beginning of a critical mass, especially out here on the cutting edge of innovation, I am very happy to see you.

So I can tell you that the Commission itself will continue to be committed to this area. We are happy to provide at least an initial framework for discussion, and I hope at the end of the day to be able to talk about some of the observations that we may be able to make collectively. So thank you very much and we will see you throughout the day.

MR. LEMLEY: If we could have the panelists for the Obviousness Panel come on up? We have a distinguished panel. We are going to hear from Professor Rochelle Dreyfuss at NYU; from Todd Dickinson who, for the next week or so, is at Howrey Simon Arnold White, and will then become IP counsel at General Electric; Professor John Barton at Stanford University; and, finally, from Ron Laurie at Inflection Point Strategy. Everybody is going to talk for a very brief period of time to enable us to have some conversations among the panel, and then some conversations with all of you.

MS. EISENBERG: Thank you very much. I am losing my voice which is a good enforcement to be brief
in my opening remarks. I found this FTC report very
interesting. I look forward very much to reading the
National Academy’s report. In wading through some of the
testimony in the Powerpoint slides and all of the
wonderful resources from the FTC study that were up on
the web, I was struck by the widespread perception in
various quarters that the non-obviousness standard has
been falling, has been dropping, that it is not therefore
doing the job that it had been doing in the past of
separating out the wheat from the chaff, of
distinguishing those inventions that need the incentive
of a patent in order to be called forth from those that
are likely to be forthcoming in short order. In any
event, because they are the low-lying fruit in the
particular art, something that is within easy reach of
ordinary practitioners. And so I began reading through
the cases in chronological order and the picture that
emerged was of the sort of systematic marginalization
over time of the views of the person having ordinary
skill in the art to the point of irrelevance, really, in
recent decisions. This is very different than what you
would expect from looking at the language of the statute.
I apologize for having no Powerpoint slides, maybe you
can think back to Peter Munell’s excellent slides
yesterday, and right now you see behind you the language
of the statute which says that “if a patent may not be obtained, though the invention is not identically disclosed or described,” blah, blah, blah, “if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art.” Now, reading that language, it sounds like the person having ordinary skill in the art is the ultimate determinant of what gets a patent. That is the person whose judgment and perceptions should control. And that makes sense, that is a sensible standard if the point of the requirement is to distinguish those inventions that are likely imminent with or without a patent from those that are not. So it seems to call for an examination of what the invention would have looked like at the time it was made to the inventor’s contemporary peers in the technological community. But this poses, of course, a couple of administrative difficulties in implementing such a standard. First is the time frame, this is a difficulty that has been much remarked upon by the courts, particularly the Federal Circuit which is constantly admonishing the examiners to avoid falling into the hindsight trap. They are very aware of the difficulty of telling today what would have been obvious,
you know, two years ago. The worry there, of course, is that the standard will be set too high, that something that seems obvious enough once we have it in hand, in fact, was not obvious before that point. The second difficulty, though, is the one that I am concerned with, and one that has been ignored, which is how do you bring to bear upon these determinations the perspective of a person having ordinary skill in the art if the standard is administered and reviewed by people who do not have ordinary skill in the art? The Federal Circuit, again, has been obsessed with the first difficulty, but has virtually ignored the second difficulty. When it speaks of the second difficulty, of the difficulty of discerning the perspective of a person having ordinary skill in the art, it conflates the two issues. It says the reason that we look to the level of ordinary skill in the art is to avoid hindsight, when in fact it is a really different problem, and it is a problem that points in the other direction. The worry with hindsight is that the bar will be set too low, the worry with the difficulty of implementing the ordinary skill level is that the bar - excuse me, it is the opposite - the worry with hindsight is the bar will be set too high, the worry with the PHOSITA problem is that the bar will be set too low.

Now, the Supreme Court in its decision in
Graham v. John Deere listed level of skill as one of the basic factual inquiries that needs to be determined en route to evaluating the obviousness of the invention, but the Supreme Court never actually used that standard in any way, used that skill level in any way, in figuring out whether the particular invention before it was patentable, and that was true in other cases as well. They would point to a level of skill as the statute required them to do, as something you have got to determine, but then once they determined that, they would set it aside and they would look at the prior art and they would do their own evaluation of whether the differences between the prior art and the invention were obvious or not. The lower courts have done the same thing. They recite that they have refined level of skill, they make findings sometimes. They will say, you know, the ordinary practitioner is somebody with a Bachelor’s Degree in Mechanical Engineering and six years of experience working on this or that, and then they do nothing with it. Sometimes they forget to make those findings and then, on appeal, the Federal Circuit will say, “Well, this is harmless error.” And as they have applied the standard, it has got to be harmless error because it is not doing any work. So instead they all focus instead on the prior art references, the written
record of prior art, and what it reveals. The person having ordinary skill in the art is consulted as a reader of references, rather than as an evaluator of obviousness. So they will refer to the skill level, to the training, to discern what the reference would reveal, but not to go beyond that and evaluate whether the invention would have been obvious.

There are a number of reasons, I think, why this has happened. First is what I call the “plotter presumption,” the presumption in the case law that the person having ordinary skill in the art is unimaginative, uncreative, is not an innovator, thinks along conventional lines, and this was expressed most starkly perhaps in a past issue they quote in the paper from Judge Ritch in the case of Standard Oil vs. American Cyanamid, where he says, “The statutory emphasis is on a person of ordinary skill and one should not go about determining obviousness under Section 103 by inquiring into what patentees, i.e., inventors, would have known or would likely have done faced with revelations of references. A person of ordinary skill in the art is also presumed to be one who thinks along the line of conventional wisdom in the art and is not one who undertakes to innovate whether by patient and often expensive systematic research, or by extraordinary
insights, it makes no difference which." So he is presuming, in other words, that the person having ordinary skill in the art is somebody who falls beneath the skill level of patentees. This is, I think, a deeply flawed approach that cannot possibly be right. It seems inconsistent with the statutory language and it seems to be either circular or a downward spiral, more likely a downward spiral because what happens is, if you exclude patentees in determining what is the level of ordinary skill, then you are constantly looking below that level to figure out what ordinary skill is, but then the top of that range, presumably, is patentable, right? And so then you drop the level down further. You exclude the most innovative of the plotters and, then, because they become patentees, so we have kind of a race to the bottom. It sort of inverts the relationship between the person having ordinary skill in the art and the standard of patentability. So rather than PHOSITA setting the standard of patentability, we have the standard of patentability setting a ceiling on the skill level that we are willing to ascribe to PHOSITA. It is just completely inverted. So that is one, I think, fundamental problem is that, by presuming that PHOSITA has no capacity to innovate, we have made anything that is different from the prior art appear obvious. Second
move, I think, that has accelerated the marginalization of PHOSITA has been the Federal Circuit taking a strong position that the determination of non-obviousness, that the ultimate determination of non-obviousness is a question of law subject to plenary review, rather than a question of fact. And, of course, it is a mixed question of law and fact. The standard itself is a legal question, but the application of that standard to the facts of particular cases is something that involves - it is essentially a case specific factual determination. They do not see it that way. But if it were seen as a factual determination, then you could consult some person out in the field there to figure out what it means. If it is a question of law, then the evaluator’s judgment does not matter and, in fact, PHOSITA is incapable of determining questions of law. PHOSITA has no skill in the art of law.

Another move has been the elevation of evidence of secondary considerations or objective evidence that the Federal Circuit calls it, evidence of how the invention was received in the marketplace as bearing on the question of obviousness. If you read the statutory language, it talks only about the technological evaluation of the evidence from the perspective of technological workers of ordinary skill. The so-called
secondary evidence, or objective evidence, is all about how customers receive the invention, how it was received in the marketplace, which, again, makes the perspective of customers more relevant than the perspective of technologists.

Another move has been the — and all of these were outlined again yesterday, I feel like I can refer to them in summary fashion — the suggestion test for combining the disclosures in references. If we go back — how old is Winslow Tableau? If we go back something like 30 years — '63 — 40 years, 41 years. We pictured the person having ordinary skill in the arts sitting at his bench surrounded by prior art references, able to cull together these prior art references with ease in order to innovate. Today, the Federal Circuit insists that there be some sort of explicit showing of motivating suggestion to make the combination. They have retreated somewhat recently, say, allowing combination of references where the nature of the problem seems to call for it. They seem to be retreating somewhat from what for a time seemed to be an ever-accelerating trend towards focus on the written record of prior art in determinations of non-obviousness. But, still, the focus is primarily on the disclosures of the prior art, detailed reasoning, and away from the judgment of PHOSITA. And I think this
focus on prior art obscures an important dimension that
PHOSITA brings to bear upon technological problems, which
is tacit knowledge, judgments, insights, the sort of
thing that is not articulated in prior art references,
things like a sense of whether the equipment is working
properly, for example, that somebody who is working in a
field would have an intuitive feeling for, but you are
not going to find that by looking in the text of prior
art references. So how to get this tacit knowledge of
ordinary practitioners into the system of evaluating
claimed inventions is a problem. We have examiners who
are skilled, well-trained people, and that is one
important source of information and it is a good reason
for the Federal Circuit to defer, in my view, to the
decisions made in the PTO about obviousness, much more so
than they have done. But the examiners are not current
practitioners; they are, at best, former practitioners
whose tacit knowledge is likely to be dated and
atrophying. Litigation experts in the particular patents
that matter most, who argue about the validity of a
patent, are another source of input, but they are
adversaries, hired guns. There is too much at stake by
that point. It is not the sort of process that is likely
to yield dispassionate technical appraisal of how an
invention looks to real practicing technologists. So it
would be better if we could figure out ways to allow the PTO to consult with outside technological practitioners in making determinations of obviousness, that would allow them to document obviousness in circumstances where the written record of prior art is an inadequate foil for making that judgment. And there are certain circumstances where there is particularly likely to be a problem, like with the Patent System and into a technology that previously was outside the Patent System, like business methods, for example, where the written record of prior art is a very inadequate source of guidance as to what would have been obvious. Now, there are some difficulties in trying to figure out how to do this. Any agency that makes technological determinations faces this problem and most of them have some sort of mechanism for consulting the views of outside technologists, they will have scientific advisory boards, they will have peer review panels, they will have something in place that will allow them to do that. There are some challenges to bringing those kinds of mechanisms to bear within the PTO.

First of all, there is the extraordinarily broad range of technologies that the PTO addresses. You cannot really have a standing scientific advisory board that would advise PTO across the broad range of...
inventions that come before it. The PTO makes many small
decisions, such as Mark pointed – was made so well by
Mark Lemley and his “Rationale Ignorance at the Patent
Office.” The PTO makes many decisions, most of which are
of no consequence to anybody whatsoever, and occasionally
they make a really important decision. It is very
difficult to expend a lot of resources in getting all of
those determinations right up front, so you do not want
to have a really high cost system. If you get compared
to FDA or EPA, they make a lot of focused decisions where
there is a lot at stake, that is an easier context for
bringing in this outside expertise.

Confidentiality is another issue that would
stand as an obstacle. We have a statutory requirement of
confidentiality for pending patent applications, even
with 18-month publication you can opt out of that system
if you are not applying outside the U.S., and so that
would be something that would need to be addressed.
Conflict of interest is obviously a serious problem. If
you bring ordinary technology – ordinary practitioners
the relevant technology in an area where you are making
decisions in industrial technology, those people may
often be working for competitors of the patent applicant
and have a material conflict of interest in the judgment.
Some of these issues also plague journal peer review or
grant peer review, and I think there are ways of
addressing them and managing them. Okay.

MS. DREYFUSS: I just passed Becky something
that said “Stop.” She is so good. Alright, well, we
want to thank Pam and Mark and the Berkeley Center for
allowing me to come here. I was a participant in a very
small way in the FTC Study and on the NAS Committee, and
it is nice to have an opportunity to get some things off
my chest. The first thing I wanted to talk about was
confusion, as was talked about at this panel, you see
there are really three issues on obviousness, and unless
you disaggregate them, people wind up talking past each
other. One issue is the way the PTO is implementing the
standard, and people talk about how, you know, the
teacher is doing a great job, the examiners are really
dedicated, well, you know, that is terrific and it could
be true, but if they are being told the wrong thing to
do, then their output is not going to be great. The
second thing is about the way the court is interpreting
the standard, and what we heard on that was, “Well, you
know, the Federal Circuit is still citing Graham against
John Deere, what could be wrong?” Well, you know, is
citing John Deere a great sign? It is close to half a
century old, too, that case, and if it lays out a rule
and a methodology that are not suited to modern research,
then I it is not going to work out very well. Third, people talk about the standard itself and that is really quite a different issue from the other two. So all three issues, they need to be discussed separately.

Let me start with the PTO. I am an academic, I am not the best person to evaluate its current performance, but I will start with the assumption that it is doing the best job under the circumstances, but that is a big qualifier. And one issue is funding, and I take Mark’s point, rationale ignorance, as well, that there are diminishing returns to increasing funding. Nonetheless, I suspect that more funds would help. But, as important, there is a question about the source of the funds and this notion of user supported PTO. The conflict you hear is about whether some funds should be diverted. I think that is a total red herring. It seems to me the rhetoric of user support is fine when you are talking about Yosemite, and when you are thinking about, you know, public parks. And if you want, you can think about examiners as a core of park engineers because – or park rangers, rather – because they are protecting the public domain, but the analogy breaks down when you consider the users. At Yosemite, it is the folks who enjoy the public land, but at the PTO, the users are the privatizors, the patent applicants. And I would like to
see this idea of user support dropped, in part because it does not necessarily measure the amount of money that would be rational to spend on examination, but mainly because the rhetoric fuels this notion that the PTO is there for the applicants and not for the public. And it is also symptomatic of a bigger problem. Although park rangers actually do see loggers from time to time, examiners do not often see the people whose interest they are protecting. And in that connection, I would like to point out some side benefits of the opposition approach. That is going to be talked about on a separate panel, and the really key points, I am sure, will be touched upon there, but there are a couple of side benefits that are worth considering. The people who are arguing for the public domain, they are not often seen in current practice, as I said. And it would expose the Office to the effect of its decisions on the public. It would also do something else, and that is it would create a career ladder that might help retain examiners who would otherwise go off to practice, and there might even be a ladder that would lead to a Federal Circuit appointment, and that would bring to the Federal Circuit the PTO’s perspective on what its decisions do. And I think that would be good too.

That brings me to my next concern, and that is
the Federal Circuit and how it interprets the standard of
obviousness. Now, I remember the days of Monday morning
quarter backing, when the invention was used as a road
map for anticipatory prior art, and in that context, I
can see why the court did much of what it did. Thomas
Edison’s paper showed that inventiveness can be about
combining known art, and so requiring the examiner to
articulate why a person of ordinary skill would think of
combining is actually a good thing. As sciences mature,
the roots to making certain discoveries become known, but
sometimes without making it actually easier to accomplish
that result. And so the obvious to try doctrine is
important because it focuses the decision maker on how
many alternatives the inventor faces and his actual
chances of success. Unlike my colleagues, including the
one to my right here, I do see a potential for secondary
considerations. If they were seriously combined with a
nexus requirement, I think they would help focus the
Judge on whether the inventor was unique among folks in
his field. But I, too, see reason for concern - the
tacit knowledge problem Becky just talked about, the
obvious to try doctrine, it is fine to think about the
number of alternatives, but when deciding if a number is
a big number or a small number, the role that
instrumentation and automatic machinery now plays in
research really needs to be considered, and you do not see that very much in the cases. And I also have to agree with Becky that in many fields, the level of skill in the art is not only not right, but not much thought about. Perhaps we need a different perspective on collaborative work. Some people have suggested the PHOSITA, the team having ordinary skill in the art, and we need factor in work that is done by instrumentation, as I said. The court is still using the standards of In Re Bell and In Re Devel cases that were decided – work that was done decades ago, and John Duffey has alerted me to a recent case on which the court introduced the concept of nascent technology where a person of ordinary skill in the art has little or no knowledge. That is Chiron against Genentech. If nothing else, that is likely to breed a lot of litigation on what nascent is. So there is important work to be done in implementation. And I like Becky’s idea of using experts to flesh out some of this, it is certainly an intriguing idea and well worth considering, but I do have some skepticism. First, who will these outsiders be? I have a hard time getting my head around the idea of the expert on what is ordinary. We could choose ordinary people in the art, but how are we going to choose them, and once they are on a panel of expert people, are they going to continue to
think that they are so ordinary? I think about my colleagues and the elitist way in which they talk about people at other law schools, endocrinologists, what do they know? And I have a concern that this expert panel might drive down this standard of what is considered ordinary, rather than driving it up. Also some process questions on how will these experts be utilized? Do you have a standing panel of people? If people get called on a lot of times, I think people tend to find it difficult to serve under those circumstances. If it is an ad hoc committee and one person serves only once, then there is going to be learning curve issue, much like the one that the PTO faces in training its examiners. I am especially concerned because this approach has been tried and found wanting in other adjudicatory contexts. For example, the FDA has tried it on Boards of Safety and they did one on the safety of Aspartame, the sweetener and, in somebody else’s words, I cannot remember who, it was a pig’s breakfast. It was hard to find people without any ties to corporations, many people said that picking the experts effectively picked the results, and scientists showed themselves to have a rather poor understanding of distinguishing between scientific questions and legal questions. Now, since the FDA tried that, there is an extensive literature now on court appointed experts and
how to choose them and how to train them, and maybe that
would actually be a useful place to start looking to
implement Becky’s suggestion if it was thought to be a
good idea. I also think that experts at other points
would be good – the NAS report talks about the need to
help alert the PTO to emerging technologies so they can
start gathering the right literature and staffing the
office correctly. Experts might be very helpful on that.
And I will talk in one more minute about some other areas
where experts might help. But what I suspect is that the
true problem actually lies elsewhere. To my mind, it is
no accident that the Federal Circuit does not update the
level of skill in the art. I think it is happy with a
low level of skill in the art because it likes the result
of its being low, which is to say, in fact, that it likes
narrow patents.

Remember, the PHOSITA standard applies not only
to obviousness, but the Chiron case I talked about was
about what the PHOSITA knows for purposes of enablement.
And the less the ordinary artisan knows, the less she is
enabled, and the narrower the claim. And I think that is
where the Federal Circuit is really going – to a system
of narrower claims. It is clear in other areas too, the
written description cases, their own opinions in Festo
and Hilton Davis betrayed a certain interest in having
very narrow claims. Unfortunately, the court has not actually explained why that is so, so it is hard to evaluate why they want to do that. In part, I suspect the court thinks that if a claim is narrow, it won’t be very dangerous, and that means that it won’t matter so much if it is not examined right, or the level of school and the art is not properly set. But I wonder if that is really true. I think the court may well be following itself. Narrow claims create lots of work for patent lawyers, but what that actually means is high transaction costs. Patent thickets are a problem that many people on this panel have written about, they create difficult entry barriers if you do not have a patent portfolio to trade when assertions are made, then you are in real trouble. The increased wear and tear on the Patent Office because they exacerbate whatever problems there are because people have to keep filing in order to protect their investment. So I think it is actually foolish to think that narrow patents are less dangerous. Of course, in part, the Federal Circuit may also believe that narrower patents correlate with better notice, but I am skeptical about that too. If you have notice, you need crisp edges to the claim, but what those crisp edges contain, whether it is broad or narrow, that is not so relevant to the question of notice.
Now, I highlight this issue not just to criticize the Federal Circuit on narrowness, but also to demonstrate another point about this concept of PHOSITA. When the Court sets the level of skill to accomplish a narrowing function, what it is doing is creating a construct, a social construct to achieve a particular goal. In this sense, PHOSITA is not a snapshot of reality, it is not meant to be a fact-based historical measure of inventiveness. As we see, it does not much mirror what we know about invention, or inventors, or artisans of ordinary skill in the art. It is a concept that is constructed so that the system does what the Court wants it to do. And if we think it is the wrong standard, it is not because we know of specific patents that should never have issued; rather, we think it is wrong for systemic reasons, because systematically we think there are too many patents, transaction costs are too high, etc. And so at the end of the day what we really need to think about is getting the system to operate in a way that we want it to. We need to think about obviousness for sure, but also the scope of claims that best serves industrial and creative needs, the distance between inventions on the innovation ladder. Should the boundary of one invention touch on the boundary of the next invention? Which is the way it
works right now. As we have it structured, PHOSITA is key to all of those concerns, but do we really want the same standard of PHOSITA for everything? Maybe we need different standards in there. What should the standard be for each thing for which PHOSITA is used. For that, a panel of experts could be useful, but I would not use them as retail adjudicators of particular cases, rather wholesale in helping us to think about all the roles, the non-obviousness and the knowledge of persons with ordinary skill in the art, play in creating the system we have, and in creating the system that our modern age and new technologies of research actually require.

MR. DICKINSON: Thank you very much. Let me join the others in certainly thanking Berkeley for hosting today. As some of you know, I am getting ready to move back to the East Coast, so I was packing up and, actually, movers are at my house today. I was packing up my office yesterday and I made sure that in the box that went directly to my office I put my Berkeley Law and Science Technology Journals there to make sure I had a good set of references. I also want to thank my – as was suggested I am going to go work for GE, and I want to thank Ron Myrick who is here today, who was my predecessor, for doing a great job there and leaving me with a great legacy to build on. I often get cast as the
pragmatist, I guess, as a former Commissioner of the Patent and Trademark Office in a lot of these panels. Maybe the reality check or the – certainly with panels with a lot of folks who are academics on it, bringing a different point of view. What is interesting I said to somebody else is that I end up sort of in the middle of the road broadly speaking. I go this afternoon, for example, to give a speech at the nano-biotech conference in the city, and their principle concern is the PTO is too tough on them, that they cannot get what they need out of it, and that they do not spend the resources they need. So there are interesting and robust debates about what the Patent System in particular means today and how we deal with it, and in the characterization of this form, reform it, which is also interesting because traditionally, I think, or at least the last couple major times we had patent reform in this country, starting with the '52 Act, and then the reforms in the 1980s around the CFC, and most recently in the American Inventors Protection Act, much of that reform was driven by the IP community, the insiders, if you will. And a lot of the discussion we are having here today, at the FTC, at the NAS, the IPO panel on Monday in Washington is coming from outsiders, are traditionally those who are outside the system, so it is a very interesting and I think
appropriate debate. But, again, I am the pragmatist. As we have sat here this hour, I am going to guess that the Patent and Trademark Office will have allowed 100 more patents. In the next hour they will allow another 100 patents, and after that they will allow another 100 patents. It is not a stream, it is a torrent, and it keeps coming very rapidly. So a lot of what we have to talk about and remember as we talk about the reforms or the issues around obviousness or anything else, are the fact that we are dealing with a very big process which is hard to change, is susceptible to it, but that it has a lot of aspects to it and a lot of nuance in it, and that small changes can make big effects, have big effects, and that a lot of unintended consequences certainly and clearly can and sometimes does apply to the PTO.

Let me talk about – one of the things I have talked about the FTC report a lot and testified before it several times, and also was a participant in the NAS report at certain places. One of the premises about the FTC report is that there are questionable patents out there, and that is actually the phrase that gets used. I think that probably everyone would agree that there are patents that have issued that should not have for one reason or another, or that raised a concern of one sort of another. But the challenge, I think, is that we have
not come to the place yet where we have really defined what we mean here by questionable patents. And in so doing, I would suggest we are not quite at the place yet where we have the evidentiary back-up to justify, certainly politically justify, frankly, going to the policy makers and getting the kind of changes that are suggested. And I think we need to continue to work there. When we say questionable patents, do we mean the stick patent that issued, or waiting-in-line-for-the-toilet-on-the-airplane patent that issued, the ones which people traditionally take a poke at because they sound odd or ridiculous, or why did somebody spend the $3,000 to get it in the first place? Or do we mean patents like genomic patents which are getting in the way - perceived to be getting in the way of research or a business method patent which maybe just offends somebody’s sense of what ought to be patentable in the first place. It is not quite - I am not quite sure. The critique comes from a lot of different aspects and a lot of different places, and so I think we need to be a little more clear about what we mean by questionable patents and why we should reform a system in view of them. How many are there? One of the issues we will get into later today is lowering the standard of review from clear and convincing to preponderance of the evidence. Well, you lower the
standard of review for questionable patents, you lower it
for all patents, and you make patent portfolios and
individual patents less valuable, and when you do that,
you start to cut into I think significantly the
intellectual base of the – or the intellectual capital of
the country, not to say it is not justified, but why are
we doing it and how many are we doing it for? I still
think we need to take some care to define.

Also, because, don’t forget, the statute
basically allows the applicant to get a patent unless it
is anticipated or obvious, and that is just – you could
argue that maybe it should be the other way around, and
people do, but that is the current statutory standard.
So I think we need, with all due respect to the FTC and
to the NAS, I think we need more evidence of this
lowering of obviousness that is perceived to be out
there. Do I believe it is there viscerally? I think I
could make a case in some areas that that is the case.
Do I believe that uniformly that is happening and
happening in such a way as to warrant wholesale changes?
I think that is a much tougher case to make. I think the
evidence for the lowered standard of obviousness is thin
at this point. And if we are going to proceed in some of
these ways, I think we have to take a lot more time and
care and put some more energy into developing it. And we
have got great economists who, I think, and great patent folks, who are in a position to develop that. For example, the FTC report was almost all based on anecdotal evidence. There was very little empirical evidence adduced at all. The NAS did a few more studies on many topics, and I think it backs that up a little bit more.

With regard to the U.S. Patent and Trademark Office, they have traditionally been more conservative, frankly, than the courts, traditionally. They have proceeded very cautiously in terms of moving into new subject matter traditionally, and they have been very rigorous, I think, in terms of how they tend to implement the obviousness standard, at least initially. Because I say, one of the biggest complaints I often have to deal with in my current practice is the complaint that folks have that the office will not allow their case, despite the fact they believe it is clearly allowable, and they cite – they write extensive briefs to back that up. One of the interesting things about – I think about the NAS study – is that it is going to use at least two examples, genomics and business method patents, which frankly is about three or four percent of the number of patents issued each year, to drive the change in obviousness. Now whether that should drive that change at 3 or 4 percent, should drive that change or not, we can argue as
well. But business method patents have now, because of
the second level review, only 17 percent of them have
been getting allowed – only 17 percent of business method
patents in Class 705, on average, get allowed. The
bigger complaint from the folks who want those patents
is that they are not getting them out of the office, not
that too obvious business method patents are issuing. So
I think we have to examine that a little more closely.
Some issues – I think there are some areas where we ought
to look. I proposed two rules that affect this area when
I was in the office, one is what is called Rule 105, that
one made it, and that allows the examiner to make an
inquiry of priority of the applicant on their own
initiative. It is relatively under utilized, as I
understand at this point. I think it could certainly
stand to be utilized more. It was widely opposed by the
Intellectual Property Community, by the patent bar, in
particular. But we held the line on that one and that
one became implemented.

I also proposed another rule. It would allow
examiners to apply general knowledge that they had. This
is a topic of several speakers, it is a topic of general
discussion, and I would disagree with Professor Eisenberg
to a degree. I think examiners are not these stale
Ivory Tower folks who are not keeping up with the art at
all; on the contrary, they are on the cutting edge of the art all the time. It is coming across their desk in a steady stream and they deal with the state of the art at this level, of the current state of the art at a very high level. So I think there are opportunities for them to apply general knowledge if they are aware that they are able to now. The CFC really does not let them do that, they have gone so far – I respect and admire Judge Newman enormously, but she wrote an opinion last year and went so far as to say – or two years ago – that examiners could not even apply common sense to the examination of patent applications, and I think that is really pushing the line a little far. But, having said that, that rule that I proposed was shot down. It was so widely opposed that we had to back off of that rule. With all due respect to the panelists, I do not remember any of them sending a letter and saying that rule was a good idea.

The FTC dealt with obviousness in two particular ways, commercial success and motivation to combine. Commercial success, I take the point of the study, I do, Graham says that you can use commercial success as support for non-obviousness, and the report suggests that we may be getting undue balance to that, I think is the phrase. That may be happening in the courts, it certainly does not happen in the office,
frankly, because people do not have a lot of commercial success to bring to the PTO at the time the application is pending, and it is very difficult to get that kind of evidence introduced, so I do not - while I take the point that the FTC makes, I do not think it is that big a deal, frankly, in commercial success, though it is not a bad issue to take a look at.

The motivation to combine is a tougher one principally because the CFC has continued to push the envelope, I think, on that issue. However, one reason why they do it is that it is awful easy. It is awful easy to apply hindsight once you have got references in front of you. And to have Reference A which has got Element A, B, C, D, which has three more elements, and D has three more elements, and to say, "Well, look, anybody could have put those three things together, they are in front of me right now, I see it." That kind of hindsight is easy, and perhaps too easy, and so what I think the CFC is saying is you need to come up with even more rationale for combining those. Could we change that? Could we tweak that a little bit? Sure, we could. But I am, as most of you know that have heard me speak, I am more of a calibrator than a wholesale change guy, and so I think that is a calibration. What the real issue I think - well, let me talk to the peer review thing real
quickly. I think that Professor Dreyfuss articulated a
number of the problems with it. A peer review panel for
those last 100 patents that we just have issued, or the
one patent that issued in the last minute I have got here
is a big challenge. I get it if you are going to have
peer review panels for genomics, or you are going to have
them for very sophisticated technologies. Where is the
peer review panel for that largest of classifications in
the PTO – golf equipment? Where is the peer review panel
for boxes? Where is the peer review panel for what we
used to euphemistically call “vermin control,” or
mousetraps? They are out there, but getting those folks
together for a peer review process is a pretty daunting
task. We do do parts of those things. The Office,
rather, does parts of those things now. They have for
very advanced technologies biotech, business methods, now
nanotech. They have quarterly customer partnerships
where anybody who wants to can come in and meet with the
examiners as a group, they can meet with the senior
leadership, there are structured learning that go on,
there are seminars that go on. They are very valuable.

Also, when a new technology comes along, to the
extent they can, the Office – I did it with business
methods – tries to draw on those communities to help
teach the Office. We brought in, for example on business
methods, the Securities Industry Association, the Check Cashing Association, the American Banking Association, a number of those organizations to train examiners both on the art itself and also where to find the art, and I think that is a pretty reasonable mechanism to work on. So where does that lead us? The PTO needs more money, frankly, the examiners need more time, and that is a function of money, each hour of additional time across the PTO costs between $15 and $18 million, so they need more money. They need greater access to prior art, and they need better search tools - they have great search tools, and they need even better search tools. Thanks very much.

MR. BARTON: Let me try to concentrate on a particular example. I think I am pretty much known as a non-obviousness hawk, but I am going to try to give a more balanced picture if I can and describe a little bit of what is at stake and sort of the philosophical differences on where you go with different non-obviousness standards. And I am going to concentrate on one of the principles of the CAFC, the principle of obvious to try, and I must say I was very helped in my study of this by Brad Wah (phonetic) who is sitting right there in the third row, who did a lot of work for me in this area while he was a student at Stanford.
Obviousness to try at one point was a basis for saying "You can’t get a patent." In other words, this patent results from a research effort that you suspect is going to lead to an answer to a problem, you undertake the research effort, get the answer, and since it was obvious to try this particular research effort, you should not get a patent. Judge Rich came along and stated as follows, "Slight reflection suggests, we think, that there is usually an element of obviousness to try in any research endeavor, that it is not undertaken with complete blindness, but rather with some semblance of a chance at success, and that patentability determinations based on that as the test would not only be contrary to statute, but result in a marked deterioration of the entire Patent System as an incentive to invest in those efforts and attempts, which go by the name of research."

In other words, we want people to do research even though it is obvious to try the research and, to encourage them to do the research, we therefore grant a patent. Now, interpreting the CAFC’s obviousness to try cases is a nightmare, and they certainly have ended up somewhere in between those two extremes, and I think sort of a basic situation of where they are is you can get the patent in spite of the fact there was obvious to try in their strategy, depending on how likely success looked when you
undertook what was going to be obvious to try. Okay, now let me apply that to a particular example, the genomic patents. At one time, of course, it was genuinely very difficult to get the sequence of a gene. Today, we can get the sequence of a gene from a machine. We can get an insight like whether or not a particular mutation is associated with a particular disease and know what I am thinking, now particularly if things are like the diagnostic patent such as the breast cancer patents which have been issued and have been so controversial in many circles from the medical perspective. You know how to do that now. You know, you know now how to run all the things on a chip and run a lot of tests of a lot of people and find out with pretty high confidence, you know, if you put enough money into it, you can design a project to determine what genetic sources are associated with a particular disease. Similarly, and what I put together with the genomic Patent System, and that is just my perspective, it is now pretty obvious — again, sometimes very difficult — but pretty obvious how to get the precise structure of a biological crystal, a biological protein. And yet I can now get a patent on the protein coordinates, I can now get a patent on the use of the knowledge that gene sequence is associated with disease Y; I can now get a patent on a gene itself,
I mean, subject to – I mean, obviously you do not
infringe the patent, but the separated gene, design of
pharmaceuticals based on the gene, and so forth.

Alright, so then in some sense obviousness to try
precisely affects the patentability of these categories
of information. And I do want to put it as information
because we are really patenting information in these
contexts, and there is an obvious question whether or not
this should be patentable subject matter – that is
another set of issues which is related to genomic
patents, but certainly now that we know how to get these
sequences by an automatic mechanical process – I am
overstating a little bit, of course – are they not
obvious to try? Alright, and the CAFC has, in effect,
told us no. It is obvious to try a particular research
direction, but knowing how to do the research direction
does not tell you the shape of the protein, does not tell
you the sequence of the gene, therefore it is not obvious
what the result of that research project is going to be.

Alright, so that this is a case in which the obviousness
to try principal is one which the CAFC tells us to use,
and you can see Judge Rich is looking for it, it is one
of the reasons why we issue patents which, in some
people’s minds, raise some questions.

Now, I promised to give you a balanced
perspective and, in fact, currently, because I read so
much about this set of patents, and I have written much
about it, I also want to understand the industry, so I am
trying to investigate the diagnostic genomic industry,
understand better how it works, and understand better the
role of patents in that industry. And it is becoming
abundantly clear to me that a large amount of money is
being invested as a result of the fact – almost certainly
as a result of the fact – that patents are available. In
other words, the Patent System is in this context serving
its role of providing an incentive to investment. Just
as Judge Rich suggested, the Patent System is serving its
task as an incentive to carry out research – even if you
know the research is going to automatically succeed – so
that we are then faced, and this is sort of the dilemma I
want to put you with, if we accept Judge Rich’s
perspective with the obviousness to try arrangement, then
we are going in the genomic context to say, “We grant
these patents because there is a genuine incentive factor
there, and it is genuinely working.” And we face the
cost, the cost being it is very hard for Affymetrix to
put together a chip which scans for all the different
genomic mutations which a baby might have because they
have to go back and get a license from a zillion
different companies in order to produce that chip.
Similarly, it is very hard for a pharmaceutical company to work with drugs against a protein crystal X, with in-cyclical kind of analysis of the technologies, because somebody has a patent on the use of those coordinates and theoretically the company could simply go out and measure them, so that we are indeed creating some incentives and we are also creating a set of complications. If I broaden that to industry, in general, what Judge Rich is saying is, “We want a system which rewards routine research and encourages routine research because it is good,” and he is absolutely right. But the counter argument is, “Don’t I want to preserve the monopoly, the Patent System, for those cases in which the research level is a little bit above sort of the normal level of research in the industry?” If I am going to reward sort of the normal process of industrial innovation, if I am going to reward that with patents, you know, sort of Model A to Model B, if I am going to do that, then I am going to increase the number of patents and I am going to create significant problems of having to negotiate cross-licenses and all that kind of stuff. So I want to suggest what the tensions are here. You know, my ultimate bias is pretty clear and my proposed, you know, to put my standard - but I want to make sure that you see both sides of it before I do that. You know, my bias
would be the CAFC is currently saying the standard is whether the invention would certainly have been made by a person of minimal skill in the art who was unable to integrate the different concepts present in the art, and I would like to turn that into “to grant a patent only if the invention is more substantial than that regularly made by a person of average skill in the art, being funded and supported in a way that is typical in the relevant industry.” And at least my proposal as to how to do that is a little bit different from Rochelle’s and Becky’s, but it is - you know, but I think that is one of the dimensions we need to be talking about because, there is no question, it is a hard standard to apply, it is a judgment standard in any call, and I think that has a strong tension, given the actual pressures present on the examiners of driving it down, particularly given what the CAFC is saying. But at least my proposal would be to try to include what the patent application - or maybe in some other context - some kind of indication of sort of the way routine innovation is going in this industry. How much do you change the technology from the pentium computer, from the pentium chip to the itanium chip? That is sort of the standard baseline. Does this go above that baseline or below? Now that is a judgment call, too. But I am wondering if there is a way to get
that kind of evidence into the process.

MR. MYERS: Ron?

MR. LAURIE: Thanks, Mark. I just wanted to say what a pleasure it is to be on this panel and part of this program. I just wanted to give you a little bit of disclosure on my particular perspective, which I think is different than anyone else up here, and that is that — I take great pleasure in telling people that I used to be a lawyer — I am now operating at the intersection of patents and capital formation in a firm that calls itself an IP Investment Bank, and I can tell you absolutely that patent quality is essential to ensure that financial markets make correct investment decisions in connection with technology. I see this every day. Any uncertainty about the value of a patent creates misallocation of resources in the financial community. I would like to make just introductory remarks on the “but for” test that is set forth in the report. I think the “but for” test is a useful contextual construct in many cases, and certainly reflects one of the key policies underlying the patent laws, and that is, of course, the policy of incentive by reward. If the incentive is not necessary to produce the invention and its commercialization, then there is no point in offering the reward. I think, however, there are two other policy bases for the patent
laws that the “but for” test does not address. One is
the public disclosure or dissemination of technology
policy. The “but for” test ignores the possibility that,
even though an invention would have been made and
commercialized, that in some cases it would have been
kept secret. And this, of course, affects a very
delicate balance between the patent laws and the trade
secret laws. Certainly many, in fact probably most,
inventions will be disclosed upon commercialization, but
there is a lot that will not, particularly in the
software area where past practice was to distribute under
confidentiality. The other policy that I do not think
“but for” adequately addresses is what I call the “forced
improvement policy.” That is the motivation to design
around existing patents and thereby advance the
technology in ways that would not have happened but for
that forced requirement to avoid doing what is claimed in
the patent. With regard to the issues of motivation and
commercial success, I absolutely agree with Todd that the
PTO has got it right, there is no lowering of the bar at
the PTO in terms of obviousness. The cases that I see
being examined, especially in software and business
method areas, are – if anything, the PTO is taking a very
tough position. And I would refer you not only to the
MPP which applies to all subject matter areas, but

For The Record, Inc.
Waldorf, Maryland
(301) 870-8025
particularly to the recently published examination guidelines on obviousness in connection with business method patents. There are, I think, 20 some examples—fairly detailed examples, of how tacit knowledge and nature of the problem to be solved, and mere conversion—mere automation of a manual process, and many many other things that are not explicitly taught in any of the references that are combined, how those are folded into the obviousness decision by the Patent Office. To the extent that the Federal Circuit does evidence a trend toward lowering the bar, I have read the cases, I think many of them can be explained on other grounds. I think there is an increasing emphasis on requiring the Patent Office to build a proper administrative record for judicial review, and therefore there is a great antipathy toward what the Federal Circuit calls “conclusory statements of the skill of the art.” I think all that means is that the examiners and the Board of Appeals members have to document the basis for their tacit knowledge, and not just cite it as something they know. I think that is an easy hurdle to get over; for example, in the Internet area, the tacit knowledge that one can perform many business methods that were previously done manually or in a face-to-face manner on the Internet, that is the kind of tacit knowledge that will not
ordinarily appear in the references because it is so
totally obvious – forget that word. But it is not a
problem because it is certainly easy to show with any
textbook or newspaper article that implementing physical
processes on the Internet is well within the tacit
knowledge and skill of the art. I also think that the
trend – and I will defer to my academic colleagues on the
extent to which there is a trend – but a lot of the trend
can be explained on the basis of the general concept of
what I would call the Federal Circuit’s diversity of
opinions. I think, on many issues, you can find opinions
all over the place, and I think the more recent case law,
the Ruiz/Chance case puts us back on the right road, at
least in connection with consideration of the effect of
nature of the problem on whether the solution is obvious.

Finally, on commercial success, just a quick
note, it seems to me commercial success comes up in two
different ways and they ought to be treated differently.
The first case is where commercial success is coupled
with long felt need. There is kind of a common sense
reaction that, if there is a long felt need for a
solution, and it is recognized that that solution will be
commercially successful – now, keep in mind, that is
commercial success measured prior to the invention – so
if there is a long felt need and a recognition that
satisfying the need will be commercially successful, I think it is common sense to say that the solution is not obvious because making money is something that everybody wants to do, and if the need is recognized, and the fact that the solution will be commercially rewarding is recognized, and the invention is not forthcoming, that is very strong evidence that it is not obvious. On the other hand, where it is not coupled with long felt need, but where commercial success is just a consequence of the invention, then I absolutely agree with the report that commercial success could be due to many other things than the invention, and it is entirely proper for the burden to shift to the patent owner to demonstrate clearly that the commercial success is tied to the patented invention - that is in court. Now, I have a little trouble applying that to the Patent Office and having examiners analyze submissions of commercial success. I mean, the introduction of business method patents caused quite a disruption and a lot of people were saying that now we have to get examiners with a background in computer science that had an MBA from Wharton in order to understand the significance of the business method; ditto in spades if the examiners have to start analyzing and rebutting economic evidence of commercial success. Thank you.
MR. LEMLEY: Let me ask a couple of questions directed to the specific proposals that are before us today and then we will open it up to the floor for questions. The first has to do with the issue of combining references, right? And there has been some discussion of what Ron, I think, quite properly points out as the meandering Federal Circuit case law on the question of whether you must have an actual suggestion in a reference in order to combine it with another reference, or whether you can find motivation in some other source. And I guess the question for the panel—Ron talked a little bit about this already—what is right? Is the FTC right here? I mean, are we to be finding motivations to combine references outside the documentary corners of the reference themselves? And, if so, where is it we are going to find it and how? Right? Is it testimony? Is it some base of examiner knowledge?

MS. EISENBERG: This whole approach seems to me to be fiction upon fiction. You know, we start with the fiction that the person having ordinary skill in the art has access to every single reference, you know, sort of the Winslow Tableau fiction. And then we presume that the person does not know how to combine references unless there is some suggestion or motivation to do that.

Another point of inconsistency in the Federal Circuit’s
decisions is, is the issue whether we are motivated to combine references, which is this highly artificial question, as if, you know, somebody trying to solve a technical problem goes to the library and tries to identify references that will help them. Or is the motivation to combine elements? It seems the combining of elements seems like a much more logical way to proceed if the focus is on what can we expect of ordinary artisans in the fullness of time, with or without patent protection. On the other hand, if your focus is more on the prior art references themselves, then you start thinking about whether there is a reference to combine. Ron had an interesting point, I think, about the value of disclosure and it may be that when the prior art references themselves are weak, or when the written record of the state-of-the-art is weak, then there is a stronger interest in using patents to bring about greater disclosure, even though maybe it is not bringing about any greater innovation. So it might look different from that perspective.

MR. LAURIE: Just a quick comment. I absolutely agree with Becky because the inquiry is the state of the prior art. And to limit the prior art to what Section 102 refers to as printer publications is absolutely unjustified. Section 102a also includes “known or used
by others,” “others” meaning the public. Well, that is
in many cases the glue that holds the references
together, and to ignore that is to ignore the most
valuable method for combining references.

MS. DREYFUSS: Yeah, I mean, I think my point is
very similar to that one. We over-treat inventions as if
they are true monopolies, and Judge Rich has often said
they are not true monopolies for purposes of thinking
about what the patentee can or cannot do with this
monopoly, but they are also not true monopolies in the
sense that there are not other inventions out there that
are like that or similar. And I think if you look within
a field, you see the way that people within the field
think, and by taking an invention within sort of the
entire scope of inventions that are similar and thinking
about why is it that people in the field look at – how do
they think about the direction in which they are doing
research, you can start seeing trends in the way that
people in chemistry think, or trends in the way that
people in mechanics think. And I think all of that
helps. It does not have to be written down. You can see
the trends in the way that people think.

MR. LEMLEY: Let me follow-up on this if I
may. So if we want to look at the sort of general way in
which people think in the field, right, how they might
think about combining elements, right? And if we want to look, as Ron points out, not just at the printed publications but what is going on in the business, right, the Section 102a art the public uses, and all of that stuff, and then we also talked a little bit about secondary considerations, right, another element of the FTC report, we want to look at economic evidence, commercial indicators or success, what were people doing, how does the industry react to the invention, right? All of these are relevant questions for obviousness. They also seem questions that the PTO is going to be essentially unable to deal with, right? I mean, not only given the resource constraints, but also given the way in which we structure the inquiry, right? The PTO does not have the ability to go out and talk to everybody in the industry, right, to go out and collect evidence of public use, to go out and collect evidence – economic evidence – of commercial success. Are we necessarily by focusing the obviousness inquiry on this broader question, are we necessarily relegating it to the courts and saying the PTO is just not going to be able to do some of the things we want to do in the obviousness inquiry?

MS. DREYFUSS: I think the examiner is doing a lot of that stuff. I mean, that is just Todd’s point. The examiners are sitting there and they are seeing
everything that is in their piece of the world, and so
they are seeing each and every inventor as he comes along
- or applicant - telling the PTO what it is that they are
doing. I think the examiners actually do get a very good
sense of what it is that is in the art. And I think
Becky’s point that we should be deferring more to the
examiners, that, to me, has a lot of resonance because
that, in fact, that part they do see. They are seeing
the way that people think about pushing the frontier
slightly forward, making incremental changes. And, you
know, not to push the NAS Committee Report, but I think
the opposition procedure is also a piece of that because
it brings people from the outside in in the cases in
which the examiner has not seen stuff that is in public
knowledge, but not in print.

MR. DICKINSON: Mark, I have a one word answer
to your question - Google. You were listening to the NPR
series on search engines this week. But let me elaborate
a little more on that, and not to put too fine a point on
it, because it obviously can still be improved, but the
PTO has access to some of the world’s most extraordinary
databases, and has very facile tools for accessing those
databases. They also have print libraries with research
librarians whose whole job is to try to help them dig out
that piece of priority. Do they not always get it?
Absolutely. Are there opportunities for improvement? Always. But to premise the whole argument on the fact that the PTO’s examiners are just sort of sitting around, poking around, and doing a Google search is just not the way it works. We also have another opportunity that gets overlooked, it is another rule we put in place called Rule 99 because we have publication now at 18 months and I think what most people would support what the FTC Report does making publication universal, you have got a political challenge there with small inventors, but other than that, if you believe that there is prior art that the Office is not considering, you have an opportunity under Rule 99 to send it in. It is vastly under-utilized, still. That may be partly structural, but I think part of my job and others’ job is to make people aware that that is out there.

MR. MYERS: John.

MR. BARTON: I just want to add that I view those secondary considerations as mainly applying not for the Patent Office, but when you review the patent later in some kind of litigation. In some sense, to the extent I consider secondary considerations as success in the market, it means I do not know whether the invention was non-obvious until ten years after the patent was issued, and I am in litigation about it.
MR. LEMLEY: Let me push a little bit on this, right, and then we will open it up to questions from the floor. If the PTO has got all these great databases, right, and they have got this tacit knowledge that comes from looking at all the patented inventions, and the argument here seems – the consensus here seems to be that we owe greater deference to the examiners – why is it that all the empirical evidence seems to suggest they are not doing such a hot job of finding the right references? Why is it that the European and Japanese Patent Offices regularly find prior art references that the U.S. Patent Office misses? But why is it that the courts, when you go into litigation, you always end up litigating prior art references that the Patent Office did not find? It seems to me there is a felt sense, right, that the PTO is not, in fact, finding all the most relevant prior art.

MR. DICKINSON: Well, that is not a bad point with regard to litigation. Do not forget, very few patents actually get litigated, and when they get litigated, enormous resources are brought to bear. I am not a litigator, but my firm, for example, is primarily the litigators inside the group, and they just wheel out the big big guns. Now, whether that is good thing or bad thing, well, we can debate that, and there are a lot of aspects to that. But when you start to apply $10, $15,
$20 million to try to turn up that one piece of invalidating prior art, yeah, that is a little different than the $5,000 search you did or the 18 hours of searching that is available to the Office. But that is the flex in the system. Can we change that a little bit? Yeah, we could change it a little bit, but I think to decry the whole system because the examiner does not have $20 million worth of capability to find that one piece of prior art hidden in a library in Russia somewhere, I do not know.

MR. MYERS: Joe. Please identify yourselves when you speak.

PROFESSOR FARRELL: Joe Farrell from U.C. Berkeley. Just to follow-up a little bit on that change, I thought Mark’s question was not any blame to the examiner for not finding it, but should we take the view that the examiners do in absolute terms an excellent job?

MS. DREYFUSS: But, you know, well, there are really different questions packed into this, right? One is the question of finding the prior art, but the question we were talking about before is that question of combining it, so you might want to take the view that examiners are really good at thinking about that because of the fact that they have seen it a lot, see it continuously, see trends within what is going on, and are
able to abstract from those trends. That is a different question from whether each piece of prior art that is out there can be seen. So I think you have to –

MR. DICKINSON: We have talked about the issue of tacit knowledge, too, and I said it in those – that I think we need to give the examiners more leeway to apply tacit knowledge and what they know to be out there. And we can do that, I think, through rule-making, or we can do it –

MS. DREYFUSS: What they know to be known.

MR. DICKINSON: I think we have much more play in that regard than we should have because, again, the examiners – I came into the Office as a knowledgeable guy, but not really knowing it as thoroughly as being in it – I was amazed at the level of commitment and knowledge that the average examiner tends to have. Are there exceptions? Sure, but it is really a very high level of commitment and knowledge. It was sort of surprising to me. There are over 400 PhD scientists at the Patent and Trademark Offices. It is more than at NIST (phonetic), it is roughly how many are in NIH, I mean, that is a lot of brain power. And that is, you know, not a lot of engineers get – those are mostly in genomics and in biotech areas, for example.

MS. DREYFUSS: And there is also a difference,
I mean, a third issue is the application of law to the facts that they know, and that is another question where, whether or not you give as much deference to the examiners - I just do not know the answer to that question about how much examiners - the general examiner knows about law and knows about the application of law to facts. But each of those are different issues --

MR. DICKINSON: I was very pleased to put back in full scholarships to law school for any examiner who wanted to go, it has been cut out in the latest couple of budgets, I am disappointed in that. I think we need to get more legal training. Only four of the 26 Group Directors are lawyers now in the PTO, I believe that is scandalous. I think we need to have much more legal training, as well.

MR. MYERS: Identify yourself, please.

MS. : [From Audience - off mike]

MR. LEMLEY: For benefit of the people in the back who are having trouble hearing this, the question is why is it that the EPO regularly finds references that the USPTO --

MR. DICKINSON: How much does Chevron and Texaco - and I used to work at Chevron and Texaco - how much do they pay at the EPO to get a search and examination as opposed to the United States? They pay
roughly three times as much. That is not to say --

believe me, I agree with the general concept, there are
many times when it is perceived that the EPO, you can get
a higher quality search, in certain technical areas, in
particular. There is now, I think, given some challenges
they are facing in terms of resourcing and staffing and
other things, they have had a freeze on hiring for a long
time, for example, I think that that may be a little more
differentiateable than it may be currently, but I think
traditionally the belief was you would get a better
search, principally because they have more money – which
leads to more time.

MR. MYERS: Yes, sir.

MR. : [Audience – off mike]

MR. BARTON: Obviously, we are skating into

the territory of the panel which will discuss the

presumption of validity. The question is to what extent

must the court accept that presumption, to what extent

should we accept the presumption that the examiner did

not make any mistake, and then the related question, to

what extent should we be installing procedures that are

somewhere in between the two, that are designed to test

the validity of patents, or designed to provide, you

know, as in the European Office procedure, some

opportunity for the public to bring additional prior art

For The Record, Inc.
Waldorf, Maryland
(301) 870-8025
and, additionally, counter-arguments against the patent because, after all, the patent is necessarily granted, even in Europe, in an ex parte, you know, proceeding that has to be a fairly low cost, or it would just be insane.

MR. LAURIE: The fact that the litigation is so many orders of magnitude more expensive than the prosecution, to me, is the best reason why the prosecution ought to be as absolutely good as it possibly can be in order to avoid tremendous misallocation of resources.

MR. LEMLEY: Alright, please join me in thanking the panel. [Applause]

PROFESSOR MERGES: We are going to start out with Professor Bronwyn Hall from our own Economics Department here at U.C. Berkeley, and she is going to be joined with her co-author on some very interesting research, Dietmar Harhoff from the University of Munich. So in all the discussion of European oppositions that is thrown back and forth in the U.S. re-examination reform kind of movement, Dietmar has really got the goods, he has got the real data on European oppositions and what they are all about. And following them, we are going to have Bob Blackburn from Chiron Corporation, who is a veteran of many of the biotechnology wars and he has personal experience with the European oppositions and
lots of detailed experience with the U.S. Patent System
as well, he is the Chief IP Counsel at Chiron, and we are
really pleased to have him here. After that will be Joe
Farrell, also from our Economics Department, who is
presenting a paper that he and I are working on. I may
have a few words to say on that in the Question and
Answer period, but Joe is mostly going to handle it. Joe
is also from the Competition Policy Center and they are a
co-sponsor of today’s conference. After that will be
Doug Norman from Eli Lilly, who also has extensive
personal experience with the U.S. Patent System,
obviously from the pharmaceutical and medical services
and processes industry. And batting clean-up is Steve
Kunin from the U.S. Patent and Trademark Office.

And so, in all the discussion of sort of what
the Patent Office is doing, and how examiners are really
sort of performing, Steve has got the day to day
experience on that. So this is really a terrific panel
and I am now going to do, I think, what is best advised
which is get out of the way and let them go. So we start
with Dietmar. Thank you. We will start with Bronwyn and
then Dietmar.

MS. HALL: Okay, well, the bad news is that I
do not have much of a voice and the good news is I do not
have much of a voice – given the number of panelists! So
I will try to be brief which is going to be a struggle, and serve as a warm-up act for my colleague, Dietmar Harhoff, who has the slides.

There were two things, having listened to the previous panel, one of which came up in the previous panel, that I wanted to emphasize just out of my experience with looking at patents. And the number one point to always keep in the back of your head is that patents are extremely heterogenous in their value, and that means that figures like three percent of patents are not very meaningful, really. It is usually, you know, it could be that three percent is a completely uninteresting set of patents, or it could be that three percent is all of the value in the Patent System, and you just have to keep that in the back of your head. And I particularly mentioned this with respect to the concern for genome and software and business method patents. It is possible at least in the genome case that the reason we are focused on it is because those are valuable patents, even if they are a small number, okay? So you just have to keep that in your head when you are thinking about it. And the second thing, I won’t say much about the second point, I want to say – repeat again, which economists are always repeating -- is that more patents are not necessarily better for innovation, you know, for a long number of
reasons that I do not have time to list right now. Now, the previous panel did a really good job discussing the details of what I will call “patent quality” even though I know that is an over-used and misunderstood term, but, you know, inventive step, obviousness, the whole set of criteria like that, I wanted to do only one thing which is report on a couple of numbers which provide evidence on this question - statistical evidence, okay, on this question with respect to the USPTO, keeping in mind that it is not the USPTO’s fault that this is the case. I mean, the USPTO has been flooded with patent applications over the last 15 years. When you look at the aggregate numbers, you can easily identify a structural break that took place using the usual time series technique that took place in 1983-84 where there was just an enormous shift in the growth rate from zero percent a year to five percent a year in applications. And the budgets have not grown at the same pace, but nevertheless, here are the two facts - the first one is that if you look at U.S. originated patents and non-U.S. originated patents, and how they fare at the European Patent Office, what you find is that the grant rate at the European Patent Office, though it is the same - level playing field here - the difference in the grant rates for U.S. originated patents and non-U.S. originated patents has risen in the
past 20 years from zero percent difference to 16 percent. So U.S. applications are being turned down more often. Now, this does not say anything about the USPTO, this says something about what the expectations of U.S. applicants are, and so that by itself suggests a decline in the standard of U.S. applications, but one cannot help but think that that is not because they are responding to something that is going on in the U.S. The second fact, and this is directly related to what is going on at the USPTO, and it was discussed in the previous panel, but I just wanted to give you the fact, which is now, suppose you look at U.S. priority patents, equivalents at the EPO, okay? So we are comparing what the USPTO does with applications for an invention for which there is an equivalent at the EPO, so these are more valuable in principal patents because there are equivalents at the EPO. How do they fare at the EPO vs. the USPTO? And the answer is the difference in the grant rates - and this is Dominick Galeck's (phonetic) work, mostly - differences in the grant rates has grown from about 12 percent 20 years ago to 30 percent today. Okay? So I would argue that there has been some change in the standards being applied either at the EPO - they have raised the standards - or at the USPTO - they have lowered the standards. Could be either one, really, but that is just
the overall fact. Alright, I can tell that I am going to lose my voice pretty fast and also that I am going to run out of time, so what I want to do at this point, I wanted to talk about the benefits and costs of post-grant patent review, something that we have suggested in the step report, something that was discussed in the FTC report, something I saw, in fact, in at least one of the position statements that were in the packet that we received. I want to reinforce this idea that I think there is some value in having a post-grant review within the Patent Office, particularly for new technologies, okay? Because of the feedback effects you get from having a review, having prior art being brought in by outsiders, and this does in fact - this is going to - it is not that the Patent Office does not catch up on its searches, it is that it takes a while and it may speed it up a bit, you know, they may get the information more quickly. We are down, stop, okay. I am doing to stop. Dietmar is on.

MR. HARHOFF: Well, thanks a lot. Thanks for inviting me to this panel. I feel I am honored and it is a great opportunity to say something about the European experience on post-grant review, which is called Opposition. And let me just hop directly into a summary of empirical facts so that we know how such an institution could look. This does not mean that I am
advising anybody to assume exactly the design perimeters that are here, let us talk about design perimeters later. This is an inter-partes procedure, you can file an opposition within nine months after the patent grant. I will say a little bit about the costs. Typically what you find is that it is opponents, rivals, competitors that are opposing the patent-grant. Sometimes you also find that NGO’s like the Animal Protection Society of Vienna or GreenPeace or others are doing that, and I will argue that that is probably good that we have such an open process. How about the frequency? If you look at EPO Patent - I hope everybody can see that, but I will repeat it just by reading it off - the opposition rate, 7.9 percent of all patents are being opposed at the European Patent Office historically. It has gone down somewhat. And there is a second instance and an appeal against the outcome of opposition which is realized by 31.7 percent of all the opposition cases, so you can see that the patent holders, but as well the opponents are really going after - this is a battle for IP, very clearly, with a high frequency. Germany, by the way, has a similar opposition system and there the opposition rate is even higher, okay? And I will later argue that that has to do with the fact that in Germany you only have three months to file, and therefore you do not have time
to settle with the possible counterpart you have. What is the duration? Each instance about two years, okay? So it is quite long, adding to the already relatively long grant period, examination period that the European Patent Office has which is on average 4.2 years for decision making. What are the outcomes? Now this is the really relevant part. About one-third of the patents are revoked. They disappear. Okay? And given the structure of the system in Europe, there is no judicial appeal against that once the appeal chamber has said the patent is not there. One other third is amended, and that means narrowed - the claims are narrowed. And then, in 27 percent of the cases, the opposition is rejected. The opposition is closed in about seven percent of the cases which means that either the patent owner dropped the patent, they did not pay the renewal fees, or the opponent dropped the procedure and was never heard of again. What are the costs? Per party, per instance, between and $15 and $25,000 Euros, so if you go through both instances, it would be between $30 and 50,000 Euros. There is a very low potential for driving up your competitors' costs, and I think that is very important for not making this a harassment institution that can be abused strategically, although some strategic abuse may be going on. Which cases get to opposition? Now, again,
this is very important because we have been talking about what we would like to see in this mechanism, and what you see is that in new technical fields, for example, biotechnology, nano - many patents are nano these days, in fields with uncertainty, with asymmetric information between the patent owner and the opponent, you see a lot of opposition. When it is high impact patents, like in cosmetics, for example, although it is not an R&D intensive industry, you have high opposition rate, and typically we can show in empirical studies that it is the valuable patents, that typically opposition draws from the upper quarter of the value distribution. So let me simply summarize that and say that this is a mechanism which has in terms of economics both the quality of screening and of information revelation, because what is produced in the procedure here is knowledge about prior art, knowledge about the interpretation of prior art. Many cases do not reveal new prior art, but they deal with the interpretation of prior art, which may be contentious between the parties and, of course, this mechanism identifies high value patents. And now, my interpretation as an economist is very simple that, in a second round, once you have identified these patents, you can give them much more attention than you can in the standard examination process where maybe you have close
to 40 hours in the European system, but errors happen nonetheless because not all the information is on the table, even if you have greater resources available than at the USPTO. So there will be errors, even if there are more resources, and you need some kind of mechanism of doing that. I have some slides here which I will skip through very quickly just to tell you what this would look like and how it peters out, and then in subsequent national litigation in Germany. The European Patent Office examines and it grants a patent, and then these patents become national patents because something like a European patent is not really in existence, okay? And subsequent litigation is within the national systems of the judiciary and so forth. So in Germany, what you find is when you look at EP granted patents coming to Germany, there is a subsequent invalidity challenge that you can raise against the patent at any time — this is not time limited — and any party can do this, so this is a mechanism that the United States does not have. It is a quarter of a percent. Now, I can use these data to show you that the real welfare kick out of the system comes from striking down those 2.7, those 7,300 cases which do not proceed in the system. Their career has ended and they will not cause litigation either. Okay? There is also an effect from hardening legally the patents that
were under opposition because they withstand validity challenges much better than other patents attacked in this procedure. Let me say something about the overall litigation rate in Germany. Again, if I did this for Europe as a whole, I would have to go into basements because we do not have electronic archives of litigation files up to now, unfortunately. The litigation rate in Europe, in Germany, that is my calculation, is 0.9 percent. Litigation is less costly in Germany, it is faster in many cases in Germany. Another member of this panel has come out very much in favor of this mechanism, so all of this is speaking against and sort of an inflationary number here, compare this to the 1.9 percent in the United States where litigation is more expensive, takes longer, and so forth, I think that this is partly an impact of the opposition system as a pre-screening mechanism that take out a number of these cases. Some issues – and I will just pick a few – I have picked out a few key design perimeters. At the European Patent Office, the case is heard by a special board. There is an issue whether you want the original examiner in there or not. I hear from the EPO that the revocation rate is higher when the original examiner is not part of that board, and that might just be human nature. Which time period should you allow for filing the case? I would
argue make it short. The USPTO strategic plan set 12
months. These are 12 months during which there can be
settlement between two parties where society at large
would not like to see settlement because you do not want
to have collusion at this level. The last point I want
to make, I do not think that discovery is very helpful
here. You want to make this a lost cost mechanism, keep
it simple, so that you have the screening function and
not sort of an imitation of litigation. Thank you.

MR. BLACKBURN: Good morning everybody. Did the
clock start? What have I got here? Now, is this pathetic?
Guess how many times I have been deposed? Let’s move on.

So, actually, lately when I am giving talks, if
it is a mixed group, I say how many people are lawyers, how
many people are scientists, now I say, “How many people are
planning to depose me next week?” Anyway, hi George.

Anyway, so, why replace validity litigation? Well, for you
litigators out there, I hate to tell you, it is not about
you. I know you are saying, “What about me and my needs,”
but it is about industry. Aim it at the prosecutors and
the academics, it is not about you either, it is about
industry being able to make, as Ron Laurie put it, make
rational capital allocations. So what does industry want
first? More than anything out of the Patent System, they
want predictability, because if it is predictable, the
outcome, they can negotiate, a deal can be struck. In those cases where it is not predictable, what they want is fast, cheap dispute resolution because that gets you back to predictability. So why do you want predictability? So you can formulate a rational strategic business plan for what you are trying to do and allocate your capital correctly, whether you license, you go into another area, you do add-on research, whatever. You need a predictable system. But, you know, hey, wait a minute. Isn’t the American litigation system the best? You are either for it or against it.

So, well, building on Dietmar’s talk, I have sort of pulled out a not actually hypothetical example, although I was trying to remember what the numbers were in the middle of the night, so I am not holding these up as precise, but they are pretty close.

So, same patent, same issues, litigated three different places, here is what it cost and the time:
Germany -- $400,000, 18 months; the UK -- $2 Million, 18 months, there is discovery in the UK, alright? The U.S. -- $6-8 million, 30 months, and just got to the Markman hearing. Okay. Compare the outcomes. They were identical. The substantive outcome from the business’ perspective of all this litigation was the same. So how much justice can you afford? The dollars you spend on this
dispute resolution system do not go into R&D, do not
benefit society in another way. I know, what about me and
my needs? But if you – you can maybe sell this level of
litigation and cost if we were in a different market like
perfume or scotch, high price tends to work there, but for
the same price, for a lower price to get the same results,
it should not be selling. Okay, so let’s see, can we move
to an opposition system? Can the PTO actually deal with
the validity issues? We have heard some concerns about
their ability to deal with things. Usually that comes up
with the things like best mode, or inequitable conduct, how
would you deal with those? Well, if you have a system
where you have different defenses available in an
opposition system than you do – or you have more additional
defenses available in District Court litigation than you do
in an opposition system, somebody in each dispute is going
to want to try to get to District Court. But now let us
look at other countries like Japan and the EPO countries
where they do not have these type of defenses. Sky is not
falling, their opposition systems tend to work pretty well,
and are a substitute for things like the duty of
disclosure, etc. It works pretty well. So the simple
solution is get rid of these areas of substantive
requirements for patentability in the U.S. like most other
industrialized countries who do not seem to require it. So
do we eliminate litigation altogether? Well, I do not think anybody is seriously suggesting you eliminate litigation for the liability aspects of an infringement. But perhaps you could eliminate it altogether for validity and adopt something akin to the German model. Or you could make it an option out of litigation where, say, the District Court litigation has stayed and pending resolution, the District Court will accept the resolution on validity, and that could include a PTO opposition and a direct appeal to the Federal Circuit, but not – you gain nothing if you then have a de novo review of that process in the District Court. So the question is how does that option get exercised, is it up to the judge, can either party opt for it? Does it take both parties to agree to it? But the key thing to get the advantage of an overall cost reduction and time saving in the overall dispute resolution process is that one party in a particular case cannot frustrate access to the opposition system. Because what we can agree to ahead of time is that those of us who are in the marketplace of IP is that we end up on both sides of this, and we can see a net savings, but when we are in a particular dispute, somebody says, you know, “We will have a five percent better advantage, we think,” and I will tell you, I think most of those calculuses are wrong in this form vs. that form, then you will have a breakdown
and there will not be resort to an opposition system and
you won’t get the advantage of it.

Okay, big concern, it has been raised, will
patentees be harassed in an opposition system? Well, there
are lots of ways to deal with this. The first is adopt the
time limit like EPO does. Proposals are one year out
there. A concern here is, though, what do you do about the
invention, in particularly you will see this in biotech,
its commercial relevance to you, it does not come about for
five or ten years, and you never bother to look at this
thing to see whether it was truly something worth spending
the money in opposition, I guess. Well, you know, maybe
the way to do it is that you award costs. That would, I
think, go a long way to eliminating harassment and you
could say it is in any opposition filed more than a year
after the patent is granted, so it truly has to be a
rational business decision to bring the opposition and you
have to have – you would as a business person think you
have some pretty good grounds to do it. An alternative is
to look at some sort of standing requirement, again,
perhaps maybe after one year passes. I am a little
concerned that it will be anything close to the case or
controversy which prevents people getting access to the
courts for DJ actions, as they do today, because that has
been a real problem in the Biopharma industry. You do not
have infringement during the Hatch Waxman Exemption which
goes on for years, so there is no reasonable apprehension
of suit, yet you are supposed to be investing hundreds of
millions of dollars in bringing a product to market, and
you cannot test a third party patent that might be in the
way.

So, finally, maybe some form of res judicata is
something to think about. That is, it really would depend
very much on what the rest of the system looked like and
what the other options were for doing validity in District
Court. And I beat the clock.

PROFESSOR FARRELL: Thank you. As Rob
mentioned at the beginning, this is a presentation of
parts of what will be a joint paper between myself and
Rob. To give you the bottom line in a sentence, there
are sound systematic economic reasons to believe that the
incentives to challenge and defend patents in litigation
are often, not always, but often wildly skewed, and the
result of that is, if you are tempted to think that you
can repair rational ignorance or any other kind of
ignorance or inevitable imperfection at the Patent Office
through the litigation backstop, you are badly mistaken.

So, why do the incentives to challenge and
defend patents matter? Well, we have a cheap, secretive
error prone, according to many people, PTO process, and
the question is is there a well functioning backstop for this. Okay? Well, there are other backstops, there are other processes, which Rob can talk more about if he wants to, he knows about that, I do not really, the main one of those, as I understand it, is litigation.

Litigation is costly and I will say in a minute why I think that is important for the analysis. It is not for the obvious reason that we end up spending a lot of money. There is relatively little in between, and the real topic of this panel, which is not actually the topic of this talk, is what could we put in between. I will say a bit about that at the end, but it is not my main point. Okay? So rational ignorance and its cognates may be fine if litigation works well. Whether litigation works well depends on the parties’ absolute and relative incentives to fight in litigation. Now let me explain why that is true. In order to get the right answer, you want two things, one is both parties have enough incentives to bring forward a reasonable and adequate amount of evidence, and the other is you want the incentives to be broadly balanced so that, loosely speaking, the decisions are apt to follow the merits rather than being biased in the direction of whichever party has stronger incentives to bring forth all the available evidence. Okay? Suppose you have a lawsuit
between two parties, one of whom very much wants to win it and the other of whom, for some reason, does not really care very much? Well, even if the latter is in the right, he will probably lose because he will not spend the resources to bring forward all the evidence and put on the best case. Now you might hope if you are a real optimist, that the court system is good enough that, even if one litigant does not care as much as the other litigant, the fact that he is right will make him win. If you think that, and I am probably pushing on an open door here, if you think that, then you will predict and expect that people won’t spend very much money in litigation, and that the amount of money they spend in litigation will not vary according to the stakes. Those predictions would be false. Therefore, you have to believe that the incentives do matter for the average outcome. And therefore, if as they claimed on the title slide, the incentives are wildly skewed, you will tend to get the wrong answer, on average, coming out of litigation. That is a problem if you are thinking of litigation as any kind of good back-up for an imperfect administrative system.

So, what do I claim are the relative incentives? Well, of course, they vary. But what I want to say is that in a widespread class of cases, I would
venture to guess in the average case, the patentee cares much more than the alleged infringers. And I claim that this is apt to be true for two reasons, one of which I learned yesterday, is actually in the literature, and the other of which, as far as I know, is not. So the first one that is fundamentally in the literature in Joan Miller from Lewis & Clark has been at the forefront of discussing this, is that when there are multiple alleged infringers, a validity challenge is a public good among them. Okay? That follows from the Supreme Court’s Blonder-Tongue decision, which basically said that if one alleged infringer gets a patent overturned or ruled invalid, that becomes truth which the others can call upon. And what that says is suppose you have five alleged infringers, each of them only have one-fifth of the incentive to challenge the patent, that the patentee has to defend it. Okay? Well, five is probably a modest number, but let us take five because it actually fits with the numbers that I have messed around with. A factor of five is a big deal, given that the evidence on litigation costs suggests that spending 50 percent more than your opponent is going to make a significant difference. What is that evidence? Well, if that were not true, then people would not end up spending a significant fraction of the amounts at issue in
litigation, and they do. Okay? So a factor of five, or
whatever it is from the public good component, is a big
deal. Now, by the way, the public good issue is
reinforced to the extent that the patent holder can, as
my understanding is they quite often do, put it about
that they will discriminate based on challenges, or based
on how quickly and tamely an alleged infringer takes a
license. So it is quite cheap for a patent holder to
charge somewhat less than the otherwise profit maximizing
price for a license to tame alleged infringers, and
somewhat more to feisty ones. It is quite cheap because
the profit maximization curve is flat on top, and
therefore departing in either direction costs relatively
little. Three minutes, okay. I am going to have to
speed up. The second point, the one that as far as I
know is not in the literature, is when these multiple
alleged infringers are not just independent multiple
alleged infringers, but compete in some product market
downstream, things are worse, and the reason things are
worse is, if one of them successfully challenges a
patent, not only does it reduce its own costs, but it
reduces the costs of its rivals. And that pass-through,
it turns out, has a huge effect on the incentives to
challenge. The alleged infringers may bear little of the
excess costs of a questionable patent, even collectively.
Who bears the costs? Downstream consumers.

So, for example, suppose you have a billion dollar industry, suppose a five percent royalty is being demanded on a questionable patent, suppose there are five equal-sized firms in an industry that is using this technology, and suppose that the demand elasticity in that downstream industry is 2. Okay? Then the patentee’s stake in defending the patent is $50 million, the downstream industry’s total stake in challenging the patent is not $50 million, it is approximately $6 million, okay? In other words, this pass-through thing in this particular case is a factor of more than eight, and then there is the further factor of five from the public good phenomenon. So what?

Well, so, based on the evidence from litigation costs, this is going to mean that the patentee is going to tend to win if the merits are broadly equal, challengers can only be expected to win what should be really quite easy cases. Among the likely results? Too few challenges, inadequately pursued, too few bad patents overturned, and downstream final consumers bear the brunt. It is worth noticing that the role of litigation costs here is not so much that these challenges are costly when undertaken, it is that they may be more costly when they deter litigation. What to do. One
thing you could do is to have cheaper post-issue challenges. That will help if what is going on is that the general expensiveness of litigation makes the ratio of incentives matter more, in other words, if a cheaper process makes the ratio of incentives matter less. It could well be true, although it is not analytically obvious. Another thing you can do is have a bounty system proposed to strengthen the private incentives to challenge, you could allow multiple challengers to get together. A third thing you could do is to accept that the adversarial approach is deeply flawed and say that pushes us, despite what you might otherwise hope, to try to improve the PTO. And a fourth thing you could do is to have these competition agencies, who should be in the business of defending final consumers, do so. Thank you.

MR. NORMAN: I want to say thank you to the folks at Boalt Hall and from the FTC for inviting me here to speak, and at least pass on some information related to how some in the industry, not all, feel such a post-grant opposition procedure should be established. I would say that, coming from the pharmaceutical industry where we live on a daily basis with the Hatch Waxman Act, such that we are absolutely unequivocally guaranteed that four years post-product launch, we will be involved in a
patent challenge from a generic competitor, which carries with it a bounty of the ability to obtain a 180-day co-exclusivity, that we are talking about a system which is tried and true for eternal litigation. And my life is little more anymore than litigating patents in Federal District Court. However, I have had some experience over the years in dealing with re-examinations and re-issues in the United States, oppositions in Japan, and oppositions in Europe. And I would be here today to advocate for a United States opposition system that is not as tightly wound as the Japanese, but perhaps a little more tightly wound that the European system. The elements that I believe would be most desired in a U.S. post-grant opposition system is one that has a set period of time in which to request an opposition. In Europe, we have nine months, others have proposed here in the United States 12, yet other commentators have come forward and said, above and beyond the 12 months, there ought to be some period during the entire pendency, the life of the patent in which a challenger can come forward and request an opposition much along the lines that you could get declaratory judgment jurisdiction in the Federal District Court to bring everything back to the Patent Office and run one of these sort of cheap validity – supposedly cheap validity challenges, before the USPTO. I would be

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
less in favor of something like that because of some questions that I will raise later, much of it dependent upon the diceyness of declaratory judgment jurisdiction as it is currently being interpreted within the Federal District Court System. I would say that, of course, all evidence needs to be brought forward at the beginning of the opposition, the patentee ought to have the right, of course, to be able to respond in kind. Discovery should be allowed, but ought to be limited to some reasonable manner. The vast, vast, vast majority of expense that arises from Federal District Court litigation in the United States arises from discovery. For instance, now that everything is finished, I can tell you that I ran a lawsuit for Eli Lilly & Co. a couple of years ago where the Federal District Court Magistrate ordered us to produce to the opposing party every document within Eli Lilly & Co. that had the name of the chemical compound on it, okay? And try as we might, we could not get the Magistrate to back off that, and so we ended up producing 1.9 million documents to the opponent, less than 5,000 of which were ever found to be relevant and introduced into the court record. And so it is the outrageous expense of the way the United States Federal District Court System wants to run its discovery that is causing all of the problems that we all admit to now in litigations.
However, before the Patent Office, we do need to have some sort of limited discovery, the Patent Office has experience in interference proceedings whereby the Administrative Patent Judges at the Interference Board certainly know how to run appropriate discovery within the confines and the bounds of what would be truly relevant to the issues at hand. It is quite important that the Administrative Patent Judge be legally trained to the extent that, if we are going to follow the Federal Rules of Evidence and, as most people say, we ought to get to some level of estoppel, whether it be issue or claim preclusion, but some sort of estoppel arising out of a post-issuance opposition, then it is quite important that we actually follow the Federal Rules of Evidence and have a Judge that is willing to enforce those. Have a time limit – everyone is saying a year; that would be wonderful. J.R.R. Tolken says “the tale grows in the telling,” so do the expenses in litigation and, therefore, a time limit that would be extendable only for cause would be most important. Key elements – the time period, I have already spoken quite a bit – or a little bit – about the fact that we ought to probably have a 12-month period in which to bring the opposition, and then be limited thereafter to such an extent that, once a patent is past this 12-month period, there ought to be
some level of certainty, as Bob raised, in the patentee’s life, in the patentee’s business, to be able to determine whether or not you want to draw up an additional $100-150 million building, a pharmaceutical plant, to make this chemical compound. It would be nice to actually have a little bit of assurance that there are going to be very, very limited opportunities for those coming in to make a challenge to actually pull you back into the Patent Office. Another huge question is, in the event that we end up going towards a scheme whereby you can be brought back to the Patent Office, how do we deal with the status quo arising from the fact that many times, if someone is going to be infringing your patent and you want to bring suit against them, the first thing you need in order to maintain your business model is a preliminary injunction. If you get a preliminary injunction, then you are sent back to the Patent Office for post-grant review at any time during the life of the patent. We need some more rules and regulations and some more law around what needs to be done, how we are going to handle maintaining the status quo during the pendency of that if the Federal District Court Judge gives up the jurisdiction of the case and sends it back to the Patent Office. Again, we like to see our Federal Rules of Evidence followed, we want to see the appropriate procedures followed. I have
been involved in European oppositions, unfortunately, where I showed up for the day of the opposition and my opponent walked in and actually had a whole new stack of prior art and a whole new set of briefs, and handed them over in absolute violation of all the rules and regulations set down by the EPO, nevertheless, the Opposition Division accepted it, and I spent the remainder of two days arguing against something that was nothing more than an ambush. Along the same lines, too, we need to be concerned about how we are going to deal with expert testimony and whether or not you are going to have the opportunity to cross examine an expert who might give an expert’s report because, again, before the EPO, I have walked in before and seen a PhD sitting across the table from me when I did not bring anyone at all, and found that the opposition was quite interested in hearing what the PhD scientist from my opponent’s side had to say about the relevant level of ordinary skill in the art. I say this prevents reliance on the Astrology Factor because I was actually in litigation in the UK one time and mentioned from the witness stand that my client had taken advice before going into an opposition in the European Patent Office, and the good judge in the UK said, “From whom did you seek that advice? An Astrologer?” Sort of laying out how the UK court system,
at least, feels about the European patent opposition. A very key element that we ought to discuss is the right to amendment and whether or not this ought to be a right from the immediacy, how it ought to be dealt with, whether or not broadening amendments ought to be allowed. My stance on this would be that, from the time that you get out of the examination and you are in the opposition, you ought not be allowed to have a broadening claim as you are going forward so that the public can have some right of reliance upon exactly what has been going on in the Patent Office and whether or not the public can in any way make its decisions based upon the scope or the breadth of the claim. To guarantee a speedy resolution of the opposition, the patentee should be allowed to amend the claims only once. I say this, again, because I was in Europe one time when we spent two days going back and forth with – I think we got up to 12 auxiliary requests and it became apparent to me that the Opposition Division was not really so much looking out for the public interest, but instead was hearing from me, hearing from the other party, seeing whether the other party could come up with an auxiliary request that I might be happy with, and vice versa, and actually the Opposition Division was acting as a mediator, which I think, if we want to use this as administrative action,
may not be something that we would want to see occurring here in the United States.

Now, I set forth here what is intentionally a bad claim and, because it is a bad claim, I had some prior art instances that I was going to bring up to all of you, but I am out of time, so I will not - so no one gets to examine my intentionally bad claim. Thank you.

MR. KUNIN: Well, I, too, as the other speakers have indicated, appreciate being given the opportunity to speak at this conference today. What I would like to do initially is say that I think the Office is doing a pretty good job of examining patent applications. I want to thank Ron and Todd for defending us at the earlier panel, but nevertheless, as you can see from the Office’s 21st Century Strategic Plan, we have a number of quality initiatives underway so that we can go an even better job, and in our Strategic Plan we have shown support for establishing a post-grant review system in the United States. We have done some comparative studies with the EPO and the JPO, and I would tell you that we also find art they do not find, so consequently I think you need to understand that it really is sort of a distribution, if you will, in terms of relative examination. I think the important thing with respect to any opposition or post-grant review is that it be a
process which is predictable, reliable, and timely. I do not think it ought to be an examination system, it ought to be a low cost administrative proceeding conducted at a re-named Board of Patent adjudication, done with special dispatch by a skilled Administrative Patent Judge, namely the people of legal and scientific competence as set forth in Section 6A of the statute. One of the things that I think we need to do to make it attractive is to remove the provisions that currently exist in 315 and 317 on issue preclusion as to issues that could have been raised during the proceeding, at least during the first period, whether that be nine months or 12 months after the patent was granted, or re-issued. I think the one thing that we do need to recognize is that it is probably desirable for us to have a system that avoids patent owner harassment, but at the same time truly incentivizes people to challenge patents which they feel are weak, and this issue preclusion, an estoppel feature, is one that really needs to be given serious consideration. Maybe after the first year, if you can challenge after one year, you should have perhaps a substantial economic interest and maybe this higher level of issue preclusion would be applicable. I think we also need to make sure that these proceedings are ones that avoid some of the merger problems with other proceedings such as re-issue
and re-examination, and they need to provide a sufficient
period of time for the challenger to reply to patent
owners’ responses.

    Unlike re-examination, I think it is very
important for us to permit the challenger to challenge
claims based on all conditions of patentability. This
will get a complete resolution of validity issues. Also,
to increase reliability, these proceedings ought to be
conducted using E-processing tools and techniques. The
best approach, we feel, is one where we establish a
proceeding that, once it is initiated, could be completed
within 12 months. We do agree with the premise that, at
least one narrowing amendment should be permitted by the
patent owner, perhaps a further amendment only on a
showing of a good cause, and this would be entirely
controlled by the three-judge panel, the Administrative

    Also, probably, there should be an opportunity
for settlement in a situation where maybe there is a
proposed narrowing amendment that could be handled by way
of re-issue and, if such an amendment were provided in a
re-issue, that the parties may choose to settle the
inter-partes proceeding. Probably the single best
feature of our current re-examination system is an ex-
parte re-examination where the owner, him or herself, can
come back to the Office of Administrative Proceeding to correct or strengthen the patent. Even with respect to an inter-parte re-examination, it gives the opportunity for the examiner to hear both sides of an issue, to make a better informed decision and, of course, the appeal process is much faster than getting to the Federal Circuit in litigation. Re-examination really is nice where there is what we call “killer” 102B-type prior art that can be introduced and have a significant impact on the proceedings. Probably one of the worst features that we have heard is that there is no opportunity for the third party requester to obtain any discovery or cross-examination in affiants or declarants when evidence is presented by the patent owner in support of patentability. I think, finally, what I would like to indicate is that we are currently looking at how to put together a legislative package that would indeed establish a post-grant system that has all the various benefits of those who advocate some of the best features from systems around the world, and to avoid those things which have been already mentioned by other members of the panel which make it somewhat unattractive in other parts of the world. I think we can do this right. It is possible that this can be something that will either metamorphosize the existing inter-parte and re-examine
into a more workable system, or stand as an additional aspect of the U.S. Patent System as a way to administratively correct patents in a way that can be substantially at lower cost and quicker, and truly address some of the issues that really led in the thought processes that went into some of the early President’s Advisory Commissions on Patent Law Reform, one in the early 1990's by the then Secretary of Commerce, and see that perhaps this could provide us a good opportunity to further reform the system to sort of make good balance between what can be done in the examination of some 350,000 applications a year, and then for those that really will have a commercial impact, they could go through a second level of review in order to get the kind of scrutiny that ought to be provided, that just cannot be provided by any Patent Office in the limited amount of time you have when most people want the timely issuance of valid patents. I think the aspect of having high pendency is also a problem in relationship to good quality. So we have to have a system where at least the initial examination is very thorough, but also in a timely manner to help provide greater certainty to those who are innovating and seeking protection, as well as their competitors. Thank you.

PROFESSOR MERGES: I am going to ask the
panelists, if the question is directed to you, just try
to re-state the question quickly so our transcription
service can pick it up and follow it.

MR. GILBERT:  [Rich Gilbert -- off mike]

PROFESSOR FARRELL:  So the question is, is
there an additional problem caused by the fact that in
some sense a bunch of claims can be made and an alleged
infringer has to prevail on all of them, and in a context
with error, that makes it almost impossible to expect to
prevail.  I am not sure what I think about that.  I mean,
if all the claims were correctly patented, then you ought
to have to prevail on all of them, and I think you
pointed that out, Rich.  So is there an increased
probability of an incorrect finding of validity based on
the fact that there are multiple things?  I am not sure.
It does make some intuitive sense, but I do not have a
very firm intellectual grasp on that question.

PROFESSOR MERGES:  Yeah, Rich, it is an
interesting question.  If you sort of set it up as an
introductory probability problem and you say, "Well,
gosh, there are eight patents and they each average, you
know, 20 claims," it looks pretty hopeless.  But it is
interesting that, you know, here is one where the
cognitive scientists have really predicted reality pretty
well.  What District Courts actually do is they usually
boil it down and they say, "Okay, guys – folks," you know, patent litigators, they say "Which of these eight patents are you really putting your money on?" And which claims within them are you really putting your money on?" In other words, you know, people are kind of boundedly rational, and District Court Judges have only so much patience and time, and so what they tend to do is kind of boil it down and say, you know, "kind of the key patent and what are the key claims because I just do not have, you know, nine years to kind of process the case." One way to kind of transpose your question is to say, "How would we handle that distillation process, you know, in an opposition setting? Is there a way to focus the inquiry in a similar way?" And it is a good question. I mean, I think it is something that would have to be thought through; if we could do the same thing because there are just sort of inherent limits on how much people can process and it shows up in the system, even when you are spending $8 million, because it comes down to one or two decision makers and they are just not unlimited. You know, it is not the Cray 1 (phonetic), it is a certain judge. That is just the way it goes.

PROFESSOR FARRELL: Can I just jump in again on that? I have come across cases where a patent holder has announced that it had multiple patents and that it
was not going to litigate all of them in any one case, and perhaps that is a response to this distillation process. And that, I think, puts Rich’s question back on the table in a more forceful way – but I still do not know the answer.

MS. : [Audience -- off mike]

PROFESSOR FARRELL: So the question was what are the relative incentives if you have basically a patent thicket with multiple patent holders, and I think the spirit of the question was these multiple patents are all blocking on the things that the alleged infringers want to do. I do not know the answer to that, it is a good question. I think one observation would be that, as to any one patent, if you do not have the public goods and pass-through issues in strong degree, then there is a certain symmetry because the two are potentially fighting over the same amount of money if you are just dealing with royalties. If you are dealing with injunctions, then, for the alleged infringer, to win one battle is only to be put into another battle and I think there will be circumstances in which that is a rather weak incentive. So I think that might lead to some results parallel to the ones that I was talking about, but I do not know.

PROFESSOR MERGES: I think we should – we have
got to hear from the biotech and pharmaceutical people on
that question because that is kind of something that you
guys face all the time, multiple inputs in the product
development stream and lots of claims. There has been a
lot of writing about it, so it is time to –

MR. BLACKBURN: Well, for the subject matter
of the panel, you would want an opposition system, a
cheaper faster opposition system to deal with those. And
it would be that simple.

MR. NORMAN: Right. And Bob and I could get
even chummier spending time before the Opposition
Division. But there is sort of a dichotomy if you look
at it just from the biopharma issue, from the
biotechnology side where we do have thickets, if you look
at the pharmaceutical side, often you find savannahs and
that is not my quote, Bob Armitage said that a while ago,
but in the straight pharmaceutical industry, you end up
having - because of Hatch Waxman - having to list your
patents in the Orange Book, and if you open up the Orange
Book and look at any given drug product, you will find
very often only one or two patents that have been listed.
Now, admittedly, you will find some that have 12, or 13,
or 14, but, again, usually the biotechnology and the
pharmaceutical industries are peculiar in that, because
of the horrendous expense of bringing a product to the
market, very often people are not willing to license a piece of their technology because you need that total market exclusivity in order to make back your investment on doing all the research and development on the pharmaceutical product itself. But, again, an opposition would be quite nice to take care of these things one or two years out.

PROFESSOR MERGES: Todd, it looks like you have got a question?

MR. DICKENSON: [off mike]

MR. BLACKBURN: Well, I was actually interested in that number, too, and not so much as relative to re-examine. I think the explanation for the re-examine system being under-utilized in the U.S. is because it is such a stacked deck for a challenger. And you have an option of keeping your counter dry for District Court litigation where you have more defenses and perhaps a better chance of bringing it about, so that is why, when you give people an alternative on an individual case, they are going to make that kind of decision. But I am certain that, in part, the reason there is more or vigorous opposition practice in Europe is, in part, because of the lack of some other reasonable alternatives at some level and also a perception of a fair process - or fair enough. The thing that always
sort of strikes American lawyers who go over there, who
have been trained in American concepts of due process, it
is almost like the cultural equivalent in some countries
of somebody trying to shake hands with their left hand.
It is just really odd what they consider – like Doug’s
story – is a fair process. And I actually take, for
example, Steve’s proposal that, you know, there would be
one opportunity to amend the claims. And I am a little
bit concerned about discussions of the opposition system
that we are thinking about implementing, or might adopt
here, to start immediately dropping to that level of
detail because I think there is a lot of other issues
that have to be decided about whether that is a fair
rule. For example, I do not know how you can say you
only have one opportunity to amend if the other side can
bring in new arguments, for example. And they say,
“Well, if you don’t, we will make it where the other side
can’t bring in new arguments at a certain time,” but is
that actually the best result to a quality output? Or is
a fair iterative process something that we ought to look
at that keeps within time lines? But, anyway, that is
kind of a long answer.

PROFESSOR MERGES: We probably only have time
for one more question, so if you have a really good one.
Yeah, go ahead.
MR.: [Audience – off mike]

PROFESSOR MERGES: That is actually a plug in the form of a question, but we will take it. Well done. But it is a good plug, we like it, thank you. Well, I mean, the obvious answer is that, you know, a lower cost system is going to encourage more participation and include more public interest components than a high cost system. The one issue that you might consider in terms of design is whether or not the public agency can step into the shoes, maybe the PTO or somebody can step into the shoes of a private agency in the face of a settlement. And the settlement question is a really tricky one, you know, when you look at this. And so interesting problem. Dietmar wants to address it.

MR. HARHOFF: Of course, the cost issue is there. Let me tell you that in Europe there is an institution, Article 115, European Patent Convention, which allows third party observations, some ex partes procedure, and you come out with exactly or very very close to the same participation rate as with U.S. re-examinations. So it is really the ex-partes vs. inter-partes issue that is driving that. The other thing is, of course, and that addresses some of Joes’ concerns, Factor 5 is fine, but if you make it Factor 5 on a low cost figure, it has considerably less bite, and that
makes it even possible for organizations like in Europe, NGO’s, Greenpeace, some animal protection agency, the Free Software Institution in Europe, to oppose certain software patents. And they have been successful to some extent. Now, the settlement issue is, I think, something that one should worry about, and one needs to go away from the classical interpretation of settlements as something that is strictly benevolent because in this case it is not. It is at the cost and the expense of society. Okay? If Rollet (phonetic) has a patent and I have the information to shoot it down in opposition, and you give us enough time to figure out how to deal with this, and he gives me a license and I shut-up, okay? That is a wonderful case of dual monopoly and we do not want that. Okay? So be careful about the settlement issue. Within nine months at the European Patent Office, the averages that I hear from the patent lawyers when I talk to them after two beers or so is that there is a settlement rate of about 20-25 percent of the cases that do not even hit opposition. Now, that is low by U.S. standards in litigation, but I think it is an issue that you really should watch, and my proposal would be to make it a short time for filing – that is why my three months came up – give the parties some more time to develop the evidence, then, but allow the U.S. Patent Office to
pursue the case in and of itself if it wants to, because it is the Patent Office’s task to make sure that patents that should not be there should not be there.

PROFESSOR MERGES:  Joe, last word.

PROFESSOR FARRELL:  Yeah. I would just like to reiterate what Dietmar said about settlements. The most affected, or often the most affected people, are not at the settlement table, and the excessive incentive for cozy settlements is fundamentally the same as the incentive that I was talking about to not bring a challenge in the first place.

PROFESSOR MERGES:  We will take a break of about seven minutes, give or take, and then get back so we can be almost, sort of, close to, on schedule for lunch time. Thank you.

[BREAK]

MS. SAMUELSON:  I am Pam Samuelson. I am one of the Directors of the Berkeley Center for Law and Technology and I have the great good fortune of being the moderator for this panel on litigation issues. If we had taken two days to have a conference, I think we would probably have one session on presumption of validity, one session on subjective factors that are often very important in litigation, and possibly one session on experimental use, and one session on discovery issues and
so forth, but we decided that, for purposes of having a one-day program, we were going to kind of throw them all into one litigation panel. So this will be a little bit more of a potpourri than the previous two sessions, but I think nevertheless will both deal with some of the issues that the FTC has raised about the presumption of validity, which obviously has gotten a lot of people’s attention, but also will cover some of the issues in the National Academy Report because subjective factors were both discussed in the FTC report and also to some degree in the National Academy Report that is coming out on Monday. So we will have a chance, I think, to sort of visit quite a few issues in the course of this panel. So I would love to give wonderful biographies of all our speakers, but they all have websites, so I will simply say this is a great group and I am looking forward to hearing from them, and first we will start with Mark Janis who will be talking about presumption of validity issues.

MR. JANIS: Thank you, Pam. Thank you for the invitation to come here, and I will try my best to reduce these remarks to just a few sound bites because no one wants to be late for lunch, I know. And I apologize if it is too fragmentary, and I will use the usual Academic’s excuse -- there will be a paper and you can
read the paper -- and that will be very coherent, I promise you.

I keep hearing all this talk lately about trolls and at first I thought, “I do not need to pay any attention to this, I am from Iowa, right, we have no trolls there.” Then I began hearing that these were actually patent trolls. That got me interested and here is what I read in the transcript of a Congressional Hearings testimony within the last few months. “Patent trolls are Patent System bottom feeders who buy improvidently granted patents,” if you know what those are, “...from distressed companies for the sole purpose of suing legitimate businesses.” And this brings us to the topic at hand because these patent trolls, according to the testimony, have the presumption of validity on their side and, so, clearly, they must be stopped. This is where the FTC comes in. It is our Federal Government here to either save us or at least here to study the matter very very thoroughly. And it should be studied very thoroughly because this is a serious matter, not just a fairy tale matter at all, this patent validity litigation and patent validity disputes. What I would like to do with my little bit of sound bite time here is to think about two functions that the presumption of validity might perform, and then I want to argue that the
FTC’s proposal to reduce the standard to preponderance for overcoming the presumption of validity might overlook the first function. And as to the second, I doubt that I will have time, but I have got a few things to say about that, as well, as to the second there are arguments that are a little more plausible.

Let me tell you what I mean by two functions that the presumption might perform. Here is what the Supreme Court has to say on the matter, not as to the presumption of patent validity, but as to presumptions more generally. They might sort of do two things, 1) indicate the relative importance that society should attach to the ultimate decision. I want to call that the “Expressive Function;” 2) allocate the risk of error usually as between the litigants, and I want to call that the “Instrumental Function.” And it is ordinary to talk about the presumption and especially the presumption of patent validity, I think, in terms of the Instrumental Function, the second way. And I think that is what you find in the FTC Report and, in fact, that is what you find in the literature – a lot of the literature – about presumptions.

So, for example, in a criminal case the State should bear the risk of error, and so we have a strong presumption of validity, beyond a reasonable doubt.
standard for overcoming it. Civil case for damages – parties should bear the risk of error equally, hence we have a preponderance standard. And we can build on this – and to have a nice neat menu of options like picking the wine for dinner where we have ordinary civil case, or we have a criminal case, or we have some kind of case in between that gets a clear and convincing standard. And the FTC Report, I think, makes plausible arguments in this regard. It says the patentee should not enjoy the benefit of a strong – if I can use that term – strong presumption of validity because we have concerns about the quality of patents, so therefore the patentee should be made to bear a little bit more of the risk of error, to put it in those kind of terms. The FTC also says, and I think this is important, that the clear and convincing standard might facilitate anti-competitive uses of patents. And that is interesting because it shows us that there are obviously – and we have heard about it already today – third party effects to be concerned about here are not just a matter in patent cases of allocating the risk of error between the two private litigants, third parties have interests as well. Maybe that would lead us to think that the clear and convincing standard would be inappropriate. And those proposals are fine, but I want to turn back to the first function, the
Expressive Function of the presumption of validity, and make a few comments about that. First of all, what do I mean by the Expressive Function, exactly? There is a couple of things that one could mean. One is that a rule is expressive in the sense that it is purely symbolic, it is not designed to accomplish anything except make a statement, even if it is never enforced. That would be one way to think about it, I suppose, you know, I would rule on flag burning or something like that, even if you never expect it to be enforced, the fact that it makes a statement is significant. Another example or another variety is a rule at least whose main significance is as of a statement of aspirations, or a statement of principals, and even if it is designed to accomplish something, we do not necessarily expect to find very sharply incentives and disincentives, nor do we expect that we have real precise control over the level of enforcement, it seems to me that is another way to think about a rule that is expressive.

Let me suggest a few insights that we might gain from looking at the presumption of patent validity from this perspective, as a statement, as a symbol. One, the fact that we have a presumption of validity might be as significant, or more significant, than the precise verbal formulation that we use for the standard of
evidence for overcoming the presumption; second, while it is easy enough to manipulate the words of that, the precise verbal formulation, the words of the standard, it might be very different and a very subtle exercise to manage the message, the overlying message that is embedded in this presumption of validity, and then, thirdly, manipulating the words without paying attention to the message, the overlying message, might lead to some real surprises. Ironically, it might lead to changing nothing, while changing everything. And what do I mean by that? Well, you know, suppose you change to a preponderance standard? Is it really going to make a difference -- really going to make a difference -- in the outcome of judicial decisions? Or will judges go on and do the same thing they did before and change the words? I mean, I think there is at least some question about that. So that is the changing nothing part. Yet, on the other hand, the other actors in the system, at least in the short term, might perceive that the overall message has changed dramatically. Patents are less secure, the Patent System deserves less respect, and so forth, and the consequences that flow from that. So it might be counter-productive at the end of the day. Oh, three minutes left, I am going great. So let me just explore that a little bit by getting down to cases. First, early
Federal Circuit cases dealing with the adoption of the clear and convincing standard. If you think about this, before the creation of the Federal Circuit, most courts already used the clear and convincing standard for overcoming the presumption of validity, a vast majority of them did, yet the overlying message was that the Patent System was in distress, that the presumption was meaningless. There is a disconnect between the words that we use and the overlying message. Now, to be certain, some courts were also holding that the presumption of validity did not apply to newly introduced prior art, that certainly contributed to the message. After the creation of the Federal Circuit, the Federal Circuit adopts the clear and convincing standard. You could look at the words and say, "Well, that is hardly a watershed event, there already was the clear and convincing standard." The Federal Circuit also spoke to this issue about newly discovered prior art and they said, "Well, the presumption still applies, but yet it may be a little easier to overcome the presumption." You could look at that and say, "That is really no change from the law before," yet if you look carefully at the tone of these cases, and if you combine that with other things that were happening in the Patent System at the time, it is very clear that the message had changed.
we see this in the FTC Report today and probably all of us would say the Federal Circuit has strengthened the presumption of validity and this has changed the message. Now, one minute left, so current cases – this can work the other way, that the words can stay the same and the message can change. Look at the Rochester case where the court says a patent can prove its own invalidity, and do so clearly and convincingly. The words can stay the same, but the message there is a little bit different. Look also at trademark cases – I clearly do not have time to talk about those – trademark cases where the preponderance standard is used. Take a look at a case called Burke-Parsons-Bowlby, it is an older – it is a 6th Circuit 1989 case and you get a little bit of a scary view as to the use of a preponderance standard for overcoming the presumption of validity, very difficult to figure out what is going on there. Bottom line here – yes – I have got time for a bottom line, okay, 1) changing the words of the standard might not make a lot of difference in case outcomes. At the same time, the over-arching message that the presumption of validity sends in the Patent System is a very potent indicator of the overall health of the system, and I worry a little bit that by choosing the presumption of validity as a point of policy reform, the FTC might not have chosen...
wisely. They may create more of an adversarial tone than I think they ever intended to do. Now, other comments will have to wait. So thank you very much.

   MS. SAMUELSON: Our second presenter will be Arti Rai.

   MS. RAI: And I, too, will try to speak quickly and get everyone out for lunch at the appropriate time. I am going to focus on the presumption of validity as well, although perhaps I will take a little more sanguine view of what the FTC has done than Mark did. In talking about this recommendation I will also end up within ten minutes looking a little bit at the FTC’s recommendations on the non-obviousness standard and on opposition proceedings, believe it or not. So bear with me.

   In my view, I think the FTC has actually made some very interesting recommendations with respect to all three issues -- the presumption of validity, non-obviousness, and opposition proceedings -- and they can be viewed as a coherent whole from a procedural perspective rather than a substantive perspective -- and I will explain what I mean by how they can be viewed as a coherent whole -- but the basic insight is that I think they can all be understood by looking at the comparative competence of the various institutional actors within the
Patent System. And those of you who have read my work
know I love to talk about institutional competence, so
you will hear a little bit more about this today. So
with some caveats that I will talk about more towards the
end, it seems to me that, in the context of the ordinary
patent that is issued, there is good reason to set the
presumptionability at a little bit of a lower level than
it is currently set. Now, Mark has made some interesting
points about what will be the actual impact of the FTC’s
proposed change, and I think that is actually very
interesting to consider empirically in the context of all
sorts of different areas of law where presumptions matter
and people have done empirical work, and I think we
should continue to do that in this area as well. But for
all of the reasons that the FTC and many many others have
pointed to, perhaps Mark Lemley most eloquently of all,
ranging from burdens of proof, to incentive structure, to
workload, to the ex parte nature of the proceeding, a
patent examiner’s decision to issue a patent should
probably not be the last word on its validity. And this
is true, I would argue, even despite the fact that a
patent examiner is probably the person in the Patent
System, at least the legal actor in the Patent System,
that is closest to being the all important PHOSITA. Even
despite that fact, I think that patents that are issued
are not necessarily - one should not necessarily give
much deference in the context of issued patents, which
brings me to my next point. In contrast, when the patent
examiner denies a patent, I think there is some reason to
give weight to his or her status as a quasi-PHOSITA,
which is particularly true in biotech, for example, where
the patent examiners are fairly well-steeped in the
technology. And, to put it mildly, none of the various
institutional pressures that cause the issued patents to
be somewhat problematic come into play in the context of
denials. In fact, if anything, all the institutional
pressures run against denials. So how does this all
relate to the FTC’s recommendations in the context of
non-obviousness and opposition proceedings? Well, I
would interpret the FTC’s discussion of the non-
obviousness requirement as having been prompted by
decisions by the Federal Circuit that reviewed the patent
examiner’s denial of a patent and simply refused to defer
to the factual knowledge of the patent examiner in those
context. I would argue and have argued that the Federal
Circuit should in many circumstances, if not most
circumstances, defer to a PTO fact finding in the context
of a denial. And there is particularly good reasons for
showing this kind of deference when we are talking about
a PTO’s determination that a particular combination is
obvious because, for all the reasons that were discussed in the first panel, a PTO examiner is likely to be the person closest to the PHOSITA in terms of thinking of combinations of references. So in the denial context, there is good reason to show deference, and in the issuance context, less reason to show deference. To use the words made popular by Condoleezza Rice recently, we should have an asymmetric response to the PTO’s actions. Unfortunately from the perspective of institutional competence, thus far the asymmetric response has been precisely backwards. We have tended to show more deference because of this high presumption of validity to the PTO’s actions in the context of an issuance, rather than the context of a denial. So my view is that the FTC’s recommendations in the context of non-obviousness and opposition proceedings, particularly non-obviousness and then also its recommendations in the context of the presumption of validity are leading us towards asymmetric response in the right direction, more deference in the context of denials, and less deference in the context of issuances.

Well, what about opposition proceedings? I did mention I would talk about those. And what about the presumption of validity to attach in those contexts? Well, here I think the FTC has been pretty careful, as
well. If you look carefully at the recommendations, we have said that the decision of the PTO in the context of an opposition proceeding should be reviewed deferentially always, whether the PTO ultimately decides to grant or to reject, and I think that is absolutely right as an institutional matter because if a patent has been looked at from a comprehensive adversarial perspective in the context of an opposition proceeding, there should be deference, not only on the fact finding, but on the legal conclusions as well. And for what it is worth, for those of you who remember your administrative law, this is perfectly in keeping with the way that the Supreme Court has administered the Chevron deference standard most recently in the Mead case. So we would also nicely bring patent law into conformity with administrative law, which it often is not in conformity with.

I do have one small issue with respect to the FTC’s recommendations, well, perhaps not such a small issue, but it is an issue that I must admit I also do not have a good answer to, and that is the following: so we put in place robust opposition proceedings and there is lots of deference in the context of those opposition proceedings, not so much deference in the context of an issuance and a fair amount of deference in the context of denial. What happens if a patent goes through the system
and just happens not to be challenged in an opposition proceeding, and therefore falls into the pile of patents that are subject to a thin presumption of validity? And what if the reason for its not being challenged was that it was simply a very solid patent? Should it be put into the same pile as all those patents that are subject to the thin presumption of validity because we think the patent issuances are somewhat suspect? I do think that is a problem, but as a practical matter it may be less acute a problem than one might think at the outset. For the most part, I would imagine, although of course we are all speculating here since we do not have anything remotely comparable to an opposition proceeding, on the other hand, the European experience does tend to suggest this as well, I would imagine that the most important patents would, in fact, be the subject of an opposition proceeding, no matter how solid they were, that is, that there would be some piece of prior art that somebody would want to at least try to run by the Patent Examination procedure in the context of the opposition proceeding with respect to really important patents. So for those who are concerned, particularly in the biotech industry which I study, you know – I spend a lot of time studying – for those who are concerned, you know, what will happen if we have a lower presumption of validity
for most patents, particularly for Biotech where the patents really matter, or Pharma where patents really matter, well, I would suspect that most of those patents would go through an opposition proceeding, and thus be subject to a very high presumption of validity. But that is a problem and one that is important to think about. One way of tweaking the FTC’s recommendations a little bit, perhaps, so as to not render the thin presumption of validity entirely meaningless would be perhaps to have a higher presumption of validity even in those contexts where the patent has not gone through an opposition proceeding for situations where there is no new prior art presented, so as long as the litigant does not present any new prior art, you are subject to a very - the patentee still enjoys a fairly high presumption of validity. So that is one way of tweaking the FTC’s recommendations a little bit. But I am out of - oh, no, I have one minute left, okay.

So, that is my view of how the recommendations with respect to presumption of validity, Non-obviousness, and Opposition all cohere from an institutional competence standpoint with the slight tweak that we may not want to take the presumption of validity too far down for your ordinary run-of-the-mill issued patent because it may not have been subject to an opposition proceeding
because it just happened to be very good. Thank you.

MS. SAMUELSON: Thank you. Lynn Pasahow is going to give us some commentary.

MR. PASAHOW: Well, from a non-academic point of view, but rather that of someone who litigates patents, I was asked to give my impressions of this, and these impressions come from trying software and biotech and internet patents to judges and juries, but more from going to focus groups that we often have before our jury trials where we put on a mini trial and then watch the jurors talk about these things behind one of my glass mirrors. And my first reaction to the FTC proposal is gratitude because, in my experience, the presumption of validity causes clients who are thinking of challenging patents not to do that or who are thinking of not taking licenses to take licenses. And I think doing away with the presumption is one of the few proposals that government agencies are making today that is going to have the impact of increasing litigation and I am surprised that one of our agencies is pursuing that goal. But my other reaction is mystification because the question in my mind is this - I think that the presumption, to the extent it does anything in litigation, and that is something I’ll come back to - but if it does anything, it limits the discretion of the
jury, it puts the jury into a tighter box and controls them more. And so what we’re doing is we’re saying that the Patent and Trademark Office has some problems with its competence, and instead we are going to transfer the decision making more to the unbridled discretion of a bunch of jurors. Now, for these jurors, think of the places that are popular for patent cases and think about why. Today one of the most popular patent courts is the Eastern District of Texas, the town of Marshall, Texas, not a technology center. And without a lot of cynicism, I promise you, people go there to get the least educated jury panels possible. The question is not whether the jurors have modern science competence in whatever field they are examining patents, they have none. The question is not whether they are going to spend 25 hours studying the art and the patent, they are going to sit there and watch the lawyers do their show, and we have found in almost every trial that we have looked at, and we have looked at not only the ones we have done, but some that other firms have tried, and in no case has any juror ever read the patent front to back. No juror has read a patent front to back. So what we are doing is we are taking the PTO discretion and turning it over to these jurors in a situation where they do not have the tools to do much. Now, the Federal Circuit tells us that the decision
making by this jury is absolute, almost entirely. We are not going to give them a clear and convincing standard presumption, we are going to assume what they did was right, unless there is absolutely no basis on which they could have decided what they decided. That is the standard on appeal. So once the jury comes back and says “this patent is valid,” the only issue is is there any evidence from the disputed experts on which they could have relied. And taking it one step further, the Federal Circuit told us in the *Bio-technology v. Genentech* case that it does not matter that two national academy members have debated a highly esoteric, cutting edge issue with science as to which experts disagree, and that the jury could not possibly have made a reasoned decision. That does not matter in the slightest. The experts put on their testimony, the jury comes back with a verdict, and that is the end of it. The Federal Circuit will then accept that decision on the patent and that will be the decision that determines the fate of the validity of that patent. Given that that is the likely effect of doing away with the presumption of validity in most cases, I am perplexed. Now, of course others will point out, “Well, judges try patent cases too.” And that is true. And some judges study patent law, and some judges even have scientific training. Perhaps more importantly, judges
have the time and the incentive, they can read the
patents, they can hire technical experts that are
independent court experts, so they can have the tools to
do this right. A couple of points about judges, though.
All judges are not as interested in patent law or as
knowledgeable about it as the judges that are going to
appear before you, who are going to appear before the
Federal Trade Commission hearings. There are judges out
there who actually hate to hear patent cases and try and
spend as little time on them as possible. But the second
and maybe more important issue is, under our system,
either side can demand a jury trial. And the problem
here is one that we, the trial bar, created. In the mid-
1980's we started trying some very complex technology
cases to juries for the first time. Up until then, judge
trials, in patent cases, at least, cases about real
patents and real technologies dominated. But we started
trying some of these cases to juries and what we found,
of course, and we found it in these pre-trial focus
groups, is that one side or the other in almost every
case enjoys a huge bias to a jury. And because we now
know that, we will test that somewhere along the way and
that party in any significant case is probably going to
demand a jury trial and stick to it. And, again, that
jury may well be the jury in the Eastern District of
Texas. It seems to me that the efforts for fixing the Patent System would be much better spent on trying to improve the PTO processes as the Commission also suggests, and if we do fix the PTO processes, I do not understand why we would not want the presumption to continue.

Now, finally, just on the question of does the instruction really matter, I have some question about that based on my experience. The lawyer’s argument about how patents come about and what we are permitted to tell the jury by the judge, in my experience, matters a whole lot more than what the judge tells the jury in a very short instruction what the presumption of validity might be. So it would take a whole lot more than just changing the instruction to have any impact. There is now a videotape that was prepared by the Federal Judicial Center that describes how the patent works. I know it has been tested by different firms and I am not even sure we are getting consistent results, but at least what we have seen is that it strongly reinforces the presumption of validity of the patent. It shows patent examiners wearing suits and working on patents, and at least the impression that mock jurors give us back is, “Yeah, it looks like a good system. It causes us to believe patents must be valid if they go through that system.”
It seems to me that if someone in the government wanted
to change the jury view of what patents are and what
impact that you have on their deliberations, one of the
first things to do would be to make that a more balanced
videotape. And then the other thing is, judges have a
lot of discretion in what kind of instruction they give.
Some judges give an instruction that tells the jury that
the facts have to be clear and convincing to show that
the patent is invalid, and you have to have a strong
belief in your mind that it is right, maybe a moral
certitude is a word that is in some of the ancient
instructions. Here in the Northern District of
California, most judges use a standard instruction that
the court has worked its way through which simply tells
jurors that, in order to find the patent valid, they have
to be convinced that it is highly improbable that it is
invalid. It seems to me that a patent that has gone
through a Patent and Trademark Office procedure and has
had someone, who is skilled in the science and knows
patent law, judge this as an invention which should be an
issued patent, ought to at least have that impact on the
juror. They ought to be convinced that it is highly
probable that the government made a mistake. And then,
to close, the really most compelling thing we find about
patent validity in our jury research before trials is a
lot of our citizens believe that when the Government does something, it is probably right. This varies from geography to geography. Here in the Northern District of California, you can actually invalidate patents a whole lot easier than most other places. The Eastern District of Texas, not surprisingly given what I have told you, is one of the places where the jurors almost never think the government makes mistakes in its patent issues, and another court, and maybe one of the most important ones given all the trials there, is the District of Delaware and there, as well, the jurors almost always validate patents because they have this underlying glee in the correctness of government action.

MS. SAMUELSON: So, Ed, did you want –

MR. REINES: Yeah, let me address this a little bit. First of all, Professor Janis referred to the fact that people have used the term “trolls” and other terms such as that regarding people in the Patent System. As someone who has litigated a defamation action based on the use of various and sundry terms such as that, I advise that the word “troll” is probably safer than “patent terrorist.” So if you are going to use terms like that, or your client is going to use terms like that, there is better and worse for defamation purposes, I have had the pleasure of learning. The
comments I want to make, first of all, on the presumption of validity is it is important analytically to de-couple the presumption of validity from the standard of proof because they are two different things and they raise different issues. The Standard of proof, I think, in terms of jury decision-making is critical, it is the one thing the jurors grasp. Obviously, they will be swayed by a host of additional considerations, but when they hear preponderance vs. clear and convincing vs. reasonable doubt, those are things that they take seriously in my experience. And so it is one thing to change that. Now, there is a trend away from even informing the jury in terms of the judge of the fact of the presumption of validity. I mean, the patent exists, so in that sense it is there, it is valid, so that is the start point. But it is important to appreciate from a litigation perspective that judges are increasingly declining to inform the jury that there is a presumption of validity. Judge Shrum did that in the Eastern District of California recently and in a relatively important case that came out just about a week and a half ago in the Chiron case, Judge Rader’s panel affirmed that decision not to give a jury instruction or presumption of validity over objection and appeal, and so now there is Federal Circuit – a perimeter on that, as well as model
jury instructions in this district and others that do not have that. So if the jury never learns about the presumption of validity, at least from the judge, whether it exists or not, is less important because I think judges are used to the fact that presumptions are procedural vehicles, not substantive evidence, and they are capable of making the assessments of what weight should be given. So from a reform perspective, I think I am less concerned about the presumption of validity for those reasons, the trend away from even informing the jury of that as part of the instructions, and also the fact that judges are, I think, capable of handling that fact. Also from the reform perspective on the standard of proof, which from my perspective is where the action is, I think reform efforts should focus on the differentiation between different issues. There is a tendency to focus on prior art as the main area, and that is quite an important area. The areas that at least trouble me, personally, on the standard of proof are areas where, as a practical matter, the Patent Office is not performing any examination. So all the issues that we are talking about about the quality of an examination, or discouragement of the PTO, or anything else, do not apply to things such as inventorship, typically. I mean, there can be disputes, but in general, the Applicant
submits who the inventors are and that is it. I mean, if
you have been through the ringer, you know that there is
just not scrutiny on that. Best mode is another example.
I have never in all the file histories I have looked at
seen a Best Mode objection or, if I have, it has been in
an anomalous case. So it is on those things where there
is not really examination, certainly in any meaningful
way, and yet there is an elevated clear and convincing
standard. That seems to me to be wrong. When you move
to prior art, it is a more complicated picture and I do
not think they should be conflated. On the prior art, I
think, there is one thing where there is a joined issue,
an interference, a re-examine, or just a thorough
examiner doing the right job where it makes sense for it
to be a higher standard, and there are situations where
the prior art is never presented or, in the case of 102E
prior art, maybe did not exist at the time of the
examination, where the same level of proof should not be
required. So I would propose decoupling the two and
then, within the standard of proof issue, which to me is
the more important in terms of reform efforts, having
nuance to distinguishing the different elements. Thank
you.

MS. SAMUELSON: Great, thanks. Now we will
hear from Mark Lemley.
MR. LEMLEY: Okay, well, so let me start out with presumption of validity and then actually broaden it to some other issues that — there is a bunch of litigation reforms in the FTC Report we have not talked about yet. I think the FTC is exactly right on the presumption of validity, and here is why. The problem is that, for a variety of structural reasons, the PTO is simply not set up to make anything like a very strong determination one way or the other on the validity of a patent to which we ought to give it substantial deference in litigation. Why is that? Well, start with the fact that the applicant never has a burden of proving anything, right? The way the law is now interpreted, if I decide to patent the wheel, my invention is that it shall be round, and the examiner does not come up with prior art — or it is the examiner’s burden to come up with prior art, if they don’t, I get the patent. Right? The presumption in the Patent Office is I get a patent. Then when we get out, the presumption is, “Well, that patent was examined by the PTO, and so it must be valid.” But there is never a point at which I have affirmatively to show anything. Second, the PTO is over-worked. They get 350,000 applications a year. They devote 17 or 18 hours total over the course of three years to your patent. That means reading your application, searching
for prior art, reading the art that you submit, comparing
it to the application, writing a rejection, reading the
amendment and response you write to that objection,
probably writing a second misnomer’d final rejection,
dealing with a phone call in which you are persuaded by
the applicant to change your mind and allow it, and
writing the Notice of Allowance – all that, three years,
17 or 18 hours. Now, maybe they do a wonderful job under
that time constraint, I am willing to concede that, I do
not think the problem is examiners are stupid, right?
But I think the problem is, given the time constraints we
have and the cost constraints we have, that cannot
possibly be a full and searching examination of the kind
that you will get in litigation. The problem is worse
because the way we have structured the examiner’s
incentive, you get rewarded only for the first office
action and for finally disposing of the patent. You do
not get rewarded more for disposing of a patent that
cites 150 pieces of prior art and has 120 claims than a
patent that cites two pieces of prior art and has three
claims. As a result, those long complex patents, which
are the very ones that turn out to get litigated at the
end of the day, are likely to get less scrutiny per
claim, less scrutiny per piece of prior art, because the
examiner’s incentive is not to focus on the complex ones,
the examiner’s incentive is to get as many applications out the door as possible. Right? Couple that with the fact that there is a very strong culture in the Patent Office that issuing patents, not denying patents, is the thing to do. When you look at the mission statement of the Patent Office, it is to help our customers get patents. That may be a very justifiable mission in lots of respects – patents are good things, but it is not something that inclines examiners to resolve the doubtful case by rejecting the patent application, and indeed they don’t. Once you take continuations into account – continuations are another problem – you cannot ever finally reject a determined patent applicant. No matter how many times the examiner says, “No, I do not wish you to have this patent,” the applicant can always come back and ask again. You can wear down the examiner until the logical thing to do is issue the patent. And it turns out, as a result, when you take into account continuations, about 85 percent of all applications result in at least one patent at the end of the day.

Now, is this a flaw in the PTO? Maybe. I actually tend to think not. I think, instead, the PTO is doing what it is supposed to be doing, it is doing a quick once-over. Right? It is doing a light screen of this huge number of applications to weed some of them out, to narrow some of
them in scope to prevent people from claiming too much,
and then it is properly leaving to the litigation process
the real hard determination, the devoting of ten’s of
thousands of hours, to searching for prior art, to
analyzing prior art, they are doing that validity. But
we can’t leave that determination to the court, on the
one hand, and then, on the other hand, say, “Oh, but
because we have had 17 hours of scrutiny in the PTO, we
must give deference to that scrutiny.” Now, Lynn says,
“Wait a minute, if we do not allow - we do not give that
deference - the result is going to be juries run amuck.”
Well, let me tell you a couple of things. First off, it
is plaintiffs, it is patentees, not defendants, who are
going to Marshall, Texas, because they want the jury that
does not have the technical background. They are going
there because they know, and the empirical evidence bears
out, juries are more likely to favor the Patent Office
already, right? Because the jury says, “Wait a minute, I
do not know anything about atomic layer deposition. The
PTO has experts. They have already blessed this. I am
inclined not to second-guess those experts at the PTO.”
If we reinforce that already existing inclination by
telling them legally, “Let’s have a strong presumption
that what the PTO did is right,” the likelihood is we are
never going to get substantial numbers of jurors to take
a serious look as the litigation system wants them to take a serious look at whether or not these patents are actually valid. Lynn then says, “Well, the Federal Circuit is going to defer too much to the jury.” That is, I think, perhaps the first time I have heard anybody say that the problem with the Federal Circuit is excessive deference to what goes on in the District Court. They are in huge panels discussing the opposite, that the Federal Circuit intervenes too much. It seems to me that litigation, as Joe Farrell points out, is an imperfect system. But if anything, it is an imperfect system already biased in the patentee’s favor. Why would we want to give a better bias, a stronger bias to it? I do not know. So I think that what the FTC recommends on this issue is exactly right. At a minimum, even if you think this is too radical, either too radical to be adopted or too radical to be good policy, then we ought to take what Ed says to heart, right? At a minimum, on issues in which the Patent Office has not engaged in examination at all, either it is an inventorship issue or it is prior art that was not cited before the Patent Office, it seems absurd to give deference, clear and convincing evidence deference, to the PTO’s determination because there was no determination. So the idea that it has got to be an across-the-board validity presumption.

For The Record, Inc.
Waldorf, Maryland
(301) 870-8025
seems even more silly than the standard as it currently exists.

Final point. We have not really talked at this conference about implementation, but it seems to me that the way this can be implemented is actually quite simple. If you go back and you read the statute, the statute says there is a presumption of validity. Of course, the statute also says in copyright cases and in trademark cases, there is a presumption of validity, and that presumption, as Ed points out, is decoupled from the standard of proof. In both of those cases, it is a presumption, but it is preponderance of the evidence. It does not take statutory reform to implement this particular FTC proposal. All the Federal Circuit needs to do is say, “Wait a minute, maybe it does not make sense to be deferring quite as much as we already are.”
Alright, so much for presumption of validity.

A couple of much briefer notes on two other reform issues, one which I suspect no one else at the conference is going to talk about because it seems fairly obscure and non-controversial, is the Section 105 relevancy statement, this was briefly mentioned this morning. Todd Dickinson says – one of the things he did is he got examiners the power to demand from applicants that they explain the relevance of particular pieces of
prior art, and this seems to make sense from the examiner’s perspective if you are inundated with large amounts of prior art. What I want to know is, what do I need to read. Right? Given my time limitations, what is it that is important to me? But I will tell you as a litigator, if you start as a practical matter requiring relevant statements in Section 105, I guarantee you that in every case I defend, I will get past summary judgment with an inequitable conduct defense. If you make somebody write down, “Here is what is important in this prior art reference,” there will always be something that they left out, there will always be something that you can say, “Oh, they said it wrong, they misstated it,” right? There will be a litigation bonanza for defendants. The only thing you can do if you are a prosecutor in response to that is over-disclose. “Here is each piece of prior art, you need a relevant statement for each piece of prior art. I am going to tell you everything is relevant. Here is why this paragraph is relevant, here is why this paragraph is relevant, here is why this paragraph is relevant.” PTO’s burden actually may end up being higher, not lower. So I think it is a good idea in the abstract, and if we focus only on the PTO, it makes perfect sense. I fear a little bit, though, the litigation consequences of doing that.
Alright, final point. The FTC suggests that we need to change the trigger of willfulness. Right now, I can be a willful infringer merely because I run across a patent. My engineer reads a patent, they are aware of the patent, they are doing something which we later determine infringes that patent, they are a willful infringer at least unless we start playing a rather remarkable game in which I go get an opinion letter of counsel that says, “Oh, no, it is okay to continue doing this.” I agree to disclose that opinion letter of counsel in litigation, I therefore waive the attorney-client privilege — how far, no one seems to know, there are no less than eight different legal rules in District Courts on how much the waiver extends, right? If I play this game, I am in serious trouble, and so a bunch of lawyers tell their clients, “Whatever you do, don’t read patents, because if you read patents you get us stuck in this really sort of labyrinth and quite disturbing process.” So what the FTC suggests, which it seems to me is exactly right, as a starting matter, is we ought not say that merely because an engineer read a patent, the company is willfully infringing that patent. Right? We ought to have a higher trigger. I think that is a good idea, I think it is a necessary reform, but I do not think it is a sufficient reform. There are substantially
greater problems with the wilfulness game. I am still, whenever I get a letter, going to have to get my opinion of counsel, disclose my opinion of counsel, waive the attorney-client privilege, it distorts litigation advice, it distorts pre-litigation advice, it distorts your choice of counsel because you want your opinion counsel to be different than your litigation counsel, and so there are substantial problems with the wilfulness game that are not addressed here, but at least the FTC’s report is a first step. Well, Mark Janis and Arti Rai both said they would talk quickly, and I think what they meant is that they would talk briefly. I actually did talk quickly, but I am done.

MS. SAMUELSON: Following up on the issue of subjective factors, Jim Pooley, I think, wants to say a few things.

MR. POOLEY: Thank you. Mark is always a hard act to follow and all I can promise is I won’t say as many words. You know, first, on a point of personal privilege, because the issue of the video from the FJC came up –

MR. LEMLEY [presumed]: The Pooley Video.

MR. POOLEY: No. But I did write the script for that, and all I can say - I have since retired from that business and am now practicing law - all I can say
is, you know, we received as many comments in the other
direction of what Lynn brought up, and I take that as a
signal that we probably did what we were supposed to. In
fact, people on the other side of that debate complained
about the narrator’s comment that, you know, you may be
wondering why you are here being asked to decide these
validity questions. Well, in part, it is because
mistakes sometimes are made, and while that is being
said, you know, we cut to a scene of the over-worked
patent examiner in her office with a stack of files this
tall on her desk. And then that scene at the end where
somebody pushes the cart through the file room when it
looks like the final scene in Radars of the Lost Ark.
You know, we do try to get both sides in there. But,
moving on to the issue at hand, I had the privilege for
the last several years of working with my colleagues on
the Committee of the National Academy project, and the
basic thing that we were looking at when you boil it all
down, with the benefit of a lot of academic interest and
perspective, was why do we hear so much noise and concern
about the Patent System? Where is the sand being thrown
into the gears of the machine? And in large part, we
found that it was in the enforcement system. And here I
have to say I agree very much with Bob Blackburn on this
point, you know, when you talk to our clients, the people

For The Record, Inc.  
Waldorf, Maryland  
(301)870-8025
who deal with this system, they will tell you the reason that they end up being so irritated about having to pay out large amounts of money for something that is not perceived by them to be of very much value intrinsically is because they are petrified of the uncertainty, the unpredictability of the outcome of the process, as well as its costs. So when it gets down to enforcement, we find, I think, some of the greatest impact of the choices that we make in designing the system on how it actually is implemented. And, in part, looking at the enforcement system, we run into the issues that Lynn mentioned about using juries for this process of considering validity questions and, of course, people from outside our judicial system look at that as something sort of comically quaint until, of course, they are in front of a jury trying to argue invalidity against the presumption. Not being able to modify the Seventh Amendment, apart from perhaps suggesting a third way in the post-grant opposition process, one of the things we looked at and one of the areas of recommendations that you will see is, is this phase of litigation in which we deal with subject elements of the parties. And one of them, Mark just mentioned and that is the subjective – the state of mind of the alleged infringer, and it plays out in willfulness. And here again we find in looking at the
question balancing the purpose of willfulness, which is supposed to provide some additional deterents against infringement, in a way very very large transactional costs that involve getting opinions that may be worthless for any other purpose whatsoever, and give people a real cynical view of the system itself, the cost of litigating the problems around the scope of the waiver of the privilege, and for the clients who face this from the outset seeing their exposure tripled, potentially, against a standard that they really can’t understand. And so it is no surprise, then, that you see companies instructing their engineers, “Do not read patents.” And so when we are looking at cost-benefit analysis here of that incremental benefit that we get in deterring infringement, we have to consider is it worth provoking a result that is 180 degrees from the constitutional mandate of using patents in order to inform the progress of science and the public knowledge. So willfulness is sort of an easy target in the panoply of subjective factors that we have to deal with in litigation. There were two others that you will see in the report that have to do with the state of mind of the patentee, one has already been referred to as “Best Mode,” and although it does not come up that often, when it does it is a real side show – and an expensive one in terms of discovery,
and one wonders what it actually gives us in terms of benefit over and above the other provisions of Section 112 in motivating the parties to do a good job in describing their invention. We also, in that particular instance, run up against a substantial irritant and problem where international harmonization is concerned because, as in the area of First to File vs. First to Invent, we are the only jurisdiction in the world that employs Best Mode. And those who try outside of our country to harmonize their efforts with our system find this to be a very very puzzling difference.

The last one of these is inequitable conduct, also referred to – I think Mark said if Section 105 were really used very much, he would be able in cases where it was invoked successfully at the Patent Office to be able, in every one of those cases, to establish an inequitable conduct claim that would get past summary judgment, which is a little bit of an example of why this particular subjective element, although it is perhaps alleged less frequently these days and perhaps less of a practical problem because it is decided by judges rather than juries, nevertheless appears to be more of an inefficiency in the system, or cost in the system, than is justified. The additional burden on discovery, the additional burden on the plaintiff from having to
consider whether it is counsel who might be participating as trial counsel, can actually take part in the litigation and trial of the case – all of those inefficiencies have to be weighed against what is probably a very very statistically improbable incremental assistance that you get in making the system work, from having this aspect available to the parties to litigating their cases. So one of the things that you will see in the report is that we have suggested that these elements which deal with state of mind either be eliminated or be substantially mitigated in a way that reduces their impact on the unpredictability and the cost of litigating disputes and patents.

MR. REINES: Could I pitch just one minute on that? Just on willfulness, one thing to keep in mind is that in Federal Circuit right now is the Knorr-Bremsey case, which looks to be the palette from which they can re-write willfulness law altogether. I know Congress right now is deliberating based on what I have heard from committees on some willfulness reform, and the FTC obviously is wading into those waters as well. I would just suggest that all of those efforts wait to see the outcome of the Knorr case so that we can see what the Federal Circuit has done to cure that area, be clear what the law is in terms of getting some stable foundations
from the Knorr case, and against that background can
determine what, if any, reform is appropriate. Thank
you, Pam.

MS. SAMUELSON: Great. Would any of the other
panelists like to do commentary? Shall I open it up?

MR. LEMLEY: Let me just – Jim maybe hobbled
in this respect on how much he can say. I was quite
interested to hear that one of the recommendations was,
as I understand it, either eliminate or put substantial
constraints on the inequitable conduct defense. Maybe
understanding more about what the NAS proposal actually
is would help in this respect. I guess I am a little
nervous about the effects of a rule that said there is no
inequitable conduct defense – not because I think the
inequitable conduct is rampant today and, indeed, you
know, there are lots of frivolous claims of inequitable
conduct asserted, but because I fear what would happen if
we sent a message that there was no punishment for lying
or failing to disclose evidence to the Patent Office.
And I wonder whether you guys have thought about that and
what you might say about that.

MR. POOLEY: Well, no, indeed that issue is
reflected in the report because it was a big part of our
deliberations in every one of these cases, I think. We
looked at what is the real objective, what is the goal of
the particular element, and how central -- important is it. Can you get there by using other methods than this one, and what is the cost? So that analysis is in the report. And I do feel a little bit constrained about talking about the details of exactly what we have recommended because the thing was not here in time.

MS. SAMUELSON: So something to look forward to for Monday. Questions, comments? Yes, in the back.

MR.: [Audience -- off mike]

MS. SAMUELSON: Could you restate the question?

MR. PASAHOW: The question is does the presumption of validity affect the ability to get a summary judgment in litigation. And for those of you who are not lawyers, summary judgment is a motion you make before trial and it is decided just upon written submissions of whatever the relevant evidence is. And technically, I think the answer is it shouldn’t because the question for the summary judgment is, “is there any evidence on the other side?” And if there is any evidence, you are supposed to deny the summary judgment. It should not matter whether ultimately the question is, is that evidence going to be sufficient and meet a mere preponderance or a clear and convincing standard? In putting aside that theoretical issue, in my experience, I
have not seen trial judges get held up on the issue of whether it is clear and convincing or preponderance for summary judgments. On the other hand, there is the aura that this presumption puts around patents that I think sometimes does impact judges, at least subjectively. In making that whole aura go away, it might impact things like summary judgment more than we can guess.

MS. SAMUELSON: Any other panelists want to - okay, in the back.

MR.: [Audience -- off mike]

MS. RAI: I can speak to that since I spent a lot of time -

MS. SAMUELSON: Could you repeat the question?

MS. RAI: Oh, sure. I take it that the burden of the question was, isn’t it interesting that the Federal Circuit, at least with respect to some of its judges, has been trending towards a plain meaning, version, of claim construction so that there is not nearly as much need to look to the PHOSITA, for example, or to factual issues more generally. I think that this is part of the - I mean, I could speak at great length about why I think this is part of the Federal Circuit’s desire because it feels like it is the most competent actor in the system to try to really control all aspects of the system, and it is not a crazy position to take for
the Federal Circuit to believe that it is the most
competent actor in the system, but I do think that that
means that the PTO gets ignored to some extent. Now, the
only way in which it does not get ignored, as I have
indicated, is in the context of patent issuances and the
clear and convincing evidence standard gives more
deferece to the PTO than perhaps was given by the
predecessors to the Federal Circuit. But with that small
exception, it seems to me that that is a sort of
indication of the Federal Circuit’s wanting to kind of
root out factual issues altogether so as to have more
control over the system.

MR. JANIS: I was just going to say I think
the question raises an interesting point about linkages
between the presumption of validity and other issues, so,
for example, I wonder suppose we did change the
presumption of validity, making it apparently easier to
invalidate patents? Would we get an equal and opposite
reaction in scope doctrines? You know, we start
construing claims to preserve their validity, really. We
see other changes at the Federal Circuit that liberalize
scope doctrines going back the opposite direction where
they have been trending. So what would happen? Who
knows? But I do think it is important to see a change to
the presumption of validity might well cause a cascade in

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
changes in other areas, we should not look at it in isolation, I don’t think.

MR. LEMLEY: Going back to Mark, one of the things that has always struck me as remarkable about prosecution practice distinct from litigation practice is exactly how little claim construction seems to matter in the prosecution process. Right? I mean, we get to court and we fight over the meaning of words that you would not possibly think could have a disputed meaning, right? I mean, there are Federal Circuit decisions interpreting the terms “A” and “Or” and “To” and “When.” But none of that seems really to happen in prosecution, right? And maybe it is just a function again of the time constraints and how detailed the analysis is, but we seem to sort of skate through prosecution without substantial discussion about what the terms mean, and so there is a bit of a tabula rasa, right? The Federal Circuit’s later change in how we will interpret those terms may not affect prosecution as much because it is just not being thought about as much in prosecution.

MS. RAI: Well, there is an obvious reason it is not thought about as much in prosecution. You think about those terms like “on” and “in” and all that only when you are confronted with an infringer who says that “on” and “in” and what have you do not take the infringer
outside the scope of your claim, so -

    MR. LEMLEY: You see it for validity too, although it is often an infringement driven doctrine.

    MR. REINES: Just a couple comments. One is I think there is just a practical problem if you are going to attempt to run some sort of concordance between the law at the time of prosecution vs. at the time of enforcement, or District Court litigation. I mean, there are all kinds of areas in law that change all the time in radical ways, and so I think we have to be somewhat humble about our ability to bring that into sync, on the one hand. On the other hand, I think the point was addressed, actually, by Professor Lemley’s comment that, really, if you think about examination it is sort of a reasonably good once-over pass, and that that is not going to get into the level of going through the dictionary library and then to experts and what they understand this to mean. So I think that is addressed in the sense that we have to recognize that there is not full blown claim construction of the style of Texas Digital or anything else taking place during prosecution, in general. I think the way that the Patent Office attempts to address this, and others can address this in more detail, is through assuming the broadest general meaning of the claims, and maybe that rule needs to be
given more vitality in order to address the practical reality that the Patent Office is not going to perform a full blown claim construction on every word in a 100 claim application.

MS. SAMUELSON: Yes?

MS.: [Audience -- off mike]

MR. PASAHOW: Well, that is a good point, but –

MS. SAMUELSON: Could you repeat the –

MR. PASAHOW: The point was that if courts gave deference to opposition proceeding statements about claim construction, that would eliminate some uncertainty – well, a lot of the uncertainty. It is a good point, but often as you are talking about the validity of a patent, the issue of claim construction is less intense because everyone who is challenging the patent, and the examiner under the governing rules who is looking at it, simply assumes that the words have their broadest meaning – or the broadest meaning they could have to one skilled in the art. Often the examiner is that person, too. So the issue does not come up as to every word in the claim that is going to get litigated about when you start comparing it to a product. And whoever’s product it is is trying to find some word that arguably doesn’t apply.

MR. LEMLEY: It also may depend a little bit
on the structure of your opposition proceeding, right?

Is this a proceeding in which we are going to have
Administrative Patent Judges write opinions giving the
reason for rejecting a challenge, in which case they may
be explaining why they think that the patent has a
particular scope, and therefore avoids the prior art? Or
are we going to fall back, in essence, on a Prosecution
History Part II approach in which my representations in
front of the Administrative Patent Judge may be binding
or helpful in interpreting the meaning of the claim
because I made them?

MS. SAMUELSON: Ron?

MR.: [Audience -- off mike]

MS. RAI: Although presumably, even if we were
going to give full deference to whatever the opposition
proceeding yielded with respect to constructions in
particular context, if there was nothing said about other
words, there would be no reason to give – there would be
nothing to give deference to, just as there is nothing to
give deference to with respect to the PTO’s failure to
examine particular issues like Best Mode, or what have
you. So I am not sure it ends up being such a big issue
because –

MR. [Audience -- off mike]

MS. RAI: Well, that is what I mean. And then
those would have to be – I would assume that that would
just be litigated de novo because there – well, probably
to some extent de novo, anyway, because there would be no
prior opposition proceeding holding on that question.

MR. LEMLEY: Well remember, of course, Markman
is a question of law and under Cybor there is no
deference even to District Court determinations of what a
term means, so the likelihood that there will be
deference to the Patent Office Administrative
determination of what a claim means seems dubious to me,
so only if you actually appealed the opposition to a
Federal Circuit would you get a defined meaning of the
claim term.

MS. RAI: Well, FTC recommends that, as a part
of the opposition proceeding legislation, Congress
mandate deference on questions of law –

MR. LEMLEY: Of – yeah.

MS. RAI: – even, yeah. So.

MS. SAMUELSON: Well, on that cheerful note,
it is time for lunch. It is my understanding that lunch
will be served in the back of the room and we will
reconvene at 1: 40 in order to hear Judge Whyte, but you
have almost an hour to enjoy yourselves.

[Off]

JUDGE WHYTE: Good afternoon, everyone. I was
asked to give the bench’s reaction to some of the proposed reforms that have been suggested by the FTC and others, so I thought I should begin my task or assignment by sending out an e-mail to my colleagues and asking them for input, and what I did was I sent them a two and a half page summary of the Executive Summary of the Report, and referred them to the 315-page report that was on the Web. And I thought it would be useful to give some of the responses that I received. I got a high percentage of returns from my colleagues and let me start by reading a few of the more insightful ones. The first one I received was only two words: “Good grief.” Then, from someone – well, I will just read it, “The meaningful reform would be the elimination of jurisdiction for the District Court in patent litigation. And quote me on that.” I won’t give you the author, but his brother is on the Supreme Court. “I have a few suggestions you may want to seriously consider. Require patent litigators to wear boxing gloves, allow courts to charge patent attorneys an hourly fee for Markman hearings.” And the final insightful one, I will read to you, it says, “These patent cases involve more acrimony than any other category of cases which I have, including an actual fistfight in a deposition.” Well, that gives you a little flavor of some views.
Let me now turn to a little more substantive comments. These comments are somewhat the comments of the judges that I surveyed with a sort of heavy gloss of some of my own thoughts. I would say it would be fair to rule or say that the judges in general affirm the FTC recommendations. I think they felt they were well thought out and generally made a lot of sense.

I would like to comment briefly on some observations about the Patent System from the court standpoint and perhaps with a gloss, as I say, of my own. I have essentially three points. One is that too many patents are issued. Whether the figure is 98 percent, which shocked me, that I read in the report, or only 74 percent, it seems to me that that – maybe it is too wrong a word, but is absurd. It almost reminds me of the Emperor’s New Clothes – if you are in the system, you look and you say, “Well, that is the way it goes, that is okay.” If you step back, and some of us like myself – when I became a Federal Judge, I had absolutely no experience in intellectual property or patent law, and I think the most shocking thing I learned after I had been on the bench for a while was that the percentage of patents that are applied for actually end up being issued. And I think, since I was shocked, I teach an extern course at Santa Clara Law School, I have asked the
extern class what percentage of patents that are applied
for do you think are issued. I have had high school
students into the court and I have asked them, and at
least their perception or belief is, “Gee, it would be a
very small percent of applications that are issued
because a patent is an invention, and inventions just do
not come along every day.” But it seems – and I kind of
agree with that, and it seems to me we have got a system
that needs a real look as to trying to change so that we
really have an invention when we issue a patent. And I
think there are some ways that this might occur, one
obviously is that the PTO change its approach. That is
difficult to do, but it seems to me that an examiner’s
attitude, particularly if we continue with this ex-parte
process, has got to be courteous, but very skeptical of
any application.

Also, it seems to me that the FTC’s proposal
for a post-issue reexamination procedure – and I
understand Professor Merges is writing an article on this
– has appeal, but I was curious and I did not see much
discussion in it as to the effect on a later infringement
validity lawsuit between two private parties, what effect
the post-issue reexamination procedure would have. If we
are talking about something that would have some sort of
Chevron deference, in other words, essentially the
District Court would get out of the business of reviewing validity decisions, that might make some sense. Then other questions that were raised in my mind is, well, would there be some sort of exhaustion requirement if you are challenging validity? Would you have to exhaust, or at least try to exhaust this post-issuance reexamination procedure? If such a system would eliminate or lessen later litigation, I think it makes some sense. If, on the other hand, we ended up with a system that just added an administrative layer to the process, I think that would be bad. So I think the idea is a good one, but there are some unanswered questions, at least in my mind, and I think my view there is consistent with those of some of the other judges.

Secondly, and this I know was talked about this morning – unfortunately, I was not here, I would have liked to have been - is with respect to the presumption of validity and the clear and convincing evidence standard with respect to validity determinations. I think now, to some extent, and a little bit depends on the court you are in, that the existing law is kind of a double whammy against the party challenging the patent because if you instruct a jury that a patent is presumed to be valid, and it has got to be proved invalid by clear and convincing evidence, you really are suggesting there
are two things, 1) there is the clear and convincing
evidence standard, and then, 2) there is also a
presumption of validity. And it seems to me, really,
what the presumption of validity is is a mechanism for
shifting or explaining the burden of proof. So at least
if we had a current system, I think it should be made
clear, and I think in most model instructions now, the
committees that have prepared those instructions, have
gone this route, that, say, something along the lines
that since the patent was issued by the Patent Office,
the burden of showing invalidity is clear and convincing
evidence, but it says nothing about a presumption because
a presumption itself really is not evidence. It also
seems to me that if we do not change whole-heartedly the
burden of truth to a presumption of validity as opposed
to clear and convincing standard that there ought to be
made clear a distinction between what deference is given
to the Patent Office’s decision based on what the Patent
Office had before it. For example, if an applicant
disclosed certain references and pointed out the argument
against patentability, and then answered it, it seems to
me that applicant should be entitled to some
consideration – heavy consideration – if the Patent
Office then issues the patent and it is later challenged.
Conversely, where the applicant fails to raise certain
matters for material prior art, and the file does not show that the examiner ever saw it, then it seems to me that the presumption of validity has little weight or should be given little effect. The fact that if you did have sort of a duel standard along those lines, one of the things it would encourage, or that it would have the effect, it seems to me, of encouraging applicants to do searches, as opposed to now not feeling they have to undertake a search because they might find something that would be harmful.

The willfulness issue is another issue that is a constant concern to the court. It is a real pain, to say it a little more bluntly, but I do not know my audience well enough, but there are constantly problems with, well, if you rely on an attorney opinion to defeat willfulness, how much of the attorney-client privilege have you waived? Are trial counsel’s notes available? It is just a nightmare. And for those of you who are practitioners or law professors who have studied the issue, or anybody that is interested, you will find that the courts are not consistent at all as to how they treat that issue. My reaction to the Federal Trade Commission’s recommendation of kind of a bright line rule that willfulness is only available if the patent holder has been given written notice of infringement or there is
evidence of direct copying, makes a lot of sense. The only thing I would add to that is, to the extent that one interprets the law currently as allowing or calling for an adverse inference if you do not have an attorney opinion, I think that law creates a lot more problems than it solves and I think it also risks being a real interference with what is otherwise a pretty highly held privilege, that is, the attorney-client privilege.

The last area that I wanted to speak to just briefly is the question of obviousness. The FTC’s recommendation, I think, is an interesting one, and that is that we do away with the need to find a suggestion to combine in the prior art and ascribing to one of ordinary skill in the art an ability to combine or modify prior art that is consistent with the creativity and problem solving skills of someone skilled in the art. I think theoretically that sounds like a good idea, and generally I react favorably to it. The one concern I do have, though, is it seems to me that gets away from an objective standard and you would be guaranteed in almost every case a battle of experts. And I may feel a little more strongly than other judges on this, but I am very skeptical of expert witnesses. That is one reason I don’t like the willfulness issue as it now exists because I think you tend to develop - attorneys are good
advocates and you develop cadres of attorneys that are basically paid advocates that come in - and I do not want to say somebody that is paid will say anything, but I think I found when we were dealing with the willfulness issues, or it was common practice to have a patent law expert testify at trial, that I found those experts to be very much paid advocates, as opposed to someone who was truly independent and giving an honest opinion. So that concerns me. I like the idea, I think obviousness is something that needs to be tightened up, but I do have some question about the practicality of the suggestion that is made by the FTC. One concern I do have about tightening up obviousness, though, is if we do that, does that mean that we are going to get rid of the patents such as the one for swinging by pulling the chains on the swing in different directions, the method for swinging? Or the method for picking up a box without bending your back and only bending your legs? Or, my favorite, the method of painting using a baby’s butt, dipping it in paint and stamping it on a canvas. If we tighten it up too much, we are going to lose a lot of our humor. And in summary, I think the majority opinion of the judges is that the FTC’s recommendations should be affirmed. There is a dissent that says reverse with directions to include a recommendation that District Court jurisdiction over
patent disputes be abolished. I would be happy to take any quick questions if we have got a couple minutes. I think I was supposed to end at 2:00 and it is right at 2:00, so maybe that is it. Thank you.

PROFESSOR SHAPIRO: Let us get started. Now that Commissioner Thompson is here at my side, welcome. I am Carl Shapiro. This is the Industry and Institutional panel. We are going to try to really bring in industry here more directly and see if we can have ideas into action as promised or suggested. I am a professor here at the Business School. I come more from the antitrust side, but I have long been interested in antitrust and intellectual property issues. I think also a lot about competitive strategy, so I am particularly keen to hear today from our wonderful panelists how the Patent System or its flaw are really affecting business. My perspective – I put the cards on the table right at the front – is if the Government is going to be granting monopolies, they should do it when there is a good reason to do so and not just because we have got a process that favors people who are hoping to get such grants.

COMMISSIONER THOMPSON: From the Government’s side, there are very few good reasons to do so.

PROFESSOR SHAPIRO: There is my co-moderator. You have heard from him.
COMMISSIONER THOMPSON: There are a few, there are a few.

PROFESSOR SHAPIRO: So let me explain what we are going to do. Commissioner Thompson reserved special intervening rights, okay, I think he is going to raise his pinky and then everyone has to stop talking –

COMMISSIONER THOMPSON: That has never worked before.

PROFESSOR SHAPIRO: I am going to be the time-keeper. And with a dozen panelists and many topics to go through, this is - I tend to take my job seriously, so let me demonstrate my tools of the trade. When there are time limits, and in addition to the pathetic waving of the stop sign, we will have - be quiet now - that means now would be a good time to wrap-up. However, I understand from law enforcement that sometimes one needs a higher threat of action if people don’t comply, and as many of you patent attorneys understand, that the threat of what can come next, you know, can affect things since you often negotiate in the shadow of litigation. And I want to take - a point of personal - this will take one minute to tell a story here - this involves Jose Capablanca (phonetic) who was the world chess champion during the 1920's and he had a championship match against Allakein (phonetic) in 1927, and they were bitter rivals.
Capablanca was Cuban and he was a big cigar smoker, not surprisingly, and of course Allakein negotiated that Capablanca could not smoke his cigar during the chess games. But there they show up to the first game, Capablanca is with his cigar. Allakein complains, says, “We agreed you wouldn’t smoke;” Capablanca says, “I’m not going to smoke, I just like to hold my cigar while I play.” And Allakein thought about it and said, “But I am very concerned about the threat that you will smoke.” So I have to have a threat. I will demonstrate it once, I will not light up my cigar. If you go on too long, we have a noisemaker here that will make the point. Everybody get it? Okay. Here is what we are going to do. We have great industry representatives here and we have representatives of several associations of attorneys. I think together we can really get a sense of how some of these FTC proposals are being greeted by people who live and breath this in their businesses and through all stages of the patent process, through attorneys who know these far better than I do. Okay, so - and I think you hopefully have heard the other panels. I think the problems are well set up. I am not going to repeat that. We are going to go right into really how does this affect companies and where are the Bar Associations at on some of these proposals. Okay, I
think we have heard a lot about, concern about patent
quality, okay, what does it mean in practice and what do
the people who know these things best as practicing
attorneys – what is their reaction to these proposals?
And I think it is very important here to bear in mind
that even companies that have a lot of patents do not
necessarily think, “Oh, stronger patents, more patents is
better.” Okay, it is not that simple. In fact, many of
them with many patents are concerned that there are too
many bad patents out there at the same time. In addition
to the industry representatives, and I am not going to go
through and introduce everybody since they will have
their chances to speak, and I do not want to take the
time for that, we have representatives of five important
associations, so let me just mention those associations
and the people can speak more about that, the ABA
Intellectual Property Law Section, the AIPLA, the
Intellectual Property Owners, Bio, and the U.S. Council
for International Business. So a number of the panelists
will be speaking on behalf of those organizations, other
panelists will be speaking on behalf of their companies,
and some clever panelists will wear two hats and will
have to tell us which hat is on when they speak. Okay.
One of the good things here is that a number of these
organizations are in the process of responding to
evaluating the FTC proposals, so we will be able to hear where they are at, okay? In most cases, they do not have the formal final approvals yet, but we will be able to get an early read on when they are coming out and I think that is very very helpful.

The way I want to run this, then, is three phases, first I am going to give each company representative a few minutes to tell us about how the Patent System and flaws in the Patent System really affect his company. Okay, what do they care about? How is this causing problems in the real world for their businesses? And where is their company most concerned and most interested in change? Some elements of those. Then we will spend most of our time walking through the FTC proposals one after another and getting the sense of where people are at, is there a consensus or not on certain proposals? And then the finale. We will see with Commissioner Thompson leading us where we will go with all of this and what can be done. I am going to go through the eight company representatives in alphabetical order by name of person and we start with Robert Barr from Cisco. Make sure you have a mike.

MR. BARR: Okay, thanks Carl. First, since you are asking us to do this, I want to object to the dismissal of this kind of evidence as anecdotal. I have
heard it a few times now in reaction to the FTC Report and it – one person’s anecdote is another person’s case study is the way I look at it, and I think the FTC did a great job of synthesizing a lot of anecdotes into a very coherent report that showed I think what you are about to hear that some of us in the industry – that more than one of us in the industry have some issues. That said, I want to say we are a stakeholder in the Patent System, we are a major owner of patents and an investor in the system. We want patent quality. We want patents to be respected. I do think it is pretty simple. Patents are like children and yours are good and everybody else’s are bad, so, you know – well, our patents are therefore of high quality. Secondly, in addition to being a patent holder, we are what I can only call a potential defendant, or a deep pockets, or a company with revenue, whatever you want to call it. So we have an interest in avoiding infringement. In fact, if I could choose my job and do it, I would say my job is to avoid infringement like I do with copyrights and trade secrets and laying down the law, as it were. But with patents, that is pretty difficult. We used to call it a minefield out there. Thanks to Carl, we now call it a thicket, which I think is a better image because it is not just a bunch of mines that we have to avoid, it is an overlapping morass
of patents that is virtually impossible to avoid. In corporate-speak, that is a risk management problem of the highest order. It is virtually impossible to avoid all those patents because of the sheer number of them, but in addition to that, the unpublished patents, the published patents that you do not know what they are going to turn out to be, the numbers are pretty big, and Intel representatives have quoted numbers like 80,000 patents on a microprocessor, it is just a clue to what is going on.

Why have we gotten to this situation? Well, for one thing, to many people, patents are a business in and of themselves. They are a revenue-generating operation that, you know, has high margin and relieves them of the terrible responsibility of bringing innovative products to market, they just tax others. So patents are a business. But, secondly, the reason we are in this situation is because those of us who are involved in the thicket contribute to it. We stockpile patents. We increase – every time we find out that everybody else is increasing patents, we increase. So you have a vicious cycle of stockpiling of patents, mutually shared destruction. What is wrong with that? It is a drain on resources, money, engineering time that could better be used for innovation. That is all I want to say. Thank
PROFESSOR SHAPIRO: Thank you. Next, Bart Eppenauer from Microsoft.

MR. EPPENAUKER: Thanks. It is a pleasure to be here today. I will put my comments in the context of the report itself in terms of the issues that we see. And first and foremost the issue of the law of willful infringement, and it is really good to see the report come down the way it does, and we are hopeful that the Knorr-Bremsey decision comes out the right way. But, regardless, we wholeheartedly agree with Judge Whyte that it is a real pain for companies to deal with willful infringement allegations. We face it in just about every case that comes against us, regardless of whether we had any knowledge of the patent, if the patent was issued the day and the next day we get sued, well, we will get a willful infringement allegation based on some press release, perhaps, that was issued about the filing of the patent five years previous. I mean, we really have had to deal with a situation like that, and it is one where we completely agree that willful infringement ought to be limited to cases where there is specific written notice and, going even further, specific identification of patents and the claims, and how the claims apply to the products so it is really before that willful infringement
allegation triggers - you have that. Another difficult
or tenuous willful infringement allegation that we faced
before is in cases where a company’s patent was cited in
one of our own patents - in prosecution, one of many
thousands of patents we have, and it just so happened
that this company’s patent was cited, and now we are
fighting a willful infringement allegation because it is
just not clear what kind of knowledge is required, and we
certainly do not think that that kind of thing is at all
sustainable and would put an incredible burden on
companies. So we are really happy to see and we fully
support the willful infringement change in the law. We
hope the Federal Circuit does the right thing and look
forward to that decision, as well as the waiver issue on
attorney-client privilege, that really is a difficult
proposition and we fully support having no adverse
inference established based on whether or not you decide
to disclose your attorney opinion because you just do not
know how far that is going to go with a particular
jurisdiction, if you are going to have to give up all
your trial counsel notes and things, that is a difficult
thing. So I think, first and foremost, that is really an
important point to us.

The second point, perhaps, in relation to the
post-grants review proceedings, I think it is pretty
clear that there is a major increase in patent litigation in the IT industry and certainly Microsoft faces an increasing number of patent lawsuits where we are the defendant. And on top of that, we have many many more assertions prior to litigation where we spend a fair bit of time negotiating and analyzing those assertions. So in that respect, I do echo some of the comments I heard earlier today which is, it is not just an issue of what are the questionable patents, or what are the bad patents, if you will, but it is really an enforcement issue. You know, the PTO very well may have granted a patent that, if you look at the file wrapper and – is that it – sure thing, good, one more minute before the big thing comes up. So I think in that context, the post-grant Opposition would be very helpful to try to avoid litigation disputes. And one of the things that is interesting and we would like to see how this plays out is the time duration. One year from issuance in some industries might work really well, and in a lot of the cases that we see come our way, it is many years after the patent is issued that we just first learn about the patent that we are sued, and it is not going to be real helpful to us, the post-grant procedure, if you can do something, some threat of a lawsuit, or an actual lawsuit where you can institute this proceeding, and in some
industries like ours where there are so many thousands of patents out there in the Information Technology space, it is kind of difficult to monitor all of that and to select the ones that you would want to pursue in an opposition proceeding. So it is going to be interesting to see that. That is it for me for now.

PROFESSOR SHAPIRO: I do not know if you want to speak at this point on behalf of 3M, or if you want to --

MR. GRISWOLD: I think I am here on behalf of the AIPLA, and so I will tie it together with my AIPLA comments. I can, but they kind of join. You would expect that they would join at the hip. I will do it later with the AIPLA.

PROFESSOR SHAPIRO: Okay, well then we have Sean Johnston from Genentech.

Mr. JOHNSTON: Hello. Thanks. I will start by commenting or making the observation that Jim Pooley’s comment earlier today resonated with me when he said the so-called sand in the gears are really in the enforcement system, and that is the area that we have the most concern with. And, in particular, I will go quickly through three areas where we think the FTC has made some good observations. First, is in the need for a new and improved post-grant review process. This was the topic
of the discussion of the panel this morning, so I won’t
belabor the point, but suffice it to say that, like many
other businesses, we encounter bad patents and have a
hard time dealing with those. We end up in litigation
too often dealing with bad patents, patents that we
believe are invalid, that eventually are found invalid on
appeal, and it is an extremely costly, time consuming
process not only in costs from the perspective of paying
outside counsel to litigate these matters for perhaps
many years, but also the opportunity costs of taking away
scientists and engineers from work that they would better
be devoting to scientific research, rather than to
depositions and giving expert reports and the like.

The second thing is, as a number of people have
commented, reigning in the proliferation of what we
believe are unmeritorious, intrusive, willful
infringement claims that I am afraid too often are
brought just for strategic coercive purposes to try and
exert the maximum amount of pain or potential pain on a
litigant. And I think in this area, in addition to
whatever the Court of Appeals may decide in the Knorr-
Bremsey case, at a minimum, we should codify some
requirement that there be a bifurcation of the
willfulness issue away from infringement and validity
issues, and let the patent owner make out a willfulness
claim, if they can, only after they have established validity and infringement of their patent claims.

Regarding the FTC’s comment on the so-called thicket of patents, I encourage focus on one particular patch or aspect of that thicket, which I know has been the subject of discussion by a number of different panels and groups amongst the – along the time line here, and that is the patents that are directed primarily to materials, methods, and machines that are used solely in research activities. So some people would refer to these as the so-called research tool patents. The point here is not to take away or put these patents sort of in a second class status, but the fact of the matter is these patents are proliferating in number. Again, I may be hung up on transaction costs, but dealing with these sorts of patents on a one-off basis is extremely time-consuming, there are tremendous transaction costs, and I think we need to find a better way of dealing with that and, for example, I think it is worth taking a look at the scope of the experimental use exemptions, seeing if there is some possibility of making some changes there, perhaps finding a market-based, more efficient way to license these things such as through a clearinghouse akin to the Music Copyright Clearing Houses, and just overall. Finding a way to deal with these in a more
efficient way. And my last comment, then, will be just a
general observation. I cannot help sitting and hearing
the comments this morning, in particular people
commenting - I think someone referred to it as the
"willfulness game," the proliferation of just an
excessive number of inequitable conduct claims, the sort
of cynical use of the Eastern District of Texas for
filing cases. I think you cannot help but hear that and
come to the conclusion as was once said, that we have met
the enemy and he is us. I think it is perhaps ironic if
we take a step back, this same group that is organized
here today, that is complaining about this, that were
often the ones who are going back to our offices, to our
outside counsel, and actually making these sorts of
claims, making these sorts of filings. So at the risk of
sounding like I have been in Berkeley too long - I don’t
live in Berkeley - I think we all should take a step back
and perhaps exercise a bit more self-restraint, self-
discipline, and take a more far-sighted perspective on
how we approach these various issues and not rely
exclusively on legislative or regulatory reform.

PROFESSOR SHAPIRO: Okay, well, as an
antitrust person, I am always a little cautious when
people want to propose [off mike], but in this area it
seems like a good idea to talk about policy.
MR. JOHNSTON: Thank you.

PROFESSOR SHAPIRO: Next, Jay Monahan from eBay.

MR. MONAHAN: Thank you. If some of these problems are the sand in the gears, then eBay is in the business of building gears. We have built an E-commerce platform which, as you know, has met with enormous success. The interesting thing is, almost five years ago to the day I started at eBay, the only time I ever heard the word “patent” was if somebody was referring to patent leather shoes being sold somewhere on the eBay site. And there was a long period of virtual silence, never got a letter, never got lawsuits, nobody ever talked about it, and then over starting probably three and a half years ago we started to see more letters. And the letters sometimes were followed by lawsuits. And many of the letters, in fact, I would hazard to say most of the letters, when you actually dug into them, you realized that were either facially ridiculous, or an incredible stretch of construction, and in my view if you applied a Rule 11 analysis to it, it never would have exceeded Rule 11. Now, in fact, there was one case where I got a letter and I said, “You know, you have got to be kidding me.” I cannot tell you how many times I have said that, but I went to Google to the Google News Groups, which I
pray and thank Google for every day, and in two hours
found dispositive killer prior art. And I said there is
something wrong with this picture. It has driven the
cost of my life, of my life as a lawyer at eBay up. I
now spend more of my time on patent issues, both our own
portfolio, as well as defensive issues, than any other
single issue, which was clearly not true a few years ago.
We worry about these letters because of things like the
willfulness standard. It would be great if I could just
say, “This is ridiculous” and throw it in the trash can.
We obviously can’t do that. We engaged in a very
reasoned analysis and, in some cases, we get very
expensive opinions of counsel which, in some cases, sit
on the shelf because you never hear again. In fact, most
of the time you never hear again, but that does not mean
it is free to me. We also get a lot of what I call
“squirrely” letters and this is an issue which will have
to be considered when we talk about what a willfulness
standard ought to be because many times the letters do
not say “Dear Jay, Your X product is infringing my
patent,” it will say, “We noticed that you recently
announced your such and such feature. We think that you
might be interested or benefitted from taking a license
to our portfolio.” So are they accusing me of something?
Well, I do not know the answer to that, but I can
guarantee you if there is litigation, they are going to say they did, and I am going to be dealing with that issue in litigation. Lawsuits - lawsuits - we are in a whole new world. The presumption of validity is a problem. It is something which is trumpeted by Plaintiffs, it is something which is difficult to get over. Summary judgment is also difficult to get over. And I think that there is something that is outside the scope of this conference, which is what about the role of the judiciary? Because I think there is a reluctance among some members of the judiciary to do what I would say is the right thing, which is to grant summary judgment, to issue a Markman ruling that construes the terms and lets the chips fall where they may, and I do not think that happens as much as it ought to. And, finally, big verdicts and big settlements - verdicts happen and, by the way, I am litigating in Marshall, Texas and in Delaware as we sit here today, and I have to balance as an eBay lawyer the need to fight these cases to demonstrate our resolve against these ill-conceived patents, but at the same time do what is right for the company when it comes to balancing risks. And, unfortunately, as the FTC report points out, the balance has been disrupted. If there was a balance, there no longer is a balance. And we are here pleased to be a
part of this conference, we have some thoughts on some of
the reforms that make the most sense which we are going
to talk about in a minute, there are others which we have
not yet formed full opinion on, but really welcome the
opportunity to finally try to do something about this
important area.

PROFESSOR SHAPIRO: Thank you, Jay. Next I
would like to turn to Kulpreet Rana from Google.

MR. RANA: Thanks. So my perspective on this
issue has really changed over time. I was thinking about
it earlier and I remember when I was in law school
thinking about the Patent System from a very theoretical
viewpoint and, oh, there are these interesting issues and
tensions, and then I had the good fortune of clerking at
the Federal Circuit, please do not stone me for that, and
that was also like a fairly academic perspective, though,
thinking about some of these patent issues. You are
still in a bit of an ivory tower as an Appellate Court.
Next up was law firm practice and, you know, that was a
bit of a transition period, but it was not until I
actually entered industry at Google that it became very
evident to me what the real world impact is of the Patent
System. In short, I think it is really just a mess from
the perspective of trying to deal with the issues that
you face when you are in-house. As with other people on
this panel, Google approaches this issue from the perspective of a company that obtains patents and also has patents asserted against it. And, you know, I think it is hard to make some of these – to think about some of these things, generally, because there are places where the Patent System is probably working fine.

And, so, making generalizations tends to raise kind of concerns on other sides. But there are also places where it makes it difficult as a business person to provide the kind of advice that you need to, and one of the main high level areas of that is just in terms of the – and a few people have mentioned this before – the lack of certainty or predictability that is engendered, and this ties into the examination process, and if you don’t have a clear sense of what the quality is of patents that issue or what their value is, it becomes hard to make business decisions about that. There are those who would take advantage of that ambiguity by, you know, in conjunction with the presumption of validity, to try to extract value. And certainly the fact that litigation is one of the main ways of resolving that right now does not help because it is a high cost alternative, and so that encourages settlement even where it may not make sense. But that is just one context.

That same ambiguity and uncertainty comes into play in
other areas, as well. If we are trying to assess the
value of patents that we have ourselves for purposes of
licensing, it is difficult to do because of the
uncertainty. If we are interested in acquiring another
compny or a portfolio, it becomes hard to evaluate that
because of the uncertainty.

So, you know, for us, having something that
would create a little bit more certainty would help with
making business decisions. So we certainly think that
some of the FTC’s recommendations are a useful step in
that direction and we are happy to kind of participate in
that discussion going forward. And I am going to grant
the rest of my time to my colleague, Michael Schallop.

MR. SCHALLOP. I wanted to just set the
background for a couple of scenarios that are practical
scenarios that I think similarly situated companies,
software companies, of about Semantec’s size will run
into from an inside counsel perspective. So Semantecs is
primarily a software company, which means that we develop
products and release those products in generally a six to
nine month time frame. So you are talking about a pretty
rapid development cycle in a product life cycle that in a
software product space, you know, may not exceed three,
four or five years. It is characterized, I think,
accurately in the FTC report as an area where there is incremental innovation. We come out with a new product feature and, very shortly after, competitors, once they see that feature, if they had not already been developing it for their product, will soon enough develop that similar or maybe an improved feature along the same lines in their product. It is very front-loaded, kind of like law school, all the work and rewards are generated by the initial product development. The industry, because it is incremental innovation is, you know, correctly characterized, I think, in the report also as a defensive patenting area, which means that it is a numbers game. You have an incentive to try to patent as much of your distinguishable product features that you can get through the Patent Office, which from hearing from the staff, that is probably one area where we have certainty. You have a pretty good chance of getting a patent through, depending on claim scope.

So, as a practical matter, that means that we need to file patents on those distinguishing features, on key product features, and do these reviews for products, you know, fairly often. At the same time, you have engineers and developers who are under a lot of pressure to get new products and new features out. With that in mind, I think that the focus in some of the
recommendations on patent quality may be the best way to start to make sure that we can address what is really – and I think Bob would address it as the MAD game. And it is always going to be a numbers game, even if we try to address some of the enforcement issues, whether it is standards of proof and presumptions with obviousness, because in a numbers game, just having patents issued, whether or not they are ever going to stand up in court, serves their purpose, depending on the different contexts with certain competitors. So I do think that addressing the patent quality up front makes a lot of sense and has the advantage of putting more of the burden on the patentee to prove the patent is entitled to get through the Patent Office, rather than post-grant procedures which, again, the transactional costs are going to be born by the potential defendant or targets.

The second scenario that we often face is, if you are a company that has a revenue stream, you are inevitably going to be a target by either your competitors and/or what the report refers to as “hold-ups,” “patent hold-ups,” or referred to earlier today as “trolls.” Addressing the patent thicket issue, I think, requires you to have really good information as to what patents are out there and the Patent System today is designed to disincent you from actually studying your
competitors or other third party patents out there, which I think really disrupts the balance of the Patent System, which is, you know, the disclosure is the exchange to encourage innovation and is the basis for the Patent System’s goal of evolving technology.

PROFESSOR SHAPIRO: Thank you. So our last industry representative here in this first part is David Simon from Intel.

MR. SIMON: I thought the best way is - for those of us who are up on the panel in the industry have faced these problems all the time, but to try to make it a little bit more clear as to how the uncertainty is a problem, use something that Professor Shapiro may be aware of in terms of LBJ’s One-Handed Economist, which is, early on in my career at Intel, I got called in to handle a problem. It was a problem with nine zeros after it, and I, just having been outside counsel for my entire career, started with, “Well, on the one hand,” whereupon the Senior V.P. who I was talking to’s hand came down on top of mine and said, “David, if another hand hits the table, I cut it off. What do I do?” This guy was a little scary, by the way, so that was particularly unnerving. But, be that as it may, the problem that we all - those of us who are in-house, all face, is we have to give advice on what are we going to do, and we are
facing a huge amount of uncertainty. You know, and if you just think about some of the FTC issues such as the willful infringement issue, you know, in response - and I am the guy they turn to, saying, “What do we do?” whenever somebody sues us. I have to say what we are going to do. Well, that is an opinion. Immediately I say what we are going to do, now is that going to be open for discovery? It raises a whole host of issues that just completely raise too many uncertainties. Similarly, we get these patents in which, you know, I mean, there are some really good patents, we have got some really good patents - and by the way, our success rate on getting patents is over 100 percent - so - well over, by the way - but the point being, you know, you get these patents and you take one look at them and you say, “You know what we ought to do with this patent,” but, you know, you have to go through all that analysis, you have to go talk to your engineers, and it is very distracting and it is very taxing. And, in fact, it also causes us to, of course, both for prior art purposes and to make sure that we have lots of stuff out there of our own, it causes us to file what I personally think is an inordinate number of patents, and every year my CEO says, “Go get more,” to the point where my patent filing budget and prosecution budget is now more than half the size of

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
our Corporate Research Lab’s budget. That, to me, seems
to be out of kilter. And, you know, obviously — and by
the way, that does not include litigation, that is a
separate budget which is also roughly the same.

So, you know, you are looking at a huge tax on
the industry and you are looking at a whole host of
problems that come with that. Every case that we have
brought, we have got to take our leading engineers,
particularly the most senior ones who really have the
intimate knowledge of what is the prior art, pull them
off of the projects they are doing and, by the way, these
guys work 18, 19 hours a day, six to seven days a week.
They are incredible. And say, “I need you to help me
find prior art on this,” or, “I need you to help me
explain why we do not infringe on this.” And that is a
huge task which I really do not think society is getting
the benefit for, to the point — just to give one
practical example if I have the time —

PROFESSOR SHAPIRO: You do.

MR. SIMON: Okay, just got it in there. We
got sued several years ago on a patent where we felt we
could get the license for $2 million. I have had a
number of people come up to me afterwards and say — and,
by the way, this is the case that we used the term
“patent terrorist” which got us sued for libel, which
had, by the way, very interesting issues in collateral litigation – but because truth is a defense, right? But the point being that when you – it cost us $3 million of outside counsel fees to win on summary judgment and get it affirmed on appeal. We probably could have gotten the license for $2 million, and I am not throwing into that literally hundreds if not thousands of hours of various engineers’ time on helping us on this case plus in-house counsel work on this case, as I think my time has some value, at least. And when you looked at that and said what was the right thing? Should we have paid? Should we not have paid? You know, I asked my CFO that and he said we did the right thing because it only cost $3. I said what if it was $10? And he said, “I am not going to give you that answer today. Thank you.

PROFESSOR SHAPIRO: Thank you. Thank you, all. So next I want to walk through – we are going to walk through each of the FTC’s proposals in order – why not? And I am going to frame it up and then turn to certain of the panelists to give reactions, where they are at on that proposal, pluses and minuses. The goal here is so we can really hear – try to learn where there is consensus, where there is not, and get a sense of where this process could go – again, from people who really live and breath this stuff. So let me start – I
will read each of these briefly just to make sure we are all on the same page since you may not have your handy dandy copy in front of you, right — 1) FTC Proposal 1, this is the post-grant review: "As the PTO recommends, enact legislation to create a new administrative procedure to allow post-grant review of and opposition to patents." Okay, and of course there was a whole panel on this, this morning. And yesterday Rob Merges, I think, laid out some of the basic facts — 180,000 patents a year are issued — what was it? 17 hours per patent on average by the examiner, it takes over two to three years. I think he gave a number of $3,000 dollars spent for a patent. I think Mark Lemley gave an impassioned piece this morning on why the PTO’s structure is not set up really to — it is a quick look, okay? It is a quick look. And I think maybe Joe Farrell described it as “error prone,” but of course there would be those that would dispute that.

So, at the same time, there is a re-examination procedure, but it is basically not used at all. I think Rob Merges reported that it was only used 20 times in the past five years. Okay, so a trivial number of times. So that is not working, at least not useful and effective. Okay.

So, I will add that the National Academy of
Science’s Report calls for an Open Review Procedure, basically of third party challenges before Administrative Patent Judges at the PTO, so they are on the same page here, or close to it. Okay. So where are folks at on this? Is this something that everybody wants and can go forward? And, if so, how would it be designed? Because, as a number of people have said, even if you want this, how are you going to structure it? The devil may be in the details. Okay? I would like to turn first to Robert Sacoff.

MR. SACOFF: Thank you very much. I am the Chair of the ABA IP Section, and we are one of the organizations that Professor Shapiro was referring to when he talked about some of the organizations being mid-stream in their policy formulation, so I have to state the disclaimer that my views as I state them are not really capable of being attributed to the ABA, which really requires a lot of procedures to go through, or the ABA IPL Section. We have had a task force which I appointed upon turning to the FTC report that coordinated a lot of different committees, and we have had a lot of really good and hard work done at the committee level, resulting in resolutions in some cases in the various recommendations, and some other cases - not resolutions, but reports. The post-grant opposition procedure is one
that the developing view, as I will call it, is to support. We have a resolution that will be adopted, finally, or voted down, and that is always possible, at our June summer conference in Toronto, favoring in principle legislation creating a post-grant Opposition Review procedure in which the patentability of issued claims without any limitation on issues subject to the procedure, can be reviewed by Administrative Patent Judges, the Board of Patent Appeals and Interferences. And some of the details, obviously, are yet to be determined. This is a fairly – it is always a major step when you create a new procedure, and I do not think we know exactly what it is going to look like yet, or what we would like it to look like yet, but the suggestions in the deliberations and the developing views include filing an opposition within nine months of the date of the patent grant, allowing all patentability issues to be challenged, not just obviousness, or non-obviousness and novelty, to provide complete inter-partes proceedings, some discovery – we do not quite know how much discovery because that affects a great deal the cost and the length of time that it is going to take. The view is that we would like to see such a challenge conclude within a year and to have appeal ability by any of the parties to the Court of Appeals for the Federal Circuit. So that is
what I will say about that.

PROFESSOR SHAPIRO: Would you say it is the position – the tentative position, that will go without saying – that a cost-effective post-grant review procedure is really crucial to having the Patent System work properly, and we do not have that now?

MR. SACOFF: Well, I think that is a little bit of an overstatement to what the resolution is. This is a procedure that we are in favor of, and we would not be in the favor of it if it were not considered an improvement to the Patent System. I mean, we start putting adjectives about crucial and indispensable, and I am not sure that those are going to be in our position, but we favor it.

PROFESSOR SHAPIRO: Okay, fair enough. I would like to go next to Gary Griswold, then.

MR. GRISWOLD: Gary Griswold, I am representing the AIPLA. I am past President of AIPLA, but in this particular circumstance, I was Chair of the committee that put together the report that responds to all of the recommendations of the FTC Report. We are further along than ABA, apparently. We have the report in its basically final form, closely ready to go. I mean, we are about ready to push the button. We have – I can tell you, and I won’t give you any of the details,
whatever you want, we support basically six and a half of these guys and we don’t support three and a half. So I can tell you which ones those are if you want me to later.

PROFESSOR SHAPIRO: Yeah, why don’t we do that? We will go through one by one, but let’s focus on the first proposal now.

MR. GRISWOLD: And that is what I was going to do.

PROFESSOR SHAPIRO: Good.

MR. GRISWOLD: Thank you. And what I will say on that is that we do support oppositions. We have developed the details of a proposal relative to how opposition should be handled, and that was approved by the Board this week. It does involve a nine month period for bringing the opposition. We do not believe that this process should be available, except on agreement of the parties throughout the life of the patent. In other words, we want to walk before we run. Maybe, Bob, you have approval now and you can give us the full scoop -- it may be the Chair of the ABA calling you, okay! But anyway, let me go on. Our deal is that we would not include all issues of patentability, only those issues that can reasonably be tried without significant discovery, and those are 102, 103 based on patents and
publications, 112, first and second paragraph, no best mode, non-statutory double patenting, it would be based on the written record. There would be cross examination of the affiants put in the evidence. There would be a hearing before the Administrative Judge. There would be a limited estoppel. I will not get into every detail because I am sure you do not want to hear that, but it will be coming out shortly and we do have a well-developed, well-vetted proposal that we think is ready for prime time very soon.

PROFESSOR SHAPIRO: Thank you, Gary. Next, Herb Wamsley.

MR. WAMSLEY: Thank you, Carl. I should say who Intellectual Property Owners Association is, particularly since three members of the Board of Directors are on this panel, which causes me to state things carefully. As we go through these resolutions, I will be giving our tentative view, which has passed the first review by the Board, which will be reviewed again by the Board next week. IPO’s members, which really overlap as a practical matter a lot with the ABA and the AIPLA, but the members of the Board are Chief Patent Counsel of larger companies primarily, including Microsoft and 3M and Intel. We think we are in favor of post-grant Opposition. We are still trying to sort out
the details, not quite as far along as AIPLA, but we are
definitely in favor of it. We are looking at two models, I guess, mainly, which are similar, the FTC report and the Patent and Trademark Offices 21st Century Strategic Plan, it was called. It was issued in 2002, which has a very detailed proposal. I think there is not complete consensus yet on whether the time period for opposing a patent post-grant should be a limited period such as nine months or a year, or whether it should be a longer period. And there is a lot of variations on that. As you may have heard earlier in the program, I was not here this morning, but the PTO, for example, proposed a period for opposing for several months post-grant plus the opportunity to propose any time during the life of the patent, and I believe within a four-month period after you are subjected to a reasonable apprehension of suit. So that is one area. I think another area we are still trying to sort out is just how broad these proceedings should be, how many issues you should be able to raise, and what the costs should be. But I think IPO members—and my feeling would be large U.S. patent holders, in general, seem to have a pretty broad consensus on needing a procedure post-grant that is substantially more expansive than the inter-partes re-examination proceeding that was enacted in the American Inventors Protection Act
in 1999. And on where we are at, I would say that IPO - at least ten recommendations, the post-grant Opposition is one of our big three, at least, if not the biggest one. And I believe I have finished within my time.

PROFESSOR SHAPIRO: Good, thank you. I would like to turn next to Jeff Kushan who represents BIO.

MR. KUSHAN: Thank you. BIO is a trade association that represents the biotechnology industry, has a membership of about a thousand companies, and the only common trait about those companies, really 85 percent of them, is that they do nothing but lose money. And the only asset that they have is either a patent application or a patent, and so they are a bit sensitive about patent issues, probably more sensitive than any other industry. On the issue of post-grant Opposition, most of the members of BIO strongly support a rigorous post-grant Opposition procedure. That view is not uniform and, in large part, that non-uniformity is because the critical issue is what are the attributes of the system that have to be there and have to be identified before we can actually have a consensus view? And, in fact, most of the discussion within BIO so far has been to start to focus in on those attributes of the system. Many of the things you heard earlier today and that have been repeated are the variables that are in
discussion now. I think one – I can touch on a few things which – and give you some insight into the deliberative process that is going on now. One issue is – and it was foreshadowed in the comments from Eli Lilly this morning – is that, unlike most industries, there is a special need for certainty in the area of pharmaceuticals and biotech inventions, and that is, when you are about to launch a product, or when you are about to build a plant, or when you are at that really critical part of development down the path, you do not want to have the patent thrown back to the Patent Office in a proceeding that could end up putting a large cloud over that investment. And so one variable seems to be the period of time during which one can raise issues, and I would say, at least with regard to the non-prior art based issues, there seems to be a view that about a year or a little bit longer than that might be the window that should be appropriate. It is important in this process to appreciate that, you know, you are going to have a trade-off in that time limit because most biotech inventions are not going to have a known commercial value in a year, but there is still enough monitoring activity that you can engage in to make a step in. A second issue that seems to be supported is to actually extend the issues to 112 grounds. That topic, in particular, is a
dominant topic for many patent applications in the biotech sector where there is not a lot of prior art – well, there is a fair amount of prior art, but the main issue in a lot of cases is 112. The third variable that seems to be supported is the need to have better management of the proceeding, and here it is kind of a trade-off right now because many of our members want to have a simplified procedure for simple issues that does not make it a really expensive proceeding like litigation, yet on – you also want enough adult supervision in the proceeding so that you know you are not just going to get a re-hash of the original examination. And then the last issue that we are struggling with is, there has been some debate about, you know, how to make the proceeding more rigorous, and that goes into the area of discovery-like activity in a proceeding. And many of our members, a small minority in total, but many of our members have lived through enough litigation now that they don’t want to see the torture of litigation imported into a Patent Office environment. And so, while there is a legitimate need to have experts and deposition of experts, there is a great reticence about turning it into a proceeding that, you know, you are going to have essentially replicated the cost of litigation for no benefit in the Patent and
Trademark Office. I am going to stop at that point because we are still struggling with a lot of other parameters that have not been talked about in the discussions so far, and we do not really have uniform views.

I also, like others in the industry posture, many of the members sitting in the audience are next to me, and so I want to just reserve the right to jump in, but they may be my own views and not that of BIO.

PROFESSOR SHAPIRO: Okay, thank you, Jeff. Next, Ron Myrick who represents USCIB.

MR. MYRICK: Thank you very much. First, I would like to make a little disclaimer and my views here are being expressed as my own – except where I specifically attribute them to the USCIB, they are not the views of my firm or any client. I am delighted to talk about this issue. I think it is an easy issue in one sense to support. It is hard as the dickens to make happen. When I got started in this profession a rather long time ago, we were privileged to be provided something called reconsideration at that time, a very long time ago, some of you will remember it. It was a pilot program. It was the forerunner to re-examination. So we have been working on making this kind of post-grant review work for a very long time. Have we succeeded? I
do not think so. And I think the devil is in the
details, absolutely. The comments that Jeff just made
about cost are going to be determinative. The real
success of any post-grant procedure is going to be
determined by whether or not it is used. And Mr. or Dr.
Harhoff’s comments this morning were very worthwhile in
regard to the success in Europe, however, he also made a
passing comment, which I think – I hope I quote correctly
– in that the numbers or percentages have been going down
in Europe. Is that correct? Yes. And it is an
important note because, frankly, I know some senior IP
counsel of some major companies in Europe, and they have
abandoned the Opposition System in Europe. And why?
Because they paint a target on themselves. So I think
one of the issues, and it has not even been addressed in
the panels this morning, or thus far, is how do you
handle the fact that having raised your hand to be an
opposer, you have told the other side how interested you
are in their patent, and you may not win that opposition.
So it is a very important issue. I think the other issue
that is determining whether or not this will be a
successful system that we propose will be substantially
the issue of estoppel, whether or not you are going to be
bound by what comes of this result and permanently bound,
perhaps. Somebody mentioned res judicata. I do not
thing that res judicata is going to get very far if you want to be able to use this system and make it a success. So I think there are lots of devilish details to be decided in connection with opposition that will determine entirely whether it is a success. And, remember, it is only a success if people really use it, and we have been trying for nearly 30 years to make reconsideration, then re-examination work, and, still, nobody uses it.

PROFESSOR SHAPIRO: Thank you, Ron. I want to just turn briefly to a few of the other panelists so they can indicate where their companies are at. Bart, where is Microsoft on this?

MR. EPPENAUER: We do favor this [off mike] and the devil is going to be in the details, and we want to be able to use this procedure and, clearly, as Ron points out, within a one year time frame if we start opposing patents, that will raise a flag that we are very interested in, you know, if we lose that, I am sure we will be dealing with it for a while. What I do like is the PTO’s view that if you have a reasonable apprehension of suit somewhere down the road, from a lack of patent time, you can engage in and you are already sort of at issue at that point anyway, so that would be a real strong mechanism that we would support.

PROFESSOR SHAPIRO: Okay, Sean?
MR. JOHNSTON: Yeah, very briefly because I commented before, we are supportive of this. I agree with Ron, it has got to be a system that is economical, it has also got to be fast and efficient or, you know, we will just be repeating the litigation process all over again.

PROFESSOR SHAPIRO: But do you want to limit the time to the nine months or the one year?

MR. JOHNSTON: No, I think – yes, I think that is a wise component of the overall process, to put some time limits and nine to 12 months seems like a reasonable one, somewhat akin to what the European system is.

PROFESSOR SHAPIRO: Okay. David, do you want to speak for Intel on this?

MR. SIMON: Sure. I think what you have is a real dichotomy between the Bio and Pharma and the Electronics, Software and probably much other, is generally no reason for me to challenge a patent unless it becomes a problem for me, and because otherwise I would be challenging lots of patents that I have no incentive to challenge in the ordinary course, other than to paint that big target, as Ron said. So if, in the general case, if it has got a time limit, I won’t use it much unless there is somebody I know who is going to be a problem for me out of the chute, and this is my best shot
at them. If there is no time limit, I will use it a lot, and I think that is the real consideration. And I understand that the incentives in Bio and Pharma are very different, and it may even be that what we need is a two-industry approach, or multi-industry approach.

PROFESSOR SHAPIRO: Would it help if the issues - somebody said maybe prior art could be handled one way and other issues another way, would that help bridge this gap between the different industries?

MR. KUSHAN: Well, I mean, this is a good topic to engage on because I think it is something we have to start out. I think the 112 issues may be more time relevant, so even if we looked back five years, a written description as we have seen and applied five years ago compared to what it is today is very different as a legal principal, and also evidence in that area may change over time. I think one question is, you know, what we do not want in the pharma bio industry is to have a crippled system to fight about our patents, take over the patent, and dispose of it in the PTO. And so maybe the question is, if you allow challenges after some window that we know we can take it back to a District Court and fight there because it is too commercially important to us to leave it in the hands of the PTO with the limited discovery or limited proceedings around it.
And I do not know if that is something which is going to be digestible to the software and non-biotech sector, but I think the critical factor is, you know, you just do not want to have your patent in the Patent Office when you have spent $800 million getting a drug and you are about to launch. It is just a very uncomfortable discussion to have with your CEO. So it may be not the best fear, but it is a legitimate fear of these companies, and we have to find some kind of reality in limiting the access.

PROFESSOR SHAPIRO: Well, I think that shows that the estoppel issues, the ability to appeal relates to the time period. I mean, there is a complex set of factors that has to be crafted. We are not going to be able to do that now, but some of these associations that have grappled with this, I think, it will be a really good next step to see what they are doing. Does anybody else want to –

MR. GRISWOLD: If I could just make one comment. The reality of all this when we debated this for AIPLA was can we put together a proposal that actually has legs and can get through Congress, because we have been involved heavily in the legislative front for a long time and the AIPA was a big event. I do not think we have anybody here that is an independent inventor. I can tell you that there are issues here that
are compromised based on what we think would be acceptable in the independent inventing community. For example, a limited estoppel. And also the idea of when you can bring these activities. So you have to keep in mind what is passable and what you can get started with, and the other piece is I still believe it is important that we walk before we run. We heard a lot about how the PTO operates over the last – at least this morning, and I think we better be careful that we have a process in place in a nine-month period that works, and then maybe we can take it on until later on in the patent’s life.

That is our view.

PROFESSOR SHAPIRO: Last comment?

MR. MONAHAN: Just a very quick comment. The other issue that I think is important, at least from our perspective, is retroactivity, assuming you can do that, because if I cannot deal with patents that have been applied for or issued, say, since ‘95 or ‘92 or ‘93, then before there was a second-look policy, a lot of my problems are coming from a particular time frame, so I think I need to be able to apply this, whatever these procedures are, to those. And then, going forward, perhaps there would be a time limit. I actually like the idea of a time limit of some sort, but having basically “all bets are off” once somebody threatens me, and then,
what was the reasonable apprehension of litigation, I
would have some rights triggered at that point.

PROFESSOR SHAPIRO: Okay. We have got nine
more of these, although we are not going to do every
single one. So let’s move on to the second FTC proposal
- well, let’s summarize. My sense, just to try to wrap
that up, there is a lot of incentive to do something,
there is probably areas where people can come together,
but work needs to be done to get that drafted, something
that is going to work politically, and we will be talking
at the end how to make things happen. Okay? So on to 2.
The second proposal is: “To enact legislation to
specify that challenges to the validity of a patent are
to be determined based on a preponderance of the
evidence.” Of course, rather than the current clear and
convincing evidence. Well, again, we have heard about
that earlier today. I think many people would think –
most people think this is a very big deal. There are few
people that think it would not matter, but I think most
people think it would be a very big deal. I think part
of his impassioned plea this morning, Professor Lemley I
think presented very nicely the argument in favor of
this, which I would summarize as saying, “Why should
patents get that big presumption if it is such a quick
look going on now?” Okay? Now, that raises the issue of
how this proposal interacts with other proposals. Okay?
I think one could take the reasonable view, if you fix a
lot of the other problems so the patent quality goes up,
then the patents would – then there would be a stronger
presumption – maybe clear and convincing – would be
warranted, but it is not warranted now. So we get into
interactions. I think people would say strong medicine
and the question is, you know, is it really – do we need
to do that, or maybe we should work on other pieces
first? Okay. I want to be very quick –

MR. GRISWOLD: I would like to comment on this
because no one has come forward with the comments that
AIPLA – how they analyzed this. And it actually is kind
of relevant to this whole discussion on how we looked at
this issue. And I would be interested – or you could
call on whoever you want, but I would like – I think we
ought to get out in front on what we really have today
because nobody – at least the way our people that have
looked at this, no one today stated this the way our
people analyzed this.

PROFESSOR SHAPIRO: Well, why don’t you – so
go for it. Tell us – I think there is a fair bit of
consensus among the associations about this, not the
details, but not being thrilled with this proposal, so if
you could say why and where you guys are at, and then
actually –

MR. GRISWOLD: I can sum –

PROFESSOR SHAPIRO: Go for it.

MR. GRISWOLD: I will sum it up quickly.

PROFESSOR SHAPIRO: But there is no precedent that interrupting me means you get time.

MR. GRISWOLD: I only did it because I thought it would be helpful. What we didn’t hear today, unless I was missing it, are the people that looked in this for the AIPLA, which does not support this proposal, by the way, and you have to separate the presumption of validity from Burden of Proof. Okay? Now, we are looking at the Burden of Proof, and that is what this recommendation is about. Our people say that, today, the standard for factual predicate for invalidity is clear and convincing. Okay? The standard for the factual predicate is clear and convincing. The standard for the persuasive force of that factual predicate is preponderance. That is today. So this is what our group said, okay? Now, I know you do not agree with that, Mark, perhaps. But I want to put this out here. And our people would say that this would convert, they believe, the standard for the factual predicate to preponderance, and move it from clear and convincing. So I wanted to get that out there. And the reason I interrupted you is because I think that may stir
things up a little bit.

PROFESSOR SHAPIRO: Okay, that is fine. It was helpful, I agree with you. Bob, maybe you can talk about what the ABA – well, there are probably sections out on this --

MR. SACOFF: Basically that is right, I mean, to the extent that looking into our membership is a window into the IP lawyer community, I think you will find that this is probably one of the more controversial recommendations in the report.

PROFESSOR SHAPIRO: That means you are against it, right?

MR. SACOFF: Yeah, well, the developing view in the ABA IP Section, I think, is to oppose this. I think the general thinking is that lowering the burden of proof for the facts, as Gary correctly points out, lowers the confidence factor and raises the unpredictability factor for all patents and not just patents that we might call questionable or dubious. And the feeling is in our section that, when correctly applied, the current standard is appropriate and conducive to the right level of certainty.

PROFESSOR SHAPIRO: Okay. And my sense, talking with other people, is that other organizations that are similarly placed – I think, isn’t that right,
Herb, for IPO?

MR. WAMSLEY: That is right, Carl. We are against it, too. You know, basically we are into fixing other things in the system and trying to fix them fast, and we are into fixing the Patent and Trademark Office, Willfulness, post-grant. And those are things that can be done, but this one we are against.

PROFESSOR SHAPIRO: Jeff, very quickly - from BIO.

MR. KUSHAN: BIO has a lot of concern about this one, so we are opposed. I have to slip in a couple of rebuttals to Mark’s characterization earlier and I will do this as quickly as I can. First, one of the big problems we face in the Patent Office is they chop our patent applications up into like a hundred separate applications. So if you take his math, that is 1,700 hours per invention that they are getting for each one of our inventions of processing time, not 17. And that is an important factor to keep in mind. The second thing is there are about 3 million patents, 4 million patents, enforced today, and about 5,000 of them are in litigation right now, and we have a lot of licensing behavior which is predicated on the presumption of validity. Now, I think one thing that we have not really –

PROFESSOR SHAPIRO: I could see why the patent
holder is in a stronger position because of the
presumption, but what do you mean “predicated on?”

MR. KUSHAN: Well, it is predicated on - well, in our sector, quality is not a big problem in the
sense that if you have - we certainly have issues of validity
of patents, but it is not perceived to be as bad as other
sectors. And I will say this because we have a better
prior art foundation, all of our art is in the
literature, our issues are fairly mature, and, again, the
Patent Office is chopping up our patent applications into
microscopic pieces, and so a patent examiner gets 25
hours to take a little tiny piece in our world, he is
going to get a pretty good answer. And in that setting
we feel generally comfortable that many of the patents
that get out are going to be valid, and I think that
concerns that other sectors have may not be as pervasive
as they are on the biotech sector.

PROFESSOR SHAPIRO: Okay, so the presumption
you feel maybe more warranted in your area. So only one
man can stand up and tell us, well, besides Mark Lemley
already did, Bob, tell us what -

MR. WAMSLEY: No, I cannot say anything bad to
Mark and I will just say that 1,700 hours under the law
if they are dividing up your patent applications, those
are separate inventions. And I just can’t say it any
better than Mark.

MR. MYRICK: This is one position that USCIB does have. I do not necessarily agree with it fully myself, but I want to state it on the record that USCIB is against Recommendation 2, however, I do believe personally now that, to the extent that clear and convincing applies to something that is unexamined, it is unjustifiable, so I think there is a balance here that can be drawn, but for the record, I need to say that USCIB is against this provision.

PROFESSOR SHAPIRO: Let’s go on then, I think we got a good sense of there is sort of the lack of support, at least in those quarters. Number 3 having to do with obviousness, “Tighten certain legal standards used to evaluate whether a patent is obvious, and this touches on the commercial success test and the suggestion test were both raised here. Maybe Bob, you wanted to talk about this one, I think, in terms of –

MR. BARR: I do not think that not a presumption of validity. I just want to say on that, going back on that and just say, a) that is a, you know, be reminded that is not in the statute – I mean, excuse me, the presumption of validity is in the statute, a burden of proof is not, so a judicial creation that I do think is unjustified. The reason I went back to that is
because people have said, “Well, let’s fix the other
stuff first.” This is pretty easy to fix, the burden of
proof, if we decide to fix it. The issues around
obviousness are much harder to fix, I think. It is
harder, and we had a really good panel this morning on
it. I learned some things and some new ideas, but I do
think the standard itself as written is correct. I think
as applied by the Court and the Patent Office as told to
apply it by the Courts, because I do not blame the Patent
Office, I know they try to reject some things that they
think are obvious, and then the court reverses them, so I
will try to only make one enemy with these comments – one
institutional enemy. But I think it is – in my mind,
when you read it, it is a subjective standard, and the
attempt to apply objective tests to it have led to a
lowering of the standard that has caused – it is The
basic cause of the problem that we face of people of
ordinary skill in the art – don’t let my engineers know I
called them that, by people in the art sort of stumbling
into potential infringements of patents that should not
have issued, because it should not have worked that way.

PROFESSOR SHAPIRO: Let’s again hear from the
association representatives about this obviousness
proposal, maybe Gary, want to do this again? Pretty
briefly, but –
For The Record, Inc.
Waldorf, Maryland
(301)870-8025

MR. GRISWOLD: I will do it briefly. Our view on that one was that we put this in a support category because, and the way we looked at it, it really was not advocating a change in existing law, and if is not to change existing law, then we are okay with it. But if it is a change in existing law, put it in the case law because there are some things you get off the reservation, but if you are going to get what the basic law is on this, the case law —

PROFESSOR SHAPIRO: Wait, it says tighten certain legal standards. Are you in favor of tightening the standards? Or do you just want to leave them where they are?

MR. GRISWOLD: I want them to be applied the way I think most of us think the existing law is, and that is what our view was. You will see it in the paper. That is the way of art.

PROFESSOR SHAPIRO: Okay, Bob?

MR. SACOFF: We do not favor changing existing law.

PROFESSOR SHAPIRO: Or tightening standards?

MR. SACOFF: We think the standards are correct and, if applied correctly, that is the way it ought to be. Okay?

PROFESSOR SHAPIRO: Herb, do you want to talk
some for IPO on this?

    MR. WAMSLEY: We do not favor changing what we have perceived to be the case law currently. Now, let’s say on that suggestion to combine issues, it appeared to some of us that, just about the time the Federal Trade Commission started its hearings a couple years ago, there were two or three cases that came out of the Federal Circuit that might have been aberrations, and those cases appeared to say that you had to have an explicit teaching of a motivation to combine in the references. But I think even the final report of the FTC has a footnote or a clause in it acknowledging that some of the cases that came a little later seem to be swinging back. And I think if you look at the group of the cases decided from the Federal Circuit over the last two, three or four years, or at least that is what some our people think, is that they were really consistent with what the FTC Report is recommending. So we do not see a need to change anything.

    PROFESSOR SHAPIRO: Okay, I think we will leave that wonderful clarity on that question and move on to – I want to kind of lump together to some degree the fourth and fifth proposals. The fourth one says “provide adequate funding for the PTO.” Now I found very few people who favor inadequate funding for the PTO, and the
National Academy of Science certainly is on board here, too, with supporting. So the question, I think it really is how much money? What does adequate mean? Should we think of that in terms of fee diversion, or what? But I think the bigger set of issues are, are we going to link resources to performance, or some sort of reform, or pressure? Is there a quid pro quo? Because people won’t say, well, it is fine to give them more money because they are overworked and these workload statistics are pretty clear, but if they are just going to issue you more questionable patents, I do not want to give them more money. So I just want to wrap the funding issue together with Proposal 5 talks about modifying certain PTO rules and implementing positions of the PTO’s 21st Century Strategic Plan. So I want to kind of frame that together. Just a quote from the 21st Century Strategic Plan, it says, “Today the USPTO is under siege. Patent application filings have increased dramatically throughout the world. There are an estimated 7 million pending applications in the world’s examination pipeline, and the annual workload growth in the previous decade was in the range of 20-30 percent. Technology is becoming increasingly complex, and demands from customers – I think that is patent applicants, by the way, for higher quality products and services have escalated.” And they
talk about this plan will make them agile and productive. I fear that productive might mean more patents, but I am not sure about that. Okay. And they do say that the U.S. industry and the public will benefit from stronger, more enforceable intellectual property rights. So there is a little bit of flavor. And there is a whole set of proposal questions. Many people here know better than I do what they propose to do and would like to do with more resources. And I think you have heard about this notion that there is a culture maybe that they are trying to issue patents, the incentive structure there. So I guess I want to push everybody a little bit into not just the money, but whether, in addition to implementing their plans, kind of how we can really ensure in that process that patent quality goes up. Okay, ultimately we are here talking largely at this stage is patent quality. Okay, and there are a series of sub-proposals here, I won’t read them, okay? But I will let people speak to them as they will. I would like to start with Herb. I know you have been close to this process, certainly the funding side of it. We are moving along in time, so I am going to ask everybody to be really crisp here, and I will start using the bell more, and it is not personal, but it’s just I’ve got to keep us moving.

MR. WAMSLEY: Well, this is one of our
favorites at our association. We do lobbying and this is our number 1 lobbying issue right now. And I think this is one where something can be done to change the Patent System this year – there is a bill that is already past the House and it is in the Senate, HR1561, and that is a bill that brings about $200 million additional into the PTO, it has a provision to stop Congress from diverting that money to unrelated government programs. And the people that are working on this, Carl, in answer to your point, consider that their support for this bill is contingent on the Patent and Trademark Office improving quality in the several ways that the PTO has outlined in our 21st Century Strategic Plan. That plan is very detailed, it has some things mentioned here like the second pair of eyes, but they also are calling for money for more recruiting of talented examiners, for better training of examiners, for re-certification of the competence of examiners, and a number of other things. And we think the appropriators and the Judiciary Committees in Congress are looking at this as a commitment by the Patent and Trademark Office to do these things if the bill passes, and I do not think that giving this money means more patents, although it does mean working off this terrible backlog in the electronics areas, but it means more quality, too.
PROFESSOR SHAPIRO: Okay, Gary? I know you are close, as well, to this process.

MR. GRISWOLD: Yeah, I have personally spent a lot of time on this legislation and also on the 21st Century Strategic Plan. Definitely, we would not support this extra funding if it wasn’t because we thought the 21st Century Plan would turn into something, and we will be watching every step of the way. So that is the way we look at it. Relative to any combined - so we support this - we support an end of diversion. We will not accept increasing our fees 15-25 percent, which is substantial for everybody, without having an end to diversion. That money has to go to the PTO to fix the PTO, and that fix is in there. Looking at Recommendation 5 which you mentioned, the second pair of eyes, and the - we supported the second pair of eyes and the forging the balance between the public interest and the applicant’s interest, and we always looked at it that way, but I think there was a period where the PTO got a little off on a tangent of talking about customers. The public is a big customer at PTO, so, anyway, that is the AIPLA.

PROFESSOR SHAPIRO: Okay. My polling of the panel is that everybody is really there in terms of more resources for the PTO and, yeah, it is a question about how to make sure they are used well. With that framing,
does anybody else here want to just have a quick – Ron?

MR. MYRICK: Just a quick one. One thing that is not in the Strategic Plan, the 21st Century Strategic Plan, at least explicitly, and I think it is implicitly, in fact, avoided. As Mark well described today, and I think as was mentioned earlier by Jeff, in most of the Org units, they have 17 hours to do the entire job as examiners. In the bio art units, I think they get 25. That is an awfully little amount of time to be able to do the job they have to do. The 21st Century Strategic Plan does not address the fact that examiners need more time. And I would personally like to see – and this is a personal opinion – some reallocation of some of those resources to give examiners more time to do the job because I am not sure how you get more quality if you are trying to jam more stuff through the same mental pipes in the same amount of time.

PROFESSOR SHAPIRO: And I would just point out that, of course, if you do this post-grant review procedure, that is going to take a bunch of resources, too, so it puts a little more pressure on it. Bob –

MR. SACOFF: I just wanted to add a quick note on the anti-diversion. Everybody lines up on that, but since this is the one thing we actually do have ABA policy on, and I wanted to qualify myself, I wanted to
point out that calling for an end to the diversion of the
PTO user generated fees not only is a policy of the ABA
IPL Section, it actually has been escalated to a policy
of the American Bar Association, all 420 or whatever they
are thousand, the lawyers, and it was actually escalated
to one of the 11 or 12 legislative priorities of the
American Bar Association, you know, along with death
penalty issues and everything else. That is how
important this is viewed in the ABA as a matter of jobs
in the economy.

PROFESSOR SHAPIRO: And I won’t ask whose
jobs. Jeff?

MR. KUSHAN: I don’t want to prolong this, but
we do have a slightly different perspective in BIO than
in some of the other trade associations on some of the
minutiae of this question. As I mentioned before, there
needs to be – in the biotech area, we are being subjected
to a process which yields way too many patent
applications sitting inside the Patent Office, and that
has created an overhead and a backlog which is
essentially artificial, and so there needs to be a more
coherent look at how the Patent Office has structured its
examination policies to get a better work product out.
There are two elements of this, one which we have great
passion about is this issue of dividing of the
applications unnecessarily. That is very inefficient to
take and essentially segment over time and among
different examiners a single invention for examination.
The second thing which has kind of dropped off the radar
screen, which we think is unfortunate, is the idea of
defered examination, or non-mandatory examination of
every single patent application that comes in. There is
a huge wave of patent applications that lands at the
Patent Office every year, and very few of them two years
out, or one year out, have the same passion of commercial
value for the applicant.

PROFESSOR SHAPIRO: So are you willing to pay
more to have yours sped up?

MR. KUSHAN: Well, that is one model that many
countries follow. And the question that we are
struggling with, and obviously there is a balance of
letting these things languish as land mines in the Patent
Office, which we very much do not want to have, but at
the same time, if there were an obligation on a patent
applicant to pay for - to trigger the examination within
a certain period of time, by default, a certain
percentage of the work the PTO has to do would drop off,
drop off their workload. And so that kind of thinking
needs to be done and it has not yet been done by the FTC.
PROFESSOR SHAPIRO: Okay. Just to frame the whole pendency question, in the 21st Century Strategic Plan, the PTO says they hope to achieve 27 months overall patent pendency as a goal by 2008. I was not impressed particularly, but I guess it is a lot of work, so that is the sort of thing we are talking about anyhow. So it is not about to go away. Kulpreet, you had a quick comment here?

MR. RANA: Yeah, just going back to some of the comments that were said yesterday, as well, I think a lot of people here are in favor of the increased funding, and Carl, to your question about whether it should be linked to some requirements that the PTO actually improve its process, I would hope part of what we would be able to do is to actually get the PTO to buy in to some of the changes that we all think need to be made. And rather than trying to motivate them with specific requirements, if we had buy-in, I would think that would be a better process, or in combination.

PROFESSOR SHAPIRO: Okay, let me move on. I will glide over number 6 and go to number 7. Number 7 says, “To enact legislation to require publication of all patent applications 18 months after filing,” and to remind you all that the 1999 legislation required – ending up causing publication of apparently about 90
percent of the patent applications, according to the FTC’s report, and this would then kind of do the extra ten percent. Rather than go around the table, I will represent to you that everybody here is in favor of this. There is a range between “in favor” and “strongly in favor.” So I think that is helpful. Of course, part of this is to prevent submarine tactics and hold-up. It helps promote the disclosure process. Ron, I think you had an interesting point about how we can deal with the concern that somebody might file a patent, the application would be disclosed, then the patent would get rejected and they would say, “Oh, this is really not fair. I had to disclose all that stuff and I didn’t get anything in return.” If you remember that, I thought it was a very good point.

MR. MYRICK: I do remember. There is a quid pro quo here. People are giving disclosure of their vital information which they otherwise could keep as a trade secret for some period of time, an exchange for a patent. However, with the current pendency, or the target pendency at 27 months, 2008, they may not even know on the date of 18 months that they have to have their application published, whether or not they are going to get any patent at all. And I think it is incumbent upon the system to not put the applicants in
the bind of having to bet on the outcome. They do not
know whether they are going to get an examination that is
going to give them a patent when they have to let that
disclosure go, so they may have to let it go in the dark,
and that is not fair. I think what we should be
targeting is that, first, at least the first office
action, telling them whether or not they have got
anything at all in prospect to be provided to them
sufficiently in advance of the 18 month publication date
so that they can decide whether or not they want that
publication to go forward, or would like to withdraw the
case. Now, that is only fair. And because they are
giving up significant rights by that publication and they
do not know anything at this time, at least in some arts,
particularly in the longer pendency arts such as the
computer arts and the information arts. So it is I think
a challenge to the system to improve the system at least
that much — in many of the arts. By the way, I have to
say, having been with a rather large company that Todd
mentioned recently, that we did not have a lot of this
problem in many of the businesses we ran. Of course, we
ran a lot of businesses, but I think it is a problem that
is endemic in some of the information technology
businesses.

PROFESSOR SHAPIRO: Okay. Do you want to add
one thing to that?

MR. BARR: Although I agree it is a problem, I always thought it was a great feature when I was a prosecutor that we could just tell the client they could decide at the end whether to give up their trade secrets, but, Ron, why if it is something valuable, then the chances of getting a patent are pretty high? So if your assumption is they are giving up something valuable, why wouldn’t they get a patent?

MR. MYRICK: It depends upon whether or not they know how valuable it is going to be at the time they have to make that decision.

MR. SIMON: If I may? I take a very different view than Ron because, in my view, the function of the Patent System is to get technology out to society. And people are taking up a public resource, which is I believe a very valuable public resource, and if you are saying, “Well, you can start playing and then decide based on where you think it is going,” I think you are really undermining one of the features of the Patent Office, and this is a real problem because a lot of technology changes very fast, and if you don’t get the stuff out fast, you are going to have a real problem.

PROFESSOR SHAPIRO: Well, like I said, I view that as sort of a nuance, possible angle, and the one
area where somebody might object to this, I guess, it seemed to me, and then there is some back and forth on that. But overall, extremely strong support for that and, again, many patents have been subject to this already so we have evidence that it does not appear to be causing problems. So this is kind of clean it up and get it done for 100 percent.

Proposal 8 has to do with prior use rights, “To enact legislation to create intervening or prior use rights to protect parties from infringement allegations that rely on certain patent claims first introduced in a continuing or other similar application.” Okay? And there has been some discussion about this. I think a fair bit of concern about continuation practice, and how it can ensnare companies and be part of hold-up problems, I again want to keep it pretty quick, but I am happy to say – and my own research is on prior use rights, so I am particularly interested in this area – it seems like there is really almost unanimous support for this, and I would like to have a few of the folks just explain where they are at, who have crafted proposals. Gary, I know you –

MR. GRISWOLD: Yeah, I have been a prior use buff since the early 90's when actually the senate first passed a bill that was a broad prior user right, which

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
did not pass the House in time. But, the AIPLA view on this is that we don’t believe there should be a prior use right that attaches to something - a use that begins after the effective filing date. We believe that the prior user right statute today that has some limitations on subject matter and has a requirement that there be a one-year reduction in practice one year prior to the filing date, and that it does not include substantial preparation, that the statute should be changed to fix those things. But we don’t believe in moving - we don’t support moving the date downstream so that would occur during the prosecution. You get into all sorts of unintended consequences where we are not even sure of, including more derivation questions, and so we don’t support that. We think that the publication of patent applications helps us – all applications will help us on the issue of some patent claims showing up later that will be a problem, not perfectly, but that is our direction and belief.

PROFESSOR SHAPIRO: Okay. Bob, want to talk to the ABA?

MR. SACOFF: I think we are pretty consistent with that. Just in the interest of brevity, let me read you the pending resolution that we have got subject to adoption. “It is resolved that the Section supports in
principle the commercial use, including substantial preparations for commercial use should be recognized as a personal defense to patent infringement if undertaken in good faith by a person who has reduced the patented invention of practice prior to the effective filing date of the patent. Specifically, we support an amendment to the American Inventors Protection Act in '99 providing for such rights to remove restrictions on the enjoyment of such rights inconsistent with this principle.” And those are some of the limitations that Gary was referring to.

PROFESSOR SHAPIRO: Okay. I don’t know whether any of the industry company representatives – again, I heard a lot of favorable view on this. Anybody particularly feel, maybe who hasn’t spoken as much, or do you want to weigh in here?

MR. DICKINSON: I will just say, tentatively, we are in agreement with the other associations. And another point is that the type of prior user right that Gary Griswold is talking about, which is somewhat different from what is in the FTC report is what you have in several countries abroad now and that has worked well and we would like to see the more limited prior user right that was in the '99 Act expanded that way.

PROFESSOR SHAPIRO: So, I think we have a lot
of affirmation here for what the FTC is proposing.

MR. BARR: What are you saying? You are saying that the industry representatives support it, but the organizational ones don’t. Is that what you are saying?

PROFESSOR SHAPIRO: No.

MR. BARR: What you said is obviously important, I just heard all the industry organizations opposed the FTC proposal. Did I get that wrong?

PROFESSOR SHAPIRO: I think that they are all supporting it.

MR. GRISWOLD: What we support, let us be clear here – what we support is expanding the present prior user right, but the present prior user right has its effective date, the effective filing date of the patent application. What the FTC’s proposal was to also provide a prior user right that could occur by activity prior to broadening claims during the pendency of a patent application. That part, we do not support because we are concerned with the unintended consequences of derivation issues. We do not even know what would happen there. It apply to gets into a whole bunch of questions of why a person’s company prosecuted – or an individual prosecuted a case the way they did, and so we do not support that piece of it. So we support expanding the
present prior user right, but not changing the date.

PROFESSOR SHAPIRO: Okay, so it wouldn’t just apply to business methods, it would spike in that dimension –

MR. GRISWOLD: Yeah, it would apply to everything.

PROFESSOR SHAPIRO: And you don’t need to do it one year before the application –

MR. GRISWOLD: Right.

PROFESSOR SHAPIRO: Any time before. You would support that, but not so much in this continuation –

MR. GRISWOLD: Yeah, if the claim was not there and then you had a broadened claim – I even figure where they have a broadened claim or not, it is a whole continuous snake pit.

PROFESSOR SHAPIRO: Okay, so I thank you for helping. I do not think I did make it clear, hopefully we have got it clear now. Do you want to comment on that?

MR. BARR: I would like to support the FTC proposal. I wanted to highlight the difference between the industry representatives and the organizations.

PROFESSOR SHAPIRO: Any other industry folks want to say, “Yeah, I really support the FTC” and go that
MR. KUSHAN: I will mention that I am not really either in this capacity because BIO is a trade association made up of companies and not necessarily the lawyer associations. This issue is complicated and I don’t know that it can get unqualified support in any reasonable sense, but what you should — I think it is important to pull out the difference that has been pulled out, which is this is talking about vesting a right to any use of an invention after the filing date of a patent, and certainly there are instances where the continuing practice has been abused, but we have got a lot of applications pending now which have been chopped up again by the Patent Office —

PROFESSOR SHAPIRO: I heard about that, yes.

MR. KUSHAN: Sorry to keep going back to that, but, you know, it bleeds over into a lot of different topics, and so I think it is much more complicated than the FTC gave it credit.

PROFESSOR SHAPIRO: Okay. I want to make sure we have enough time for Commissioner Thompson to take us forward from here, so let us move on to 9, the willfulness and I will again read that. “Enact legislation to require as a predicate for liability for willful infringement either actual written notice of
infringement from the patentee, or deliberate copying of
the patentee’s invention knowing it to be patented.” I
will say – we are going to keep this very brief – that
there is a widespread view that the current willfulness
rule is not working well, it is disrupting the
disclosure, there are people who don’t want to even read
patents, and it gets involved with this whole issue of
when you waive attorney-client privilege. And Mark
Lemley has written a great article on this, like
everything else. So there is a lot of support here. Of
course, we get into the particulars. But I did find, I
mean, in addition to the associations which want to see
some change here, we do have the Knorr-Bramsey case, so a
lot of people are saying, “Well, let’s wait and see
exactly how that plays out and then we’ll see what else
we need,” which seems to me is hard to argue with since
it should happen this year, I guess. We heard a little
bit from some companies – I was impressed with the
strength with which a number of company representatives
felt like this willfulness thing is a real – is a problem
that can be fixed and they want it to be fixed. I don’t
know if you guys want to kind of weigh in on that, but I
heard that a lot and I think that should come through
today, not just from me, but from you guys.

MR. MONAHAN: Yeah, I think it is probably
because this is one of the biggest distortions of the system. This is one of the greatest imbalances. All of those — that extra ten percent of applications probably doesn’t do me much good because I’m afraid to look at them anyway. I have been threatened with letters with patent applications, not just patents, so I get to double my fun. I think that we support some standard that gives us some certainty. I want to know that something is required before I am on notice. I want to be able to act reasonably, I want to be able to act responsibly within my industry to try to do the right thing. Right now, there are a million different facts which are brought to bear and parties attempting to demonstrate willfulness. Oddly enough, notice is usually not one of them, at least in my experience. It is usually something which, again in my experience, was intentionally deceptively orchestrated by a plaintiff’s lawyer or by a company, and I am not asking to avoid responsibility; if you think I am infringing something, just let me know. But when you get these squirrely letters, or you get invitations to license which later get conveyed to a jury as a “you must have known, you must be willful,” that is a problem. And, of course, the result is that when you do your settlement analysis, even as tough as we are in fighting these cases, you have to factor in that additional factor.
of, “God, what if the worst thing happens and we get
treble damages?” And, you know, I have been lucky so far
not to see treble damages, but it is a factor which, like
punitive damages in civil cases, I think is out of
control now, particularly in places like Marshall, Texas,
which is why a lot of people are settling cases that are
based upon patents which probably should not have ever
gotten out of the Patent Office.

PROFESSOR SHAPIRO: Kulpreet, how does this
look from Google’s perspective? Is it similar?

MR. RANA: Yeah. I think we face some of the
same difficulties that Jay was referring to. We receive
letters kind of regularly, increasingly as we have become
more visible. We are a bigger target. I think we are
definitely aligned with the FTC’s proposal in the sense
that if you deliberately copy with knowledge that
something is patented that, you know, it makes sense that
that would give rise to willful infringement. I am a
little more - I would like to think a little bit more
about the Notice Letter provision of the FTC’s
recommendation just because I do kind of wonder what
effect that will have on people’s behavior and whether
that will give rise to - I already get plenty of notice
letters, I do not particularly want to get a ton more
that I am going to have to spend a lot of time to review.
And I think it would be interesting to maybe think about how that could tie into – for there to be some kind of a consequence for people who issue notice letters, for example. And maybe that ties into things like post-grant review that we have been discussing earlier, where maybe if you issue a notice letter that creates sufficient reasonable apprehension that the person receiving it could initiate some kind of a review, and maybe the cost associated with that is enough to regulate the conduct of the people who are, you know, sending those out. So I think it is an interesting thought. There are some things to kind of think through a little bit more there.

PROFESSOR SHAPIRO: Do you want to say something, Bart?

MR. EPPENAUER: Oh, sure. As I said before, we strongly support this recommendation. In response to your comment, I think that if you have this burden placed on the letter writing, that will reduce the letter writing because, you know, in our experience when you challenge somebody to send you sort of a soft letter, to prove it up, it takes a long time to get that information from them, and yet you are still in a willfulness situation. So I think it is really going to help. We are strongly in favor of it and we are strongly in favor of removing adverse inference and trying to avoid the

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
whole waiver of attorney-client privilege, which is a
real problem in litigation.

MR. MONAHAN: Let me just add that, I mean,
right now the letter writers have their cake and eat it
too because they can send you a non-notice letter which
costs them almost nothing, and then preserve the ability
to make an argument later, and I am intrigued by there
being a consequence because, if I had a dollar for every
letter that either we never heard from again, or never
responded when we wrote to them, you know, we would be
rich. So I think this is an important area, and I am
concerned about inviting more. But I really think if you
put a consequence, you can put a standard on these
things, that the incentive to write them would be
reduced, and the people who wrote the letters would
really believe that they have a claim. And that is what
we ought to be dealing with.

PROFESSOR SHAPIRO: Oh, and I know you have
some strong views on this.

MR. BARR: Nah, I don’t have any strong views.
A couple quick things. First of all, when the letter
writers go away, that is reward in itself, so I am okay
with that one. I support the recommendation strongly and
I just don’t think anyone has mentioned the real – what I
think is the most important basis for it is that we can
again allow engineers to read patents because, at least to me there is enough ambiguity in the case law that I have to discourage engineers from reading patents and in their prior art searches because that might be enough for willful infringement. But having said that, I will attempt to improve on what Mark said this time because he referred to his article, but he did not - I will improve on what he said, but not on what he wrote, and I strongly recommend that you read the article on willfulness - he can give you the cite or he can e-mail me - because the recommendation there, after he discusses all the problems, he solves the problems by proposing that willfulness can only - and at risk of mischaracterizing it - but it can only occur at the time you develop the product. If you copy a product or a patent at the time you develop the product, then you could be libel for willful infringement, but just because you are down the road in what Professor Shapiro calls a hold-up situation, where it is very difficult to modify your product, now you get a notice and you get an opinion, but can you back out? That is a tough problem and the triple damages penalty for not getting an opinion or not producing it in court - or for not having one that satisfies the requirements is a little drastic in the hold-up situation. So I would urge everyone to read the article,
or at least the last few pages, the Executive Summary.

PROFESSOR SHAPIRO: Okay, well, I want to close this part on I think that happy consensus that industry, I think, really wants change here, they feel this is my sense, and FTC has identified some specific ways to do that. Of course, there will be some more discussion about how to implement it. But I hope this will happen and it seems to me we have taken a step in that direction. Which means it is time for me to turn it over to Mr. Action -- Commissioner Thompson, how do we make this happen? What do we do next?

COMMISSIONER THOMPSON: Well, “Action” is an interesting word, I mean, for the Professor it – and for lawyers here, you might be interested to know that – for students and lawyers who are here, you might be interested to know that Professor Shapiro sometimes appears before me, and I do not have a bell, I do not have a rasp, and I do not even have a clock, but, you know, Casey, you need to remind me to buy those things, okay? This is very interesting. I like the technique. I am also very impressed that we are here at the end of a Friday afternoon and there are actually more people here than we started out with this morning. And that is very impressive because I began this morning by noting that today’s event had the potential to be a watershed moment.
in the future of innovation in the U.S. Now, some might
criticize that statement as a bit of puffery, but based
on the excellent discussion that I have heard today, I am
convinced that is true. So at the outset,
congratulations, give yourselves a hand.

Now comes the hard part. How do we take our
gaggle of bright ideas and keen insights about patent law
and process and turn them into something more meaningful
about innovation in our economy? Or how do we capitalize
on this opportunity to make the Patent System more
accommodating to innovation in the world that we see
today, especially in high technology and biotechnology?
And here I might have a few suggestions. First, I would
encourage the people in this room to create an organized
and continuing voice of technology and academics to take
advantage of the opportunities to support innovation
through improvement of our Patent System. I am always
struck sitting in that strange place called Washington,
D.C., that when you are considering some questions like
these questions I am reminded of the movie Ghostbusters -
“Who you gonna call?” And all of these people have
interesting views, and in looking at our report, it is
important to recognize it took almost two years to locate
all of those resources, and most policy makers are not in
that position. So creating an organized and continuing
voice is very important. Second, I think it is also helpful to create an ongoing resource for policymakers so that we can understand how intellectual property is used in Information Technology and Biotech. In the context of doing this report and being here, and listening to the many people, some of which are here today, I thought it was very enlightening to hear not only viewpoints, but positions and practices, anecdotes, and data. Sometimes that information doesn’t filter very well back East. Holding yourself out as a resource is very important. Third, I would implore you to continue the momentum generated here by developing ongoing mechanisms to discuss among yourselves the specific issues raised here today, and identify areas of consensus. Fourth, and maybe this is something that is a bit of a challenge to all of us, is talk to the public about your stake in innovation and in intellectual property, and why it is important to them. And be able to talk about the markets that you deal in and how fast they change. In other words, tell people why this issue is important. Now, I am happy to say that I can make an announcement here, and I don’t want people to say that this is a light announcement because I think it is significant, that a core group of leading technology companies are willing to take the first step today by working together, and it may
start by a public announcement, that they agree that
there is an opportunity to make the Patent System more
responsive to technology and innovation, and that they
agree to meet and have a continuing dialogue among
themselves, academics, and policy makers about the
proposals discussed here today. Now those companies
include CISCO, Intel, eBay, Semantec, Chiron, Microsoft,
and Genentech. So with that announcement, I think you
are off to a very good start. And I thank you all for
getting us to this point.

Now, although I may live to regret it, I look
forward to sharing this ongoing relationship with you all
as you refine your views and we consider how innovation
can thrive in America. So, congratulations, and thank
you all for being here.

(Whereupon, the workshop concluded.)
Certificate of Reporter

MATTER Patent Reform Workshop
Date: April 16, 2004

I HEREBY CERTIFY that the transcript contained herein is a full and accurate transcript of the notes taken by me at the hearing on the above cause before the FEDERAL TRADE COMMISSION to the best of my knowledge and belief.

DATED: April 28, 2004

______________________________
ADRIAN T. EDLER

certification of Proofreader

I HEREBY CERTIFY that I proofread the transcript for accuracy in spelling, hyphenation, punctuation and format.

______________________________
DIANE QUADE